Patent Publication Number: US-2004047877-A1

Title: Immunodominant human T-cell epitopes of hepatitis C virus

Description:
[0001] The present invention describes immunodominant hepatitis C virus T cell epitopes useful in hepatitis C prophylactic and therapeutic vaccines, derived from the HCV core, E1, E2 and NS3 proteins.  
       TECHNICAL FIELD OF THE INVENTION  
       [0002] The present invention relates to the production of novel synthetic immunogens related to the hepatitis C virus core, E1, E2 and NS3 regions and to the use thereof in the production of vaccines, therapeutic agents and the like. More specifically, the present invention relates to polypeptide compositions containing HCV core, E1, E2 and NS3 T cell determinants.  
       BACKGROUND OF THE INVENTION  
       [0003] In the few years since its discovery, Hepatitis C virus (HCV) has been shown to be a major cause of acute and chronic liver disease. HCV is a single-stranded RNA virus with a genome of approximately 9400 nucleotides that consists of a 5′ untranslated region (5′UR) of 341 nucleotides which precedes a single large open reading frame encoding a precursor polyprotein of about 3010 amino acids (Kato et al., 1990). The genetic organization of the viral genome is related to that of flavi-and pestiviruses, with the putative structural proteins located in the N-terminal region and a variety of non structural proteins located at the C-terminal end of the polyprotein. The structural proteins are the core protein (C, amino acids 1-191) followed by the putative envelope proteins E1 (amino acids 192-383) and E2/NS1 (amino acids 384-746). The terms E2 and NS1 are often used interchangeably. Another form of E2 is composed of amino acids 384 to 809 and a third form is associated with NS2. The non structural proteins are NS2, NS3, NS4 and NS5, of which at least NS4 and NS5 have been shown to be further processed into NS4 A, NS4 B, NS5 A, and NS5 B.  
       [0004] Structural analysis of HCV genomes revealed the existence of different genotypes that have been classified into types and subtypes (Stuyver et al., 1993). The sequence diversities are distributed along the whole genome including the 5′ untranslated region. The highest sequence variability has been observed in the NS2 and 3′ untranslated regions, and in the putative envelope regions encoding the E1 and E2 proteins. The core, NS3, and certain regions of the NS4 proteins displayed markedly less diversity (Okamoto et al., 1992).  
       HCV HUMORAL RESPONSE  
       [0005] Soon after the discovery of HCV, immunoassays for the detection of circulating antibodies against HCV proteins became widely available. These tools have led to an explosive increase of the knowledge in the field of the human humoral immune response to HCV in different conditions. Once it was demonstrated that HCV was the major cause of posttransfusional non-A, non-B hepatitis, the search for antibodies to HCV was added to the safety screening panel of blood products. This procedure not only increased the safety of blood transfusions but also enhanced the knowledge of the epidemiology of the virus. The fact that HCV is responsible for a large proportion of chronic hepatic infections in which blood transfusion or parenteral inoculation are excluded remains a major challenge for further epidemiological studies. The widespread use of the assays for the detection of antibodies to HCV has also led to the recognition of the regions with humoral antigenicity of the virus. The relationship between the kinetics and magnitude of the humoral immune response to the different proteins of HCV and the course and outcome of the disease remains to be established.  
       HCV T CELL EPITOPES  
       [0006] The immune response to viral antigens is almost entirely T cell dependent. T cells are required both for antibody production and for some cytotoxic reactions. HCV-encoded proteins are immunogenic not only at the B cell level, but also at the T cell level.  
       [0007] Studies describing the cellular immune response to HCV are scarce. Lin et al. (1993) describe candidate T cell epitopes within absolutely conserved regions of HCV gene obtained by means of a computer search revealing a large number of potential T cell epitopes. It has also been reported that peripheral brood cell monocytes (PBMC) from HCV-infected individuals proliferate in response to HCV recombinant proteins and that peripheral responses to core protein correlate with a benign course of infection (Botarelli et al., 1993). In the liver of patients with chronic HCV infection HCV-specific, HLA class I-restricted cytotoxic T lymphocytes (CTL) have been identified and cloned that recognize epitopes in E1 and NS2 proteins. These investigators have mainly focused on obtaining T cell clones from individual patients, and on the localization of the immunoreactive domain for the single CTL clones. Such studies led to the discovery of the epitope ASRCWVAM (aa 235-242) in the aminoterminal part of the E1 protein, and of the epitope LMALTLSPYYKRY (aa 826-838) from the NS2 region (Koziel et al., 1992). In patients with chronic HCV hepatitis intrahepatic CD4 +  T cells which specifically recognized the NS4 protein of HCV were observed. The clonotype of these T lymphocytes was not detectable in the PBMC from these subjects (Minutello et al., 1993). These studies demonstrate that in patients with HCV hepatitis, HCV-specific T lymphocytes can be isolated from the infected liver and the peripheral blood. Their role in the pathogenesis of the liver damage in HCV hepatitis and their relevance for the clearance or persistence of the virus remains to be established.  
       [0008] Although neutralization of certain viral infections is possible by humoral immunity only, most microbiological agents can only be cleared from the host with the aid of cellular immunity. Even when the neutralizing capacity of circulating antibodies is established in certain infections, T helper cell activity is generally required to allow B cells to produce the required levels of circulating antibodies, for achievement of neutralization and clearance of the infectious agent. However, certain infectious agents can only be neutralized by means of cellular immunity.  
       [0009] In the case of hepatitis C virus, it can be anticipated that T cell immunity may be required for clearance of the virus, since most patients enter into a chronic course of the disease, and since most patients infected with HCV have developed humoral immunity to most of the HCV antigens which can be employed for diagnosis of HCV infection, as described in patent applications no. EP-A-0 318 216, EP-A-0 388 232, EP-A-0 442 394, EP-A-0 484 787, EP-A-0 489 968. However, most of the antibody-positive patients have not been able to clear the virus from the circulation since they remain HCV-PCR positive and, consequently, the detected antibodies have not been protective neither sufficient to neutralize the virus. Possibly, antibodies to other epitopes which are currently not included in HCV diagnostic assays may be capable of neutralizing HCV infection. Such epitopes may be located on the viral membrane proteins E1 and E2, but protection against a wide range of different HCV species may be hampered by the hypervariability of HCV envelope regions.  
       [0010] The aim of the present invention is to provide T cell stimulating polypeptides and peptides derived from the HCV structural and NS3 regions.  
       [0011] Another aim of the present invention is to provide T cell stimulating polypeptides and peptides as defined above for use in the preparation of an HCV immunogenic composition.  
       [0012] Another aim of the present invention is to provide T cell stimulating peptides or polypeptides derived from the core region, the E1 region, the E2 region, or the NS3 region of HCV.  
       [0013] Another aim of the present invention is to provide T cell stimulating peptides or polypeptides from HCV as specified above which contain either T helper cell (CD4 + ) epitopes and/or CTL (CD8 + ) epitopes.  
       [0014] Another aim of the present invention is to provide recombinant polypeptides containing the same.  
       [0015] Another aim of the present invention is to provide therapeutic as well as prophylactic compositions comprising the same.  
       [0016] Another aim of the present invention is to provide prophylactic or therapeutic compositions comprising said polypeptides.  
       [0017] Another aim of the present invention is to provide methods for preventing or treating HCV infection based on the same.  
       DETAILED DESCRIPTION OF THE INVENTION  
       [0018] More particularly, the present invention describes a polypeptide of about 8 to about 100 amino acids comprising or consisting of at least 8 contiguous amino acids selected from the core and/or E1 and/or E2 and/or NS3 regions of the HCV polyprotein, with said contiguous amino acids containing a T-cell stimulating epitope, and provided that said polypeptide is different from any known T cell epitope containing HCV peptide or polypeptide described from any of the above-mentioned regions. The latter known HCV polypeptides and peptides are described for screening for B cell epitopes. Such polypeptides and peptides are for instance mentioned in EP-A-0 318 216, EP-A-0 388 232, EP-A-0 442 394, EP-A-0 484 787, EP-A-0 489 968, WO 92/22571, Lesniewski et al., 1993; Weiner et al., 1993; etc. The content of these applications is hereby-incorporated by reference.  
       [0019] Even more particularly, the present invention relates to the use of polypeptides as described above for the preparation of an HCV immunogenic composition.  
       [0020] The expression “HCV immunogenic composition” refers to the prevention or treatment of HCV infection.  
       [0021] Preferentially said polypeptide is different from RALAXGVRVLEDG, RMAWDMM, PTDCFRRXP, YPYRLWH, GKSTKVP, PSVAAT, IGTVLDQAE, AVAYYR, ASRCWVAM and TGDFDSVID.  
       [0022] The term “HCV polyprotein” refers to any HCV polyprotein disclosed in the art and is reviewed in Okamoto et al. 1992, such as the type 1 a HCV polyprotein of the HC-J1 isolate, such as the HCV polyprotein of the type 2 a HC-J6 isolate (Okamoto et al., 1991), the type 2 b HC-J8 isolate (Okamoto et al., 1992). According to this definition, any variation already observed within any of the described regions of HCV is to be considered as part of a the definition of HCV polyprotein. For example, numerous types and subtypes are disclosed in Bukh et al., 1993, Bukh et al., 1994, Stuyver et al., 1993 a, Stuyver et al., 1993 b, Stuyver et al., 1994 a, Stuyver et al., 1994 c. Moreover, conservative substitutions may be introduced in these HCV polyproteins according to the present invention. The term “conservative substitution” as used herein denotes that one amino acid residue has been replaced by another, biologically similar residue. Examples of conservative substitutions include the substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another such as between arginine and lysine, between glutamic and aspartic acids or between glutamine and asparagine and the like. The term “conservative substitution” also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid provided that antibodies raised to such a polypeptide also immunoreact with the corresponding polypeptide having the unsubstituted amino acid.  
       [0023] The term “antibody” refers to a molecule that is a member of a family of glycosylated proteins called immunoglobulins, which can specifically combine with an antigen.  
       [0024] The word “antigen” has been used historically to designate an entity that is bound by an antibody, and also to designate the entity that induces the production of the antibody. More current usage limits the meaning of antigen to that entity bound by an antibody, while the word “immunogen” is used for the entity that induces antibody production. Where an entity discussed herein is both immunogenic and antigenic, reference to it as either an immunogen or antigen will typically be made according to its intended utility.  
       [0025] The term “corresponds” in its various grammatical forms as used in relation to peptide sequences means the peptide described plus or minus up to three amino acid residues at either or both of the amino- and carboxy-termini and containing only conservative substitutions in particular amino acid residues along the polypeptide sequence.  
       [0026] “Epitope” refers to that portion of a molecule that is specifically bound by a T cell antigen receptor or an antibody combining site.  
       [0027] The term “immunoreact” in its various forms means binding between an antigen as a ligand and a molecule containing an antibody combining site such as a Fab portion of a whole antibody.  
       [0028] The expression “T-cell stimulating epitope” or T cell epitope according to the present invention refers to an epitope capable of stimulating T-cells. A T-cell stimulating epitope may be selected according to the present invention by monitoring the lymphoproliferative response (as detailed in the Examples section) towards polypeptides containing in their amino acid sequence at least 8 contiguous amino acids derived from the core, and/or the E1, and/or the E2, and/or the NS3 region of any HCV polyprotein. Said lymphoproliferative response may be measured by either a T-helper assay comprising in vitro stimulation of PMBC from patients with hepatitis C infection with varying concentrations of peptides to be tested for T-cell stimulating activity and counting the amount of radiolabelled thymidine uptake. Said lymphoproliferative response may also be measured by means of a CTL assay measuring the lytic activity of cytotoxic cells using  51  Cr release. Proliferation is considered positive when the stimulation index (mean cpm of antigen-stimulated cultures/mean cpm of controle cultures) is more than 1, preferably more than 2, most preferably more than 3. In order to select a T-cell stimulating epitope containing peptide, the results of these lymphoproliferative assays are compared and immunodominant T-cell epitope containing polypeptides or peptides are selected. The results of the lymphoproliferative assays against certain peptides may also be compared between clinical non-responders and responders to Interferon-α treatment. The lymphoproliferative response towards a series of synthetic, overlapping peptides representing the HCV core, E1 and E2/NS1 sequences and a recombinant NS3 protein was monitored in 32 patients with chronic HCV hepatitis as disclosed in the Examples section of the present invention.  
       [0029] Consequently, the present invention represents a selection of immunodominant T cell epitopes from a series of antigens covering the core, E1, E2 and NS3 regions. From the examples section, it is clear that not only peptide pools 2 and 3 and peptides NS1-5* and NS1-7* but also, pools 4, 5, 6 and 9 and NS3, reacted frequently with hepatitis C patients (Table 4) while infrequent reactivity could only be observed in normal controls with the same polypeptides (Table 5). It is obvious from the data presented in Table 4 that large areas of the HCV structural region, such as pool 1 (amino acids 5-72) and pools 7 and 8 (amino acids 427-578) show little reactivity with T cells of infected patients, even with patients with a response to IFN-α treatment. Most strikingly, however, it was found that while the dominant B cell response to hepatitis C in general is located to the core aminoterminus (see also Table 3), the dominant T cell response is directed towards the core carboxyterminal region (see Table 4). In the literature, ample evidence can be found that the core carboxyterminal half contains little or no B cell-reactive epitopes. Based on the present invention, it may be desirable to yet include for instance parts of the core carboxyterminal region (spanning amino acids 73-176) into prophylactic or therapeutic vaccine compositions.  
       [0030] The words “polypeptide” and “peptide” are used interchangeably throughout the specification and designate a linear series of amino acids connected one to the other by peptide bonds between the alpha-amino and carboxy groups of adjacent amino acids. Polypeptides can be a variety of lengths, either in their natural (uncharged) forms or in forms which are salts, and either free of modifications such as glycosylation, side chain oxidation, or phosphorylation or containing these modifications. It is well understod in the art that amino acid sequences contain acidic and basic groups, and that the particular ionization state exhibited by the peptide is dependent on the pH of the surrounding medium when the protein is in solution, or that of the medium from which it was obtained if the protein is in solid form. Also included in the definition are proteins modified by additional substituents attached to the amino acids side chains, such as glycosyl units, lipids, or inorganic ions such as phosphates, as well as modifications relating to chemical conversions of the chains, such as oxidation of sulfhydryl groups. Thus, “polypeptide” or its equivalent terms is intended to include the appropriate amino acid sequence referenced, subject to those of the foregoing modifications which do not destroy its functionality.  
       [0031] The polypeptides of the invention, and particularly the shorter peptides amongst them, can be prepared by classical chemical synthesis. The synthesis can be carried out in homogeneous solution or in solid phase.  
       [0032] For instance, the synthesis technique in homogeneous solution which can be used is the one described by Houbenweyl in the book entitled “Methode der organischen chemie” (Method of organic chemistry) edited by E. Wunsh, vol. 15-I et II. THIEME, Stuttgart 1974.  
       [0033] The polypeptides of the invention can also be prepared in solid phase according to the methods described by Atherton and Shepard in their book entitled “Solid phase peptide synthesis” (IRL Press, Oxford, 1989).  
       [0034] The polypeptides according to this invention can also be prepared by means of recombinant DNA techniques as documented below.  
       [0035] The polypeptides or peptides according to the present invention may, as specified above, vary in lenght. The peptides according to the invention contain at least 3, preferably at least 4, 5, 6, 7, most preferably however al least 8 contiguous HCV amino acids. Preferred lengths of peptides are 6, 7, 8, 9, 10, or more (for instance 15, 20, 25, 30, etc.) amino acid residues. The polypeptides of the present invention may be us till 150 to 200 amino acids long, but are preferably less than 100 amino acids.  
       [0036] Further contemplated according to the present invention is a polypeptide as defined above, comprising or consisting of at least 8 contiguous amino acids selected from the region comprised between amino acids 73 to 176 in the core region of HCV, between amino acids 192 to 234 and 243 to 392 of the E1 region of HCV, between amino acids 397 and 428 and amino acids 571 to 618 of the E2 region of HCV, or between amino acids 1188 to 1463 of the NS3 region of HCV, and with said contiguous amino acids containing a T-cell stimulating epitope, and provided that said polypeptide is different from any known T cell epitope containing HCV peptide or polypeptide described from any of the above-mentioned regions. The latter known HCV polypeptides and peptides are described for screening for B cell epitopes.  
       [0037] Even more particularly, the present invention relates to the use of polypeptides as described above for the preparation of an HCV immunogenic composition.  
       [0038] The expression “comprised between amino acids X to Y” includes the amino acid X and the amino acid Y.  
       [0039] The numbering of the HCV polyprotein used in the present invention refers to the numbering as used for the HCV-J isolate according to Kato et al., 1990. All other HCV isolates known in the art may be aligned to this sequence to obtain the referred HCV polyprotein numbering for each individual HCV isolate. For instance, it is known that type 2 isolates can contain 4 extra codons/amino acids in their E2 sequence, while type 3 sequences have an insertion of 2 amino acids compared to type 1 sequences.  
       [0040] The Examples section of the present invention describes T cell epitopes in, amongst other regions of the HCV structural region: the carboxyterminal region of the core protein (aa 73-176), amino acids 192 to 383 of the E1 region, amino acids 397 and 428 and amino acids 571 to 638 of the E2 region, amino acids 1188 to 1463 of the NS3 region. Groups of peptides covering parts of the structural proteins core and E2, and covering the complete E1 protein, as well as a recombinant NS3 protein have been studied. Peptides were tested as group 1 (aa 5-80), group 2 (aa 73-140), group 3 (aa 133-200), group 4 (aa 193-260), group 5 (aa 253-332), group 6 (325-392), group 7 (aa 427-494), group 8 (aa 487-578), and group 9 (aa 571-638) as shown in Table 1. Recombinant NS3 encompassed amino acids 1188 to 1463 of the isolate IG8309, belonging to the 1 b subtype group of HCV.  
       [0041] The T cell response to the group 3 peptides, as well as to the individual peptides NS1-7* and NS1-5* shows a statistically relevant correlation with a decrease in alanine aminotransferase (ALT) and viral RNA levels, which are generally accepted to indicate a more benign course of the disease. A correlation between response to ‘a recombinant HCV core protein’ and a more benign course of the disease has been described by Botarelli et al. 1993. However, no epitopes have been mapped nor has the sequence and exact position-of the recombinant core protein been described in Botarelli et al., 1993. In the present invention, a similar T cell response has been observed to the group 2 peptides (aa 73-140) both in patients responding to IFN-α and in patients non-responding to the same. On the contrary, T cell reactivity to the group 3 peptides (aa 133-200) was observed in responders to interferon-α and differed from the T cell reactivity observed to this region in non-responders to IFN-α treatment. Furthermore, after investigating the reactivity of individual peptides from groups 2 and 3, this specific response correlating with a more benign course of HCV infection, could be further mapped to specific individual peptides termed CORE 23, CORE 25, and CORE 27. Peptide CORE 19, belonging to the group 2 peptides, was also recognized by some of the responders to IFN-α treatment (see FIG. 1).  
       [0042] The present invention thus also contemplates a polypeptide as defined above comprising or consisting of at least 8 to about 104 contiguous amino acids selected from the region comprised between amino acids 73 to 176, more particularly comprising or consisting of 8 to about 68 contiguous amino acids selected from the region comprised between amino acids 109 to 176 in the core region of HCV characterized by the following sequences:  
       [0043] NH 2 -GX 1 X 2 WX 3 X 4 PGX 5 PWPLYX 6 NX 7 GX 8 GX 9 AGWLLSPRGSRPX 10 WGX 11 X 12 DPRX 13 X 14 SRNX 15 GX 16 VIDTX 17 TCGX 18 DL 19 X 20 YIPX 21 X 22 GX 23  PX 24 GGX 25 SX 26 X 27 X 28 LX 29 HGVX 30 X 31 X 32 DGX 33 NX 34 X 35 TGNX 36 PGCSFSI-COOH  
       [0044] (SEQ ID NO 58, spanning positions 73 to 176)  
       [0045] wherein X 1  represents R or K, X 2  represents A, S or T, X 3  represents A or G, X 4  represents Q, K or R, X 5  represents Y or H, X 6  represents G or A, X 7  represents E or K, X 8  represents C, M or L, X 9  represents W or L, X 10  represents S, N, T, D or H, X 11  represents P or Q, X 12  represents N or T, X 13  represents R or H, X 14  represents R or K, X 15  represents L or V or F, X 16  represents K or R, X 17  represents L or I, X 18  represents F or L, X 19  represents M or I, X 20  represents G or E, X 21  represents L or V or I, X 22  represents V or L, X 23  represents A or G, X 24  represents L, V, or I, X 25  represents A or V, X 26  represents A or S, X 27  represents R or A, X 28  represents A or T or E, X 29  represents A or E, X 30  represents V or A or L, X 31  represents L or V or I, X 32  represents E or G, X 33  represents V or I, and X 34  represents F or Y, X 35  represents A or P, X 36  represents L or I, and,  
       [0046] NH 2 -X 11 X 12 DPRX 13 X 14  SRNX 15 GX 16 VIDTX 17 TCGX 18 ADLX 19 X 20 YIPX 21 X 22 GX 23 PX 24 GGX 25 X 26 X 27 X 28 LX 29 HGVRX 30 X 31 X 32 DGX 33 NX 34 X 35 TGNX 36 PGCSFSI-COOH  
       [0047] (SEQ ID NO 48, spanning positions 109 to 176)  
       [0048] wherein said contiguous amino acids containing a T-cell stimulating epitope, and provided that said polypeptide is different from any known T cell epitope containing HCV peptide or polypeptide described from any of the above-mentioned regions. The latter known HCV polypeptides and peptides are described for screening for B cell epitopes, X 11  to X 36  having the meanings above-mentioned.  
       [0049] It is to be underlined that in the present text, X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 X 10 , X 11 , X 12 X 13 , X 14 , X 15 , X 16 , X 17 , X 18 X 19 , X 20 , X 21 , X 22 , X 23 , X 24 , X 25 X 26 X 27 , X 28 , X 29 , X 30 , X 31 , X 32 , X 33 , X 34 , X 35 , X 36  have always the same meaning as the one which is defined for SEQ ID NO 58.  
       [0050] Preferentially said polypeptide is different from RALAHGVRVLEDG spanning positions 149 to 161 of the core region of HCV.  
       [0051] More particularly, the present invention relates to a polypeptide as defined above comprising or consisting of at least 8 to about 76 contiguous amino acids selected from the regions comprised between amino acids 73 to 148, or comprising or consisting of 8 to about 15 contiguous amino acids selected from the region comprised between amino acids 162 to 176, or comprising or consisting of 8 to about 16 contiguous amino acids selected from the region comprised between amino acids 129 to 144 in the core region of HCV characterized by the following sequences:  
       [0052] NH 2 -GX 1 X 2 WX 3 X 4 PGX 5 PWPLYX 6 NX 7 GX 8 GX 9 AGWLLSPRGSRPX 10 WGX 11 X 12 DPRX 13 X 14 SRNX 15 GX 16 VIDTX 17 TCGX 18 ALX 19 X 20 YIPX 21 X 22 GX 23 PX 24 GGX 25 X 26 -COOH (SEQ ID NO 59, spanning positions 73 to 148),  
       [0053] NH 2 -X 33 NX 34 X 35 TGNX 36 PGCSFSI-COOH (SEQ ID NO 60, spanning positions 162 to 176), and,  
       [0054] NH 2 GX 18 ADLX 19 X 20 YTPX 21 X 22 GX 23 PX 24  (SEQ ID NO 61, spanning positions 129 to 149). Particularly preferred is peptide ALMGYIPLV (SEQ ID NO 163).  
       [0055] Even more particularly, the present invention relates to the use of polypeptides as described above for the preparation of an HCV immunogenic composition.  
       [0056] The present invention thus also contemplates a polypeptide as defined above comprising or consisting of at least 8 to about 44 contiguous amino acids selected from the region comprised between amino acid positions 133 to 176 of the core region of HCV:  
       [0057] NH 2 -LX 19 X 20 YIPX 21 X 22 GX 23 PX 24 GGX 25 X 26 X 27 X 28 LX 29 HGVRX 30 X 31 X 32 DCX 33 NX 34 X 35 TGNX 36 PGCSFSI-COOH (SEQ ID NO 50), and more particularly selected from peptide LMGYIPLVGAPLGGAARALAHGVRVLEDGVNYAT GNLPGCSFSI (SEQ ID NO 67), and with said contiguous amino acids containing a T-cell stimulating epitope, and provided that said polypeptide is different from any known T cell epitope containing HCV peptide or polypeptide described from any of the above-mentioned regions. The latter known HCV polypeptides and peptides are described for screening for B cell epitopes.  
       [0058] Even more particularly, the present invention relates to the use of polypeptides as described above for the preparation of an HCV immunogenic composition.  
       [0059] The present invention thus also contemplates a polypeptide as defined above comprising or consisting of at least 8 to about 20 contiguous amino acids selected from the region comprised between amino acid positions 157 to 176 of the core region of HCV:  
       [0060] NH 2 X 30 CX 31 X 32 DGX 33 NX 34 X 35 TGNX 36 PGCSFSI-COOH (SEQ ID NO 51),  
       [0061] and more particularly selected from VLEDGVNYATGNLPGCSFSI (SEQ ID NO 13=peptide CORE 27) or VLEDIVNYATGNLPGCSFSI (SEQ ID NO 73), and with said contiguous amino acids containing a T-cell stimulating epitope, and provided that said polypeptide is different from any known T cell epitope containing HCV peptide or polypeptide described from any of the above-mentioned regions. The latter known HCV polypeptides and peptides are described for screening for B cell epitopes. Preferentially said peptides are further chosen from the following list of peptides:  
       [0062] NH 2 -GX 33 NX 34 X 35 TGNX 36 -COOH (SEQ ID NO 74),  
       [0063] NH 2 -X 33 NX 34 X 35 TGNX 36 -COOH (SEQ ID NO 75),  
       [0064] NH 2 -NX 36 PGCSFSI-COOH (SEQ ID NO 76) and  
       [0065] NH 2 -X 36 PGCSFSI-COOH (SEQ ID NO 77). Particularly preferred peptides include: GVNYATGNL (SEQ ID NO 78), GVNYATGNL (SEQ ID NO 79), NLPGCSFSI (SEQ ID NO 80) and LPGCSFSI (SEQ ID NO 81).  
       [0066] Even more particularly, the present invention relates to the use of polypeptides as described above for the preparation of an ICV immunogenic composition.  
       [0067] The present invention thus also contemplates a polypeptide as defined above comprising or consisting of at least 8 to about 20 contiguous amino acids selected from the region comprised between amino acid positions 145 to 164 of the core region of HCV:  
       [0068] NH 2 -GGX 25 X 26 X 27 X 28 LX 29 HGVRX 30 X 31 X 32 DGX 33 NX 34 -COOH (SEQ ID NO 52),  
       [0069] and more particularly selected from GGAARALAHGVRVLEDGVNY (SEQ ID NO 12=peptide CORE 25) or GGVAARALAHGVRVLEDGVNY (SEQ ID NO 118), and with said contiguous amino acids containing a T-cell stimulating epitope, and provided that said polypeptide is different from any known T cell epitope containing HCV peptide or polypeptide described from any of the above-mentioned regions. The latter known HCV polypeptides and peptides are described for screening for B cell epitopes. Preferentially said peptides according to the invention are chosen from the following list of peptides:  
       [0070] NH 2 -X 28 LX 29 HGVRX 30 X 31 -COOH (SEQ ID NO 82), NH 2 -LX 29 HGVRX 30 X 31 -COOH (SEQ ID NO 83), NH 2 -GVRX 30 X 31 X 32 DGX 33 -COOH (SEQ ID NO 84),  
       [0071] NH 2 -VRX 30 X 31 X 32 DGX 33 -COOH (SEQ ID NO 85),  
       [0072] NH 2 -RX 30 X 31 X 32 DGX 33 NX 34 -COOH (SEQ ID NO 86), and  
       [0073] NH 2 -X 30 X 31 X 32 DGX 33 NX 34 -COOH (SEQ ID NO 87).  
       [0074] Particularly preferred peptides include: ALLAHGVRVL (SEQ ID NO 88), LAHGVRVL (SEQ ID NO 89), VRVLEDGV (SEQ ID NO 90), RVLEDGV (SEQ ID NO 91), VLEDGVNY (SEQ ID NO 92), and LEDGVNY (SEQ ID NO 93).  
       [0075] Even more particularly, the present invention relates to the use of polypeptides as described above for the preparation of an HCV immunogenic composition.  
       [0076] The present invention thus also contemplates a polypeptide as defined above comprising or consisting of at least 8 to about 20 contiguous amino acids selected from the region comprised between amino acid positions 133 to 152 of the core region of HCV:  
       [0077] NH 2 -LX 19 X 20 YIPX 21 X 22 GX 23 PX 24 GGX 25 X 26 X 27 X 28 LX 29 -COOH  
       [0078] (SEQ ID NO 53),  
       [0079] and more particularly selected from LMGYIPLVGAPLGGAARALA (SEQ ID NO 11=peptide CORE 23), and provided that said polypeptide is different from any known T cell epitope containing-HCV peptide or polypeptide described from any of the above-mentioned regions. The latter known ECV polypeptides and peptides are described for screening for B cell epitopes. Preferentially said peptides according to the invention are chosen from the following list of peptides:  
       [0080] NH 2 -LX 19 X 20 YIPX 21 X 22 GX 23 PX 24 GGX 25 -COOH (SEQ ID NO 62),  
       [0081] NH 2 -X 19 X 20 YIPX 21 X 22 GX 23 PX 24 GGX 25 -COOH (SEQ ID NO 63),  
       [0082] NH 2 -YIPX 21 X 22 GX 23 PX 24 -COOH (SEQ ID NO 64),  
       [0083] NH 2 -PX 21 X 22 GX 23 PX 24 -COOH (SEQ ID NO 65),  
       [0084] NH 2 -X 21 X 22 GX 23 PX 24 GGX 25 -COOH (SEQ ID NO 66), and  
       [0085] NH 2 -X 22 GX 23 PX 24 GGX 25 -COOH (SEQ ID NO 68). Prefered peptides chosen from this list include:  
       [0086] LMGYIPLV (SEQ ID NO 69), MGYIPLV (SEQ ID NO 70), YIPLVGAPL (SEQ ID NO 71), IPLVGAPL (SEQ ID NO 72), LVGAPLGGA (SEQ ID NO 94), and VGAPLGGA (SEQ ID NO 95).  
       [0087] Even more particularly, the present invention relates to the use of polypeptides as described above for the preparation of an HCV immunogenic composition.  
       [0088] The present invention thus also contemplates a polypeptide as defined above comprising or consisting of at least 8 to about 20 contiguous amino acids selected from the region comprised between amino acid positions 109 to 128 of the core region of HCV:  
       [0089] NH 2 -X 11 X 12 DPRX 13 X 14 SRNX 15 GX 16 VIDTX 17 TC-COOH (SEQ ID NO 54),  
       [0090] and more particularly selected from PTDPRRRSRNLGKVIDTLTC (SEQ ID NO 9=peptide CORE 19), and provided that said polypeptide is different from any known T cell epitope containing HCV peptide or polypeptide described from any of the above-mentioned regions. The latter known HCV polypeptides and peptides are described for screening for B cell epitopes. Preferentially said peptides according to the present invention are chosen from the following peptides:  
       [0091] NH 2 -NX 15 GX 16 VIDTX 17 -COOH (SEQ ID NO 96) or  
       [0092] NH 2 -X 15 GX 16 VIDTX 17 -COOH (SEQ ID NO 97). Preferential peptides are for instance NLGKVIDTL (SEQ ID NO 98) and LGKVIDTL (SEQ ID NO 117).  
       [0093] Even more particularly, the present invention relates to the use of polypeptides as described above for the preparation of an HCV immunogenic composition.  
       [0094] The present invention thus also contemplates a polypeptide as defined above comprising or consisting of at least a to about 20 contiguous amino acids selected from the region comprised between amino acid positions 73 to 92 of the core region of HCV:  
       [0095] NH 2 -GX 1 X 2 WX 3 X 4 PGX 5 PWPLYX 6 NX 7 GX 8 G-COOH (SEQ ID NO 99),  
       [0096] and more particularly selected from GRTWAQPGYPWPLYGNEGCG (SEQ ID NO 6=peptide CORE 13), and provided that said polypeptide is different from any known T cell epitope containing HCV peptide or polypeptide described from any of the above-mentioned regions. The latter known HCV polypeptides and peptides are described for screening for B cell epitopes. Preferred peptides according to the present invention include for instance peptides further selected from:  
       [0097] NH 2 -X 2 WX 3 X 4 PGX 5 PW-COOH (SEQ ID NO 100) and NH 2 -WX 3 X 4 PGX 5 PW-COOH (SEQ ID NO 101), such as the peptides: TWAQPGYPW (SEQ ID NO 102) and WAQPGYPW (SEQ ID NO 103).  
       [0098] Even more particularly, the present invention relates to the use of polypeptides as described above for the preparation of an HCV immunogenic composition.  
       [0099] The present invention thus also contemplates a polypeptide as defined above comprising or consisting of at least 8 contiguous amino acids selected from the region comprised between amino acids 192 to 234 and 243 to 392 of HCV, more particularly selected from the region comprised between amino acids 192 to 234 and 243 to 383 in the E1 region of HCV characterized by the following sequences:  
       [0100] NH 2 -YQVRNSTGLYHVTDCPNSSIVYEAHDAILHTPGCVPCVREGN (SEQ ID NO 164, spanning positions 192 to 234), and,  
       [0101] TPTVATTRDGKLPATQLRRHIDLLVGSATLCSALYVGDLCGSVQLFTFSPRRHWTTQGCNCS IYPGHITGHRMAWDMMYDNWSPTAALVMAQLLRIPQAILDMIAGAHWGVLAGIAYFSMVGNWA KVLVVLLLFAGVDAETIVSGGQA-COOH (SEQ ID NO 104, spanning positions 243 to 392), or any variant to this sequence derived from another type of HCV as depicted in FIG. 4, wherein said contiguous amino acids containing a T-cell stimulating epitope, and provided that said polypeptide is different from any known T cell epitope containing HCV peptide or polypeptide described from any of the above-mentioned regions. The latter known HCV polypeptides and peptides are described for screening for B cell epitopes.  
       [0102] With said peptide being preferentially different from RMAWDMM spanning positions 317 to 323 and ASRCWVAM spanning positions 235-242.  
       [0103] Even more particularly, the present invention relates to the use of polypeptides as described above for the preparation of an HCV immunogenic composition.  
       [0104] The present invention thus also contemplates a polypeptide as defined above comprising or consisting of at least 8 to about 68 contiguous amino acids selected from the region comprised between amino acids-193 to 234 and 243 to 260 in the E1 region of HCV characterized by the following sequence:  
       [0105] QVRNSTGLYHVTNDCPNSSIVYEAHDAILHTPGCVPCVREGN (SEQ ID NO 165, spanning positions 193 to 234), and, TPTVATTRDGKLPATQLR (SEQ ID NO 105, spanning positions 243 to 260), or any variant to this sequence derived from another type of HCV as depicted in FIG. 4, wherein said contiguous amino acids containing a T-cell stimulating epitope, and provided that said polypeptide is different from any known T cell epitope containing HCV peptide or polypeptide described from any of the above-mentioned regions. The latter known HCV polypeptides and peptides are described for screening for B cell epitopes.  
       [0106] Particularly preferred peptides according to the invention include:  
                                          QVRNSTGLYHVTNDCPNSSI,   (SEQ ID NO 16)                           NDCPNSSIVYEAHDAILHTP,   (SEQ ID NO 17)                       HDAILHTPGCVPCVREGNVS,   (SEQ ID NO 18)                       CVREGNVSRCWVAMTPTVAT, and,   (SEQ ID NO 19)                       AMTPTVATRDGKLPPATQLRR.   (SEQ ID NO 20)          
 
       [0107] Even more particularly, the present invention relates to the use of polypeptides as described above for the preparation of an HCV immunogenic composition.  
       [0108] The present invention thus also contemplates a polypeptide as defined above comprising or consisting of at least 8 to about 80 contiguous amino acids selected from the region comprised between amino acids 253 to 332 in the El region of HCV characterized by the following sequence:  
       [0109] NH 2 -LPATQLRRHIDLLVGSATLCSALYVGDLCGSVQLFTFSPRRH WTTQGCNCSIYPGHITGHRMAWDMMMNWSPTAAL-COOH (SEQ ID NO 106), or any variant to this sequence derived from another type of HCV as depicted in FIG. 4, wherein said contiguous amino acids containing a T-cell stimulating epitope, and provided that said polypeptide is different from any known T cell epitope containing HCV peptide or polypeptide described from any of the above-mentioned regions. The latter known HCV polypeptides and peptides are described for screening for B cell epitopes.  
       [0110] Particularly preferred peptides according to the invention include:  
                                          LPATQLRRHIDLLVGSATLC,   (SEQ ID NO 21)                           LVGSATLCSALYVGDLCGSV,   (SEQ ID NO 22)                       QLFTFSPRRHWTTQGCNCSI,   (SEQ ID NO 23)                       TQGCNCSIYPGHITGHRMAW, and,   (SEQ ID NO 24)                       ITGHRMAWDMMMNWSPTAAL.   (SEQ ID NO 25)          
 
       [0111] Even more particularly, the present invention relates to the use of polypeptides as described above for the preparation of an HCV immunogenic composition.  
       [0112] The present invention thus also contemplates a polypeptide as defined above comprising or consisting of at least 8 to about 68 contiguous amino acids selected from the region comprised between amino acids 325 to 392 in the E1 region of HCV characterized by the following sequence:  
       [0113] NH 2 -MNWSPTAALVMAQLLRIPQAILDMIAGAHWGVLAGIAYFSMVGNW AKVLVVLLLFAGVDAETIVSGGQA-COOH (SEQ ID NO 107), or any variant to this sequence derived from another type of HCV as depicted in FIG. 4, wherein said contiguous amino acids containing a T-cell stimulating epitope, and provided that said polypeptide is different from any known T cell epitope containing HCV peptide or polypeptide described from any of the above-mentioned regions. The latter known HCV polypeptides and peptides are described for screening for B cell epitopes.  
       [0114] Particularly preferred peptides according to the present invention include:  
                                          NWSPTAALVMAQLLRIPQAI,   (SEQ ID NO 26)                           LLRIPQAILDMIAGAHWGVL,   (SEQ ID NO 27)                       AGAHWGVLAGIAYFSMVGNW, and,   (SEQ ID NO 28)                       VVLLLFAGVDAETIVSGGQA.   (SEQ ID NO 29)          
 
       [0115] Even more particularly, the present invention relates to the use of polypeptides as described above for the preparation of an HCV immunogenic composition.  
       [0116] The present invention also contemplates a polypeptide as defined above comprising or Consisting of at least 8 to about 32 contiguous amino acids selected from the region between amino acids 397 to 428, or comprising or consisting of at least 8 to about 68 contiguous amino acids selected from the region between amino acids 571 to 638 in the E2 region of HCV characterized by the following sequences:  
       [0117] NH 2 -X 37 X 3  SX 39 X 40 X 41 X 42 X 43 X 44 X 45 GX 46 X 47 QX 48 X 49 X 50 LX 51 NX 54 NGSWHX 52 NX 53 TALN-COOH (SEQ ID NO 49, spanning positions 397 to 428, see FIG. 4), and, NH 2 -X 55 X 56 X 57 X 58 X 59 X 60 Z 1 Z 2 LX 61 CPTDCFRRKX 62 PX 63 X 64 TYX 65 X 66 CGX 67 GPX 68 X 69 TPRCX 70 X 71 DYPYRLWHYPCTX 72 NX 73 X 74 X 75 FKX 76 RMX 77 VGGVEH-COOH (SEQ ID NO 108, spanning positions 571 to 638, see FIG. 5) wherein X 37 , represents S, A, Q, L, N, Y, R, Y or H, X 38 represents G, S, T, A or R, X 39  represents F, I, L, or V; X 40  represents V, A, or T; X 41  represents S, D or G; X 42  represents L, I, W, F, or M; X 43  represents L, I or F, X 44  represents A, T, D or S; X 4 s represents P, Q, S, R, L, I or T; X 46  represents A, P, or S; X 47  represents K, S, Q, A, or R; X 48  represents N, K, D, or R; X 49  represents V, I, or L; X 50  represents Q, S or Y; X 51  represents I or V; X 52  represents L or I; X 51 represents S or R; and X 54  represents T or S; X 55  represents G or R; X 56  represents G. A, or K, X 57  represents A, V, G, S, or D; X 58 represents G, F, or Y; X 59  represents N, H, R, L, A, or S; X 60  represents T or S; Z 1  represents represents M or I; Z 1  represents D; X 61  represents H, L, V, T, or I; X 62  represents H or Y; X 63  represents D or E; X 64  represents A or T; X 65  represents S, T, I, or L; X 66  represents R or K; X 67 represents S or A, X 68  represents W or L; X 69  represents I or L; X 70  represents L, M or I, X 71  represents V or I; X 72  represents I, V, F, or L; X 73  represents Y or F; X 74  represents T, S or A; X 75 represents I or V; X 76  represents I, V or A, X 77  represents Y or F,  
       [0118] and with said contiguous amino acids containing a T-cell stimulating epitope, and provided that said polypeptide is different from any known T cell epitope containing HCV peptide or polypeptide described from any of the above-mentioned regions. The latter known HCV polypeptides and peptides are described for screening for B cell epitopes.  
       [0119] Even more particularly, the present invention relates to the use of polypeptides as described above for the preparation of an HCV immunogenic composition.  
       [0120] The present invention thus also contemplates a polypeptide as defined above comprising so consisting of at least 8 to about 20 contiguous amino acids selected from the region comprised between amino acid positions 397 to 416 of the E2 region of HCV: NH 2 -X 37 X 38 X 39 X 40 X 41 X 42 X 43 X 44 X 45 CX 46 X 4 -QX 48 X 49 X 50 LX 51 NX 54 -COOH (SEQ ID NO 55), and more particularly selected from SGLVSLFTPGAKQNIQLINT (SEQ ID NO 46 or peptide NS1-7*), and provided that said polypeptide is different from any known T cell epitope containing HCV peptide or polypeptide described from any of the above-mentioned regions. The latter known HCV polypeptides and peptides are described for screening for B cell epitopes.  
       [0121] Even more particularly, the present invention relates to the use of polypeptides as described above for the preparation of an HCV immunogenic composition.  
       [0122] The present invention thus also contemplates a polypeptide as defined above comprising or consisting of at least 8 to about 20 contiguous amino acids selected from the region comprised between amino acid positions 409 to 428 of the E2 region of ICV: NH 2 -QX 45 X 46 X 50 LX 51 NX 54 NGSWHX 52 NX 53 TALN-COOH (SEQ ID No 56)  
       [0123] and more particularly selected from QNIQLINTNGSWHINSTALN (SEQ ID NO 47 or peptide NS1-5′),  
       [0124] and with said contiguous amino acids containing a T-cell stimulating epitope, and provided that said polypeptide is different from any known T cell epitope containing HCV peptide or polypeptide described from any of the above-mentioned regions. The latter known HCV polypeptides and peptides are described for screening for B cell epitopes. Preferentially, the peptides according to the present invention are selected from the following list of peptides:  
       [0125] NH 2 -X 50 LX 51 NX 54 NGSW-COOH (SEQ ID NO 109),  
       [0126] NH 2 -LX 51 NX 54 NGSW-COOH (SEQ ID NO 110),  
       [0127] NH 52 -SWHX 53 NX 52 TAL-COOH (SEQ ID NO 111), and NH 2 -SWHX 52 NX 53 TAL-COOH (SEQ ID NO 112). Prefered peptides include for instance: QLINTNGSW (SEQ ID NO 113), LINIVNC-SW (SEQ ID NO 114), SWHINSTAL (SEQ ID NO 115) and WHINSTAL (SEQ ID NO 116).  
       [0128] Even more particularly, the present invention relates the use of to polypeptides as described above for the preparation of an HCV immunogenic composition.  
       [0129] The present invention thus also contemplates a polypeptide as defined above comprising or consisting of at least 8 to about 20 contiguous amino acids selected from the region comprised between amino acid positions 571 to 638 of the E2 region of HCV: NH 2 -IX 55 X 56 X 57 X 58 NX 59 X 60 Z 1 Z 2 LX 61 CPTDCFRKX 62 PX 63 X 64 TYX 65 X 66 CGX 67 GPX 68 X 69 TPRCX 70 X 71 DYPYRLWHYPCTX 72 NX 73 X 74 X 75 FKX 76 RMX 77 VGGVEH-COOH (SEQ ID NO 108),  
       [0130] and with said contiguous amino acids containing a T-cell stimulating epitope, and provided that said polypeptide is different from any known T cell epitope containing HCV peptide or polypeptide described from any of the above-mentioned regions. The latter known HCV polypeptides and peptides are described for screening for B cell epitopes.  
       [0131] Preferred peptides according to the invention are chosen from the following list of peptides:  
       [0132] X 60 Z 1 Z 2 LX 61 CPTDCF (SEQ ID NO 119)  
       [0133] FRKX 62 PX 63 X 64 TY (SEQ ID NO 120),  
       [0134] X 68 X 69 -TPRCX 70 X 71  (SEQ ID NO 121),  
       [0135] X 70 X 71 DYPYRL (SEQ ID NO 122),  
       [0136] X 71 DYPYRLW (SEQ ID NO 123),  
       [0137] YPYRLWHY (SEQ ID NO 124),  
       [0138] LWHYPCTX 72  (SEQ ID NO 125),  
       [0139] X 72 NX 73 X 74 X 75 FKX 76  (SEQ ID NO 126),  
       [0140] X 73 X 74 X 75 FKX 76 RM (SEQ ID NO 127),  
       [0141] X 75 FKX 76 RMX 77 V (SEQ ID NO 128),  
       [0142] X 76 PMX 77 VGGV (SEQ ID NO 129),  
       [0143] IX 55 X 56 X 57 X 58 NX 59 X 60 Z 1 Z 2 LX 61 CPTDCFRKX 62 P (SEQ ID NO 130),  
       [0144] TDCFRKX 62 PX 63 X 64 TYX 65 X 66 CGX 67 GPX 68  (SEQ ID NO 131),  
       [0145] X 65 X 66 CGX 67 GPX 68 X 69 TPRCX 70 X 71 DYPYR (SEQ ID NO 132),  
       [0146] CX 70 X 71 DYPYRLWHYPCTX 72 NX 73 X 74 X 75 (SEQ ID NO 133),  
       [0147] PCTX 72 NX 73 X 74 X 75 FKX 76 RMX 77 VGGVEH (SEQ ID NO 134)  
       [0148] More preferentially, !the peptides according to the present invention are selected from the following list of peptides:  
                                          IGGAGNNTLHCPTDCFRKHP,   (SEQ ID NO 41)                           TDCFRKHPDATYSRCGSGPW,   (SEQ ID NO 42)                       SRCGSGPWITPRCLVDYPYR,   (SEQ ID NO 43)                       CLVDYPYRLWHYPCTINYTI, and,   (SEQ ID NO 44)                       PCTINYTIFKIRMYVGGVEH.   (SEQ ID NO 45)          
 
       [0149] With said peptides being preferentially different from PDCFRKHP spanning positions 582 to 590 and YPYRLWH spanning positions 611 to 617.  
       [0150] Even more particularly, the present invention relates the use of to polypeptides as described above for the preparation of an HCV immunogenic composition.  
       [0151] The present invention thus also contemplates a polypeptide as defined above comprising or consisting of at least 8 to about 20 contiguous amino acids selected from the region comprised between amino acid positions 1188 to 1463 of the NS3 region of HCV characterized by the following sequence: NH 2 -GVAKAVDFVPVESMETTMRSPVFTDNSSPPAVPQTFQVA HLHAPTGSGKSTKVPAAYAAQGYKVLVLNPSVAATLGFGAYMSKAHGVDPNIRTGVRTITTG APITYSTYGKFLADGGCSGGAYDIIICDECHSIDSTSILGIGTVLDQAETAGARLVVLATAT PPGSVTVPHPNIEEVALSSTGEIPFYGKAIPIEVIXGGRHLIFCHSKKKCDELAAKLSGFGI NAVAYYRGLDVSVIPTSGDVVVVATDALMTGFTGDFDSVIDCNTCVTQTVDFS-COOH (SEQ ID NO 57), or any variant of said sequence as can be deduced from FIG. 6, and with said contiguous amino acids containing a T-cell stimulating epitope, and provided that said polypeptide is different from any known T cell epitope containing HCV peptide or polypeptide described from any of the above-mentioned regions. The latter known HCV polypeptides and peptides are described for screening for B cell epitopes.  
       [0152] Preferentially said peptides are chosen from the following list of peptides: VAKAVDFV (SEQ ID NO 135), VAKAVDFI (SEQ ID NO 136), VESMETTM (SEQ ID NO 137), AVPQTFQV (SEQ ID NO 138), YAAQGYKV (SEQ ID NO 139), VLVLNPSVA (SEQ ID NO 140), YMSKAHGV (SEQ ID NO 141), IRTGVRTI (SEQ ID NO 142), YSTYGKFL (SEQ ID NO 143), ILGIGTVL (SEQ ID NO 144), VTVPHPNI (SEQ ID NO 145), IPFYGKAI (SEQ ID NO 146), FYGKAIPI (SEQ ID NO 147), VIKGGRHL (SEQ ID NO 148), IKGGRHLI (SEQ ID NO 149), FCHSKKKC (SEQ ID NO 150), CDELAAKL (SEQ ID NO 151), LAAKLSGFG (SEQ ID NO 152), SGFGINAV (SEQ ID NO 153), FGINAVAY (SEQ ID NO 154), YRGLDVSV (SEQ ID NO 155), VIPTSGDV (SEQ ID NO 156), IPTSGDVV (SEQ ID NO 157), VVVATDAL (SEQ ID NO 158), VVATDALM (SEQ ID NO 159), MTGFTGDF (SEQ ID NO 160), FTGDFDSV (SEQ ID NO 161), KLVALGINAV (SEQ ID NO 166), VIDCNTCV (SEQ ID NO 162), or any variant of said sequence as can be deduced from FIG. 6.  
       [0153] With said peptides being preferentially different from GKSTKVP, PSVAAT, IGTVLIDQAE, AVAYYR and TGDFDSVID.  
       [0154] The present invention relates more particularly to any of the above-mentioned polypeptides wherein said T cell stimulating epitope is a T cell helper epitope.  
       [0155] According to another embodiment, the present invention relates to any of the above-mentioned polypeptides wherein T cell stimulating epitope is a CTL epitope.  
       [0156] The present invention also relates to the incorporation of any of the above-mentioned polypeptides into a prophylactic vaccine composition.  
       [0157] According to another embodiment, the present invention relates to the incorporation of any of the above-mentioned polypeptides into a therapeutic vaccine composition.  
       [0158] Moreover, the present invention also contemplates a polypeptide comprising or consisting of multiple repeats of any of the polypeptides as defined above, combinations of any of the polypeptides as defined above, or mimotopes of the peptides as defined above.  
       [0159] The term “mimotopes” refers to peptides which mimic the polypeptides as defined above immunologically. Since sequence variability has been observed fro HCV, it may be desirable to vary one or more amino acids so as to better mimic the epitopes of different strains. It should be understood that such mimotopes need not be identical to any particular HCV sequence as long as the subject compounds are capable of providing for immunological stimulation after which the T cells are reactive with at least one strain of HCV. The polypeptides as described above, may therefore be subject to insertions, deletions and conservative as well as non-conservative amino acid subtitutions where such changes might provide for certain advantages in their use. The peptides will preferably be as short as possible while still maintaining all of their sensitivity of the larger sequence. In certain cases, it may be desirable to join two or more peptides into a single structure. The formation of such a composite-may involve covalent or non-covalent linkages.  
       [0160] The present invention also contemplates a polypeptide as defined above, with said polypeptide being a recombinant polypeptide expressed by means of an expression vector comprising a nucleic acid insert encoding a polypeptide as defined above.  
       [0161] In order to carry out the expression of the T-cell containing polypeptides of the invention in bacteria such as  E. coli  or in eukaryotic cells such as in  S. cerevisiae , or in cultured vertebrate or invertebrate hosts such as insect cells, Chinese Hamster Ovary (CHO), COSI, BHK, and MDCK cells, the following steps are carried out:  
       [0162] transformation of an appropriate cellular host with a recombinant vector, or by means of adenoviruses, influenza viruses, BCG, and any other live carrier systems, in which a nucleotide sequence coding for one of the polypeptides of the invention has been inserted under the control of the appropriate regulatory elements, particularly a promoter recognized by the polymerases of the cellular host or of the live carrier system and in the case of a prokaryotic host, an appropriate ribosome binding site (RBS), enabling the  
       [0163]  expression in said cellular host of said nucleotide sequence,  
       [0164] culture of said transformed cellular host under conditions enabling the expression of said insert. Recombinant virus or live carrier vectors may also be directly used as live vaccines in humans.  
       [0165] According to a preferred embodiment, the present invention contemplates a polypeptide as defined above which is operably linked to a pathogen related immunogen such as the HCV core protein, the HCV envelope proteins E1 and E2, or the HCV NS3, NS4 or NS5 immunogens, or a HCV peptide containing a B cell epitope.  
       [0166] The phrase “operatively linked” as used herein means that the linkage does not interfere with the ability of either of the linked groups to function as described; e.g., to function as a T or B cell determinant. Thus, operatively linking not only includes covalent linkages, but also includes linkages capable of inducing T cell function.  
       [0167] The phrase “pathogen related” as used herein designates a polypeptide that is capable of inducing the T cell function that immunoreacts with a pathogen in native form.  
       [0168] The defined polypeptides can be employed as such or in combination with HCV B cell epitopes, EBsAg or HBcAg particles, HIV immunogens, HTLV immunogens. HCV peptides containing preferred B cell epitopes are detailed in for instance EP-A-0 489 968 and WO 93/18054.  
       [0169] Methods for operatively linking individual polypeptides through an amino acid residue side chain to form an immunogenic conjugate, i.e., a branched-chain polypeptide polymer, are well known in the art. Those methods include linking through one or more types of functional groups on various side chains and result in the respective polypeptide backbones being covalently linked (coupled) but separated by at least one side chain. Useful side chain functional groups include epsilon-amino groups, beta- or gamma-carboxyl groups, thiol (—SH) groups and aromatic rings (e.g. tyrosine and histidine). Methods for linking polypeptides using each of the above functional groups are described in Erlanger (1980), Aurameas et al. (1978) and U.S. Pat. No. 4,493,795 to Nestor et al. In addition, a site-directed coupling reaction, as described in Rodwell et al. (1985), can be carried out so that the biological activity of the polypeptides is not substantially diminished.  
       [0170] Furthermore, as is well known in the art, the HBcAg protein and polypeptide immunogen can be used in their native form or their functional group content may be modified by succinylation of lysine residues or reaction with cysteine-thiolactone. A sulfhydryl group may also be incorporated into either polypeptide by reaction of amino functions with 2-iminothiolane or the N-hydroxysuccinimide ester of 3-(3-dithiopyridyl) propionate. The polypeptides can also be modified to incorporate spacer arms, such as hexamethylene diamine or other bifunctional molecules of similar size, to facilitate linking.  
       [0171] Any polypeptide immunogen against which antibody production is desired can be linked to the polypeptide of the present invention protein to form an immunogenic conjugate of this invention. In preferred embodiments the polypeptide immunogen is a pathogen related immunogen and the conjugate has the capacity to induce the production of antibodies that immunoreact with the pathogen when injected in an effective amount into an animal. Exemplary immunogens of particular importance are derived from bacteria such as  B. pertussis. S. typosa. S. Paratyphoid  A and B,  C. diztheriae. C. tetani. C. botulinum. C. perfringens. B. anthracis. P. Destis. P. multocida. V. cholerae. N. meningitides. N. Gonorrhea. H. influenzae, T. palladium,  and the like; immunogens derived from viruses such as polio virus, adenovirus, parainfluenza virus, measles, mumps, respiratory syncytical virus, influenza virus, equine encephalomyeitis virus, hog chloera virus, Newcastle vieus, fowl pox virus, rabies virus, feline and canine distemper viruses, foot and mouth disease virus, human and simian immunodeficiency viruses, and the like; rickettsiae immunogen such as epidemic and endemic typhus, and the spotted fever groups, and the like. Immunogens are well known to the prior art in numerous references such as U.S. Pat. No. 3,149,036, No. 3,983,228, and No. 4,069,313 ; in Essential Immunology,  3rd Ed., by Roit, published by Blackwell Scientific Publications; in  Fundamentals of Clinical Immunolog,  by Alexander and Good, published by W. B. Saunders; and in  Immunology,  by Bellanti, published by W. B. Saunders. Particularly preferred pathogen related immunogens are those described in U.S. Pat. No. 4,625,015, No. 4,544,500, No. 4,545,931, No. 4,663,436, No. 4,631,191, No. 4,629,783 and in Patent Cooperation Treaty International Publication No. WO87/02775 and No. WO87/02892, all of whose disclosures are incorporated herein by reference.  
       [0172] The present invention relates particularly to any of the following peptides or any peptide comprised in the sequence of any of the following peptides, with said peptides containing a T cell epitope:  
                              NH 2 -X 30 X 31 X 32 DGX 33 NX 34 X 35 TGNX 36 PGCSFSI-COOH,   (SEQ ID NO 51)                   VLEDGVNYATGNLPGCSFSI,   (SEQ ID NO 13 = peptide CORE 27)               VLEDIVNYATGNLPGCSFSI,   (SEQ ID NO 73)               NH 2 -GX 33 NX 34 X 35 TGNX 36 -COOH,   (SEQ ID NO 74)               NH 2 -X 33 NX 34 X 35 TGNX 36 -COOH,   (SEQ ID NO 75)               NH 2 -NX 36 PGCSFSI-COOH,   (SEQ ID NO 76)               NH 2 -X 36 PGCSFSI-COOH,   (SEQ ID NO 77)               GVNYATGNL,   (SEQ ID NO 78)               GVNYATGNL,   (SEQ ID NO 79)               NLPGCSFSI,   (SEQ ID NO 80)               LPGCSFSI,   (SEQ ID NO 81)               NH 2 -GGX 25 X 26 X 27 X 28 LX 29 HGVRX 30 X 31 X 32 DGX 33 NX 34 -COOH,   (SEQ ID NO 52)               GGAARALAHGVRVLEDGVNY,   (SEQ ID NO 12 = peptide CORE 25)               GGVAARALAHGVRVLEDGVNY,   (SEQ ID NO 118)               NH 2 -X 28 LX 29 HGVRX 30 X 31 -COOH,   (SEQ ID NO 82)               NH 2 -LX 29 HGVRX 30 X 31 -COOH,   (SEQ ID NO 83)               NH 2 -GVRX 30 X 31 X 32 DGX 33 -COOH,   (SEQ ID NO 84)               NH 2 -VRX 30 X 31 X 32 DGX 33 -COOH,   (SEQ ID NO 85)               NH 2 -RX 30 X 31 X 32 DGX 33 NX 34 -COOH,   (SEQ ID NO 86)               NH 2 -X 30 X 31 X 32 DGX 33 NX 34 -COOH,   (SEQ ID NO 87)               ALAHGVRVL,   (SEQ ID NO 88)               LAHGVRVL,   (SEQ ID NO 89)               VRVLEDGV,   (SEQ ID NO 90)               RVLEDGV,   (SEQ ID NO 91)               VLEDGVNY,   (SEQ ID NO 92)               LEDGVNY,   (SEQ ID NO 93)               NH 2 -LX 19 X 20 YIPX 21 X 22 GX 23 PX 24 GGX 25 X 26 X 27 X 28 LX 29 -COOH,   (SEQ ID NO 53)               LMGYIPLVGAPLGGAARALA,   (SEQ ID NO 11 = peptide CORE 23)               NH 2 -LX 19 X 20 YIPX 21 X 22 GX 23 PX 24 GGX 25 -COOH,   (SEQ ID NO 62)               NH 2 -X 19 X 20 YIPX 21 X 22 GX 23 PX 24 GGX 25 -COOH,   (SEQ ID NO 63)               NH 2 -YIPX 21 X 22 GX 23 PX 24 -COOH,   (SEQ ID NO 64)               NH 2 -IPX 21 X 22 GX 23 PX 24 -COOH,   (SEQ ID NO 65)               NH 2 -X 21 X 22 GX 23 PX 24 GGX 25 -COOH,   (SEQ ID NO 66)               NH 2 -X 22 GX 23 PX 24 GGX 25 -COOH,   (SEQ ID NO 68)               LMGYIPLV,   (SEQ ID NO 69)               MGYIPLV,   (SEQ ID NO 70)               YIPLVGAPL,   (SEQ ID NO 71)               IPLVGAPL,   (SEQ ID NO 72)               LVGAPLGGA,   (SEQ ID NO 94)               VGAPLGGA,   (SEQ ID NO 95)               NH 2 -X 11 X 12 DPRX 13 X 14 SRNX 15 GX 16 VIDTX 17 TC-COOH,   (SEQ ID NO 54)               PTDPRRRSRNLGKVIDTLTC,   (SEQ ID NO 9 = peptide CORE 19)               NH 2 -NX 15 GX 16 VIDTX 17 -COOH,   (SEQ ID NO 96)               NH 2 -X 15 GX 16 VIDTX 17 -COOH,   (SEQ ID NO 97)               NLGKVIDTL,   (SEQ ID NO 98)               LGKVIDTL,   (SEQ ID NO 117)               NH 2 -GX 1 X 2 WX 3 X 4 PGX 5 PWPLYX 6 NX 7 GX 8 G-COOH,   (SEQ ID NO 99)               GRTWAQPGYPWPLYGNEGCG,   (SEQ ID NO 6 = peptide CORE 13)               NH 2 -X 2 WX 3 X 4 PGX 5 PW-COOH,   (SEQ ID NO 100)               NH 2 -WX 3 X 4 PGX 5 PW-COOH,   (SEQ ID NO 101)               TWAQPGYPW,   (SEQ ID NO 102)               WAQPGYPW,   (SEQ ID NO 103)               QVRNSTGLYHVTNDCPNSSI,   (SEQ ID NO 16)               NDCPNSSIVYEAHDAILHTP,   (SEQ ID NO 17)               HDAILHTPGCVPCVREGNVS,   (SEQ ID NO 18)               CVREGNVSRCWVAMTPTVAT,   (SEQ ID NO 19)               AMTPTVATRDGKLPPATQLRR,   (SEQ ID NO 20)               LPATQLRRHIDLLVGSATLC,   (SEQ ID NO 21)               LVGSATLCSALYVGDLCGSV,   (SEQ ID NO 22)               QLFTFSPRRHWTTQGCNCSI,   (SEQ ID NO 23)               TQGCNCSIYPGHITGHRMAW,   (SEQ ID NO 24)               ITGHRMAWDMMMNWSPTAAL,   (SEQ ID NO 25)               NWSPTAALVMAQLLRIPQAI,   (SEQ ID NO 26)               LLRIPQAILDMIAGAHWGVL,   (SEQ ID NO 27)               AGAHWGVLAGIAYFSMVGNW,   (SEQ ID NO 28)               VVLLLFAGVDAETIVSGGQA,   (SEQ ID NO 29)               NH 2 -X 37 X 38 X 39 X 40 X 41 X 42 X 43 X 44 X 45 GX 46 X 47 QX 48 X 49 X 50 LX 51 NX 54 -COOH,   (SEQ ID NO 55)               SGLVSLFTPGAKQNIQLINT,   (SEQ ID NO 46)               NH 2 -QX 48 X 49 X 50 LX 51 NX 54 NGSWHX 52 NX 53 TALN-COOH,   (SEQ ID NO 56)               NH 2 -X 50 LX 51 NX 54 NGSW-COOH,   (SEQ ID NO 109)               NH 2 -LX 51 NX 54 NGSW-COOH,   (SEQ ID NO 110)               NH 2 -SWHX 52 NX 53 TAL-COOH,   (SEQ ID NO 111)               NH 2 -SWHX 52 NX 53 TAL-COOH,   (SEQ ID NO 112)               QLINTNGSW,   (SEQ ID NO 113)               LINTNGSW,   (SEQ ID NO 114)               SWHINSTAL,   (SEQ ID NO 115)               WEINSTAL,   (SEQ ID NO 116)               GGAGNNTLHCPTDCFRKHP,   (SEQ ID NO 41)               TDCFRKHPDATYSRCGSGPW,   (SEQ ID NO 42)               SRCGSGPWITPRCLVDYPYR,   (SEQ ID NO 43)               CLVDYPYRLWHYPCTINYTI,   (SEQ ID NO 44)               PCTINYTIFKIRMYVGGVEH,   (SEQ ID NO 45)               X 60 Z 1 Z 2 LX 61 CPTDCF,   (SEQ ID NO 119)               FRKX 62 PX 63 X 64 TY,   (SEQ ID NO 120)               X 68 X 69 -TPRCX 70 X 71 ,   (SEQ ID NO 121)               X 70 X 71 DYPYRL,   (SEQ ID NO 122)               X 71 DYPYRLW,   (SEQ ID NO 123)               YPYRLWHY,   (SEQ ID NO 124)               LWHYPCTX 72 ,   (SEQ ID NO 125)               X 72 NX 73 X 74 X 75 FKX 76 ,   (SEQ ID NO 126)               X 73 X 74 X 75 FKX 76 RM,   (SEQ ID NO 127)               X 75 FKX 76 RMX 77 V,   (SEQ ID NO 128)               X 76 RMX 77 VGGV,   (SEQ ID NO 129)               IX 55 X 56 X 57 X 58 NX 59 X 60 Z 1 Z 2 LX 61 CPTDCFRKX 62 P,   (SEQ ID NO 130)               TDCFRKX 62 PX 63 X 64 TYX 65 X 66 CGX 67 GPX 68 ,   (SEQ ID NO 131)               X 65 X 66 CGX 67 GPX 68 X 69 TPRCX 70 X 71 DYPYR,   (SEQ ID NO 132)               CX 70 X 71 DYPYRLWHYPCTX 72 NX 73 X 74 X 75 ,   (SEQ ID NO 133)               PCTX 72 NX 73 X 74 X 75 FKX 76 RMX 77 VGGVEH.   (SEQ ID NO 134)          
 
       [0173] VAKAVDFV (SEQ ID NO 135), VAKAVDFI (SEQ ID NO 136), VESMETTM (SEQ ID NO 137), AVPQTFQV (SEQ ID NO 138), YAAQGYKV (SEQ ID NO 139), VLVLNPSVA (SEQ ID NO 140), YMSKAHGV (SEQ ID NO 141), IRTGVRTI (SEQ ID NO 142), YSTYGKFL (SEQ ID NO 143), ILGIGTVL (SEQ ID NO 144), VTVPHPNI (SEQ ID NO 145), IPFYGKAI (SEQ ID NO 146), FYGKAIPI (SEQ ID NO 147), VIKGGRHL (SEQ ID NO 148), IKGGRHLI (SEQ ID NO 149), FCHSKKKC (SEQ ID NO 150), CDELAAKL (SEQ ID NO 151), LAAKLSGFG (SEQ ID NO 152), SGFGINAV (SEQ ID NO 153), FGINAVAY (SEQ ID NO 154), YRGLDVSV (SEQ ID NO 155), VIPTSGDV (SEQ ID NO 156), IPTSGDVV (SEQ ID NO 157), VVVATDAL (SEQ ID NO 158), VVATDALM (SEQ ID NO 159), MTGFTGDF (SEQ ID NO 160), FTGDFDSV (SEQ ID NO 161), VIDCNTCV (SEQ ID NO 162).  
       [0174] Moreover, the present invention contemplates an immunogenic composition consisting of or comprising at least one of the polypeptides as defined above mixed with a pharmaceutical acceptable excipient.  
       [0175] Before administration to patients, formulants may be added to the polypeptides or peptides of the invention. A liquid formulation is preferred. For example, these formulants may include oils, polymers, vitamins, carbohydrates, amino acids, salts, buffers, albumin, surfactants, or bulking agents. Preferably carbohydrates include sugar or sugar alcohols such as mono, di, or polysaccharides, or water soluble glucans. The saccharides or glucans can include fructose, dextrose, lactose, glucose, mannose, sorbose, xylose, maltose, sucrose, dextran, pullulan, dextrin, alpha and beta cyclodextrin, soluble starch, hydroxethyl starch and carboxymethylcellulose, or mixtures thereof. Sucrose is most preferred. “Sugar alcohol” is defined as a C4 to C8 hydrocarbon having an —OH group and includes galactitol, inositol, mannitol, xylitol, sorbitol, glycerol, and arabitol. Mannitol is most preferred. These sugars or sugar alcohols mentioned above may be used individually or in combination. There is no fixed limit to amount used as long as the sugar or sugar alcohol is soluble in the aqueous preparation. Preferably, the sugar or sugar alcohol concentration is between 1.0 w/v % and 7.0 w/v %, more preferable between 2.0 and 0.0 wave. Preferably amino acids include levorotary (L) forms of carnitine, arginine, and betaine; however, other amino acids may be added. Preferred polymers include polyvinylpyrrolidone (PVP) with an average molecular weight between 2,000 and 3,000, or polyethylene glycol (PEG) with an average molecular weight between 3,000 and 5,000. It is also preferred to use a buffer in the composition to minimize pH changes in the solution before lyophilization or after reconstitution. Most any physiological buffer may be used, but citrate, phosphate, succinate, and glutamate buffers or mixtures thereof are preferred. Most preferred is a citrate buffer. Preferably, the concentration is from 0.01 to 0.3 molar. Surfactants that can be added to the formulation are shown in EP patent applications No. EP 0 270 799 and EP 0 268 110.  
       [0176] Additionally, polypeptides can be chemically modified by covalent conjugation to a polymer to increase their circulating half-life, for example. Preferred polymers, and methods to attach them to peptides, are shown in U.S. Pat. Nos. 4,766,106; 4,179,337; 4,495,285; and 4, 609, 546. Preferred polymers are polyoxyethylated polyols and polyethylene glycol (PEG). PEG is soluble in water at room temperature and has the general formula: R(O—CH 2 —CH 2 ) n O—R where R can be hydrogen, or a protective group such as an alkyl or alkanol group. Preferably, the protective group has between 1 and 8 carbons, more preferably it is methyl. The symbol n is a positive integer, preferably between 1 and 1,000, more preferably between 2 and 500. The PEG has a preferred average molecular weight between 1000 and 40,000, more preferably between 2000 and 20,000, most preferably between 3,000 and 12,000. Preferably, PEG has at least one hydroxy group, more preferably it is a terminal hydroxy group. It is this hydroxy group which is preferably activated. However, it will be understood that the type and amount of the reactive groups may be varied to achieve a covalently conjugated PEG/polypeptide of the present invention.  
       [0177] Water soluble polyoxyethylated polyols are also useful in the present invention. They include polyoxyethylated sorbitol, polyoxyethylated glucose, polyoxyethylated glycerol (POG), etc. POG is preferred. One reason is because the glycerol backbone of polyoxyethylated glycerol is the same backbone occurring naturally in, for example, animals and humans in mono-, di-, triglycerides. Therefore; this branching would not necessarily be seen as a foreign agent in the body. The POG has a preferred molecular weight in the same range as PEG. The structure for POG is shown in Knauf et al., 1988, and a discussion of POG/IL-2 conjugates is found in U.S. Pat. No. 4,766,106.  
       [0178] Another drug delivery system for increasing circulatory half-life is the liposome. Methods of preparing liposome delivery systems are discussed in Gabizon et al., 1982; and Szoka, 1980. Other drug delivery systems are known in the art and are described in, e.g. Poznansky, 1984.  
       [0179] After the liquid pharmaceutical composition is prepared, it is preferably lyophilized to prevent degradation and to preserve sterility. Methods for lyophilizing liquid compositions are known to those of ordinary skill in the art. Just prior to use, the composition may be reconstituted with a sterile diluent (Ringer&#39;s solution, distilled water, or sterile saline, for example) which may include additional ingredients. Upon reconstitution, the composition is preferably administered to subjects using those methods that are known to those skilled in the art.  
       [0180] As stated above, the polypeptides and compositions of this invention are used to treat human patients to prevent or treat any of the above-defined disease states. The preferred route of administration is parenterally. In parenteral administration, the compositions of this invention will be formulated in a unit dosage injectable form such as a solution, suspension or emulsion, in association with a pharmaceutically acceptable parenteral vehicle. Such vehicles are inherently nontoxic and nontherapeutic. Examples of such vehicles are saline, Ringer&#39;s solution, dextrose solution, and Hanks, solution. Nonaqueous vehicles such as fixed oils and ethyl oleate may also be used. A preferred vehicle is 5% dextrose in saline. The vehicle may contain minor amounts of additives such as substances that enhance isotonicity and chemical stability, including buffers and preservatives.  
       [0181] The dosage and mode of administration will depend on the individual.  
       [0182] More particularly, the present invention contemplates a composition as defined above for use in a method of immunizing against HCV, comprising administrating a sufficient amount of at least one of the polypeptides as defined above, possibly accompanied by pharmaceutically acceptable adjuvants, to produce an immune response.  
       [0183] More particularly, said immunogenic composition is a vaccine composition. Even more particularly, said vaccine composition is a prophylactic vaccine composition. Alternatively, said vaccine composition may also be a therapeutic vaccine composition.  
       [0184] The prophylactic vaccine composition refers to a vaccine composition aimed for preventing HCV infection and to be administered to normal persons who are not yet infected with HCV.  
       [0185] The therapeutic vaccine composition refers to a vaccine composition aimed for treatment of HCV infection and to be administered to patients being infected with HCV.  
       [0186] The polypeptides described in the present invention can be modified with lipid (lipopeptides, e.g. PAM 3 Cys), and formulated with alum, monophosphoryl lipid A, pluronics, SAFl, Ribi, trehalose-6,6-dimycolate or other immunostimulating compounds known to those skilled in the art, as to enhance their immunogenicity.  
       [0187] Also, the present invention contemplates according to a preferred embodiment, a composition as defined above, with said composition comprising in addition to any of the T cell-stimulating polypeptides as defined above, a peptide or polypeptide containing at least one B-cell epitope of HCV, and/or a structural HCV polypetide, and/or a non-structural HCV polypeptide.  
       [0188] According to a yet other preferred embodiment, the present invention contemplates a composition as defined above for use in a method of treatment of HCV, comprising administrating a sufficient amount of at least one of the polypeptides as defined above, possibly accompanied by pharmaceutically acceptable adjuvants, to allow treatment of HCV infection. In this case the polypeptides of the present invention can be employed in the form of therapeutic vaccine, aiming at the induction of a sufficient level of T cell function for clearance of Hepatitis C virus infection.  
       [0189] According to yet another preferred embodiment, the present invention contemplates a composition as defined above, with said composition comprising in addition to any of the polypeptides as defined above, a peptide or polypeptide containing at least one B-cell epitope of HCV, and/or a structural HCV 4polypeptide, and/or a non-structural HCV polypeptide.  
       [0190] According to yet another embodiment, the present invention contemplates a composition wherein said polypeptides as defined above are mixed with HBsAg or HBcAg paricles, HBV immunogens, HIV immunogens and/or HTLV immunogens. 
     
    
    
     FIGURE LEGENDS  
     [0191]FIG. 1: Evolution of the lymphoproliferative responses and transaminase activities in HCV patient No. 632. AST depicts aspartate aminotransferase, ALT depicts alanine aminotransferase; SI: simulation index; P1 to P6 refers to the groups of peptides 1 to 6 as disclosed in Table 1.  
     [0192]FIG. 2: Frequencies of lymphoproliferation responses to peptide pools 1-9, single peptides NS1-7*, NS1-5* and recombinant NS3 protein in healthy controls, interferon (IFN) responders and IFN non-responders.  
     [0193]FIG. 3: represents the part of the sequence of the isolate IG8309 which has been tested, with said part extending from with Gly at position 41 to Ser at position 318 (SEQ ID NO 57).  
     [0194]FIG. 4: represents an alignment of the HCV structural regions.  
     [0195]FIG. 5. Alignment of E2 region spanning amino acid positions 571 to 638.  
     [0196]FIG. 6. Aligment of NS3 sequences spanning amino acid positions 1188 to 1465. 
    
    
     EXAMPLES  
     Example 1  
     Patients studied  
     [0197] The patients studied consisted of 19 males and 13 females, aged between 27 and 71 (mean age: 49.9 years). The diagnosis of chronic HCV hepatitis was based on a) a documented elevation of alanine aminotransferase of 2 times the upper limit of normal for at least six months; b) the presence of HCV-specific serum antibodies detected by two second generation enzyme immunoassay tests (UBI test and Innotest HCV AbII, Innogenetics, Antwerp Belgium) and c) absence of clinical, histological or serological signs of other viral, toxic, metabolic, hereditary or auto-immune hepatitis. The patients were randomized to receive either the standard treatment consisting of 3 million units Interferon α-2b (INTRON A) given thrice weekly for 24 weeks or an experimental treatment consisting of an induction phase of 6 million units Interferon α-2b thrice weekly for eight weeks, followed by a maintenance phase of titrated doses of interferon of 6 to 1 million units thrice weekly until biochemical and virological remission (alanine aminotransferase activity normal, plasma hepatitis C virus-RNA undetectable) was achieved. Patients were considered clinical responders when a normalization of alanine aminotransferase activity was observed on at least two successive control visits during treatment with al least one month interval.  
     [0198] As controls for the specificity of the lymphoproliferative responses, 18 healthy individuals aged 25-58 years (mean 38.6), 10 males and 8 females were selected. These subjects were negative for HCV antibodies and HCV-RNA. One subject had a history of past hepatitis B virus infection and 7 had antibodies to HBsAg as a result of vaccination.  
     [0199] A liver biopsy was-performed in all patients prior to the initiation of Interferon-α therapy. The histological status was defined according to conventional histological classification (Knodell et al., 1981).  
     [0200] Based on the definition of clinical responders given above, 18 subjects could be considered clinical responders to Interferon-α. The most relevant clinical, pathological and virological data of both groups are summarized in Table 2. Although the responder group contained more women and the non-responder group more men than theoretically expected, the observed imbalances were not significant (X 2 -test). The duration of the disease in each subject was estimated based on anamnestic data (surgery with multiple transfusions, intravenous drug abuse, professional exposure through needle stick accident, etc.) or patient file data displaying chronically fluctuating and elevated transaminase levels. The disease duration varied from one to 32 years. The mean disease duration was 9.2±9.2 years in responders and 6.8±5.4 years in non-responders. Although the responder group contained more subjects treated with the experimental protocol and the non-responder group more subjects treated with the standard protocol, the imbalance was not significant X 2 -test). Twenty six out of 32 patients (81a) were infected with HCV of genotype 1b. The genotypes 3a, 4a and 5a were found in 4, 1 and 1 subject, respectively. Anamnestic data allowed us to retrieve the source of infection. Blood transfusions are the possible source of the HCV infection in 14 subjects, IV drug abuse in 3 patients and needle stick accidents in 3 others. No source of infection could be traced back in 12 subjects. Most patients (20 out of 32) showed pathological lesions compatible with chronic active hepatitis in a mild, moderate or severe form. Seven patients displayed signs of chronic persistent hepatitis. In two subjects the biopsy showed only aspecific lesions and in two others signs of liver cirrhosis were observed.  
     Example 2  
     Analysis of the Humoral Immune Response  
     [0201] INNO-LIA HCV AbII (Innogenetics, Belgium) was employed to detect antibodies to peptide epitopes from the core, NS4a+b and NS5a region. From each patient a serum sample obtained before the start of the interferon therapy was examined and sometimes, additional follow-up samples were also tested. All 32 patients studied had circulating antibodies towards HCV demonstrated by two commercially available enzyme immunoassays. Using a peptide-based immunoblot assay (INNO-LIA HCV AbII) we were able to partially define the specificities of these antibodies. Sera from 31 patients were examined at least once with this assay and in 20 subjects the assay was applied on two sera taken with an interval of 4 (Patient 635) to 124 weeks (Patient 606). Table 3 shows the results of this survey. Apart from the reactivity pattern with the antigens employed (4 individually spotted core peptides, a mixture of NS4 peptides defining a fifth line and a selection of NS5 peptides creating a sixth line), Table 3 also shows the HCV genotype and the moment at which the serum was taken with respect to the start of the interferon therapy. The data clearly indicate that the antibody recognition pattern of an individual patient hardly changes over time. The only differences observed in the 20 paired samples were single step alterations in the intensity of the reactions. As well in responders as in non-responders to interferon we observed the same hierarchy in the serological reaction patterns. When indeterminate or weak reactions are not taken into consideration, the following hierarchy appears: Core2&gt;NS4&gt;NS5&gt;Core1&gt;Core4&gt;Core3.  
     Example 3  
     Detection of HCV RNA and HCV Genotyping  
     [0202] Reverse transcription and PCR was performed as described previously (Stuyver et al. 1993). PCR products were further processed for genotyping by means of the Inno-LiPA genotyping assay (Stuyver et al., 1993). The results of the genotyping assays are included in Table 3.  
     Example 4  
     Analysis of the Cellular Immune Response  
     [0203] 4.1. Synthesis of HCV Antigens  
     [0204] Nine groups of peptides (pools) corresponding to-Core, E1 and E2/NS1 sequences, two single peptides not included in these pools corresponding to E2/NS1, and a recombinant protein representing the central part of NS3-HCV genotype 1b, were used for in vitro stimulation of PBMC. Each group pooled 4-6 different 20-mer peptides which overlapped 8 amino acids. Groups 1, 2 and 3 included mainly core peptides with amino acid positions 5-80, 73-140 and 133-200, respectively (Table 1). Groups 4, 5 and 6 predominantly encompassed E1 peptides with amino acid positions 193-260, 253-332 and 325-392, respectively. Groups 7, 8 and 9 comprised E2/NS1 peptides with amino acid positions 427-494, 487-578 and 571-638, respectively. The two additional single peptides (NS1-7′, and NS1-5*) covered amino acids from 397 to 428 of the E2 sequence (Table 1). A fusion protein containing the NS3 sequence was expressed in  E. coli  and covered HCV amino acids 1188 to 1463 of the Belgian isolate IG8309.  
     [0205] Peptides were dissolved in the buffers shown in Table 1 and added to the cultures at a final concentration of 10 μg/ml. At this peptide concentration, the concentration of dissolving buffers in the cell cultures was not toxic or inhibitory. Preliminary experiments were performed to ascertain this. NS3 protein was used at a final concentration of 1.5 μg/ml. Tetanus toxoid (WHO, Copenhagen, Denmark), used as a positive control antigen, was added to the culture media at a final concentration of 10 μg/ml.  
     [0206] All the peptides were synthesized on either PepSyn K resin (Millipore) functionalized with the acid labile linker 4-(a-Fmoc-amino-21,s1-dimethoxybenzyl) phenoxyacetic acid, or TentaGel S-RAM resin (Rapp Polymere) functionalized with the same linker which yields peptide amides upon cleavage. t-Butyl-based side chain protection and Fmoc-a-amino protected amino acid derivatives were used. The guanidino group of arginine was 2,2,5,7,8-pentamethylchroman-6-sulfonyl-protected. The imidazole group of histidine was protected with either t-Boc or trityl and the sulfhydryl group of cysteine was protected with a trityl group. Couplings were carried out using preformed O-pentafluorophenyl esters except in the case of arginine where TBTU (0-(1H-benzotriazol-1-yl)-N,N,N′,N′, -tetramethyluronium tetrafluoroborate, Novabiochem) was used as the activating agent in the presence of 2 equivalents of the base N-methylmorpholine and 1 equivalent of 1-hydroxybenzotriazole. Occasionally, glutamine, asparagine, and tryptophan were also coupled using TBTU activation. In these cases, the trityl-protected derivatives of glutamine and asparagine (Millipore), and the t-Boc-protected derivative of tryptophan (Novabiochem) were used. All syntheses were carried out on a Milligen 9050 PepSynthesizer (Millipore) using continuous flow procedures. Following cleavage of the peptides with trifluoroacetic acid in the presence of appropriate scavengers and precipitation with diethylether, all peptides were analyzed by C 18 -reverse phase chromatography.  
     [0207] HCV amino acid sequences corresponding to the viral nucleocapsid (core) and E1 proteins were based on the HC-J1 sequence described by Okamoto et al. (1990) Japan. J. Exp. Med. (1990) 60:167-177). HCV sequences starting at amino acid residue Gly 451  were taken from the sequences reported by Choo et al. (1991) Proc. Natl. Acad. Sci. USA (1991) 88:2451-2455. Most peptide sequences were chosen such that the peptides would overlap each other by 8 amino acid residues. 4.2. T cell proliferation assays The medium used for all cell cultures consisted of RPMI 1640 supplemented with 25 mM KEPES, 2 mM L-glutamine, so U/ml penicillin and 50 μg/ml streptomycin (all from Gibco Europe, Gent, Belgium), 5×10-s M 2-mercaptoethanol (Sigma, St. Louis, Mo.) and 10% heat-inactivated pooled human AB serum. This AB serum was obtained from healthy blood donors with blood group AB* and was only used when antibodies to HCV and HCV-RNA were absent. This “complemented” RPMI 1640 medium will hereafter be designated “complete medium”.  
     [0208] PBMC were isolated from heparinized venous blood by isopycnic density centrifugation on Ficoll Hypaaue (Lymphoprep, Nyegaard, Denmark) and suspended in complete medium. 4×10  5 PBMC in 200 μl of complete medium were cultured in 96 well round-bottomed microplates (Falcon Plastics) in the absence (unstimulated controls) or presence of varying concentrations of antigens for 5 days at 37° C. in an atmosphere of 5a CO 2  in air. 0.5 μCi (3H)-thymidine was then added to each well and 16 to 20 h later the cultures were harvested onto glass fiber filters using a multichannel cell harvester (PHD, Cambridge, Mass.) to measure the incorporation of (3H)-thymidine by liquid scintillation counting in an LKB-Wallac 8100 counter (L1 KB, Bromma, Sweden). Results are-expressed as stimulation index (SI; mean cpm of antigen-stimulated cultures/mean cpm of control cultures). Proliferation was considered positive when stimulation index was &gt;3. In some figures the results are expressed as cpm (mean cpm of antigen-stimulated cultures−mean cpm of control cultures). Standard deviations of the mean cpm of triplicate cultures were consistently below 10%.  
     [0209] The occurrence of in vivo primed HCV-specific memory T lymphocytes was examined using a lymphoproliferation assay. PEMC from 32 patients with chronic HCV were stimulated in vitro with pools of 4 to 6 partially overlapping, synthetic peptides representing the core, E1 and E2/NS1 regions of HCV type 1a, with 2 overlapping, single peptides from the amino-terminus of HCV type 1a and with a recombinant fusion protein containing the NS3 sequence of HCV type 1b. In all but 2 patients (#610 and #636) at least 2 and up to 11 (#633) assays were performed. In patient # 632 for example lymphoproliferation was examined on 8 different occasions between week 4 and 54 following the start (week 0) of the Interferon therapy. FIG. 1 shows the results of these assays in correlation with the biochemical (ALT/AST) response to therapy. Four weeks after the start of Intron-A (Schering Plough) a normalization of the transaminase levels was observed. PBMC&#39;s from the patient consistently and vigorously proliferate upon stimulation with peptide pools 2 and 3. The responses to the other antigen preparations were less vigorous and less reproducible, suggesting that the number of memory cells recognizing these epitopes is lower. Antigens that did not induce a proliferative response with a stimulation index (SI) 3 at any time are not represented in the graph.  
     [0210] To analyze and summarize the results of 135 assays performed in the 32 HCV patients, we have chosen to consider the response of an individual patient to a particular antigen preparation (peptide pools 1 to 9, NS1-5*, NS1-7* or NS3 protein) as significant when it induces SI&#39;s 3 in at least half of the assays performed. The results shown in Table 4 have been obtained using this scoring method. The Table shows the antigen recognition pattern of chronic ECV patients towards the 12 antigen preparations standardly used. Apart from the individual patient number and the number of assays performed with PBMC&#39;s from each subject, Table 4 also shows the time frame wherein these assays were executed. The start of the Interferon therapy serves as the reference point, week 0. None of the patients responded to all the antigens. PBMC&#39;s from 13 of 18 (72%) clinical responders and 12 of 14 (85%) non-responders proliferated in response to at least one antigen preparation. All but one antigen preparation, peptide pool 8, induced a proliferative response in at least one subject. The most frequent responses were to peptide pools 2 and 3. Whereas both interferon-responders and non-responders proliferated equally well to peptide pool 2 (56* and 57%, respectively), non-responders reacted less well to peptide pool 3 (29% or 4 of 14) than responders (44% or 8 of 18). Similar imbalances were observed for the reactions to peptide pools 5 and 9, that were more frequently recognized by non-responders (43% and 43%, respectively) than by responders (17% and 11%, respectively). Clinical non-responders to interferon therapy also reacted more frequently (57% or 8 of 14) upon stimulation with the NS3 protein than responders (24% or 4 of 17). However, none of these differences in proliferative response rates to peptide pools 3, 5 and 9 or to NS3 protein reached statistical significance (p&lt;0.05 in  2 -test). A striking and significant difference (p=0.01 in  2 -test) was observed for the response rate of responders and non-responders to peptides NS1-5* and NS1-7*. Indeed, 8 of 17 responders recognized one or both peptides while none of the non-responders did so. A summary of the results of all these proliferation assays is provided in FIG. 2, in which the response rates of the HCV patients as well as 18 healthy control subjects towards the 12 antigen preparations. Indeed, to establish the relevance of the proliferative responses observed in HCV patients, PBMC&#39;s from 18 healthy control subjects were stimulated with the same antigen preparations. Overall, 27 assays were performed: a single assay in 10 subjects, two in 7 volunteers and 3 in one individual. In 12 control subjects none of the antigens induced a proliferative response. In 6 subjects one or more antigens induced a proliferative response with an SI 3 in a unique assay or in at least half of the assays performed. Table 5 shows the antigens that induced the proliferation in these subjects. Although FIG. 2 suggests that proliferative responses occur more frequently in HCV patients than in healthy controls, these differences do not always reach statistical significance (p&lt;0.05). Peptide pools 2 and 3 and the NS3 protein clearly (p&lt;0.05) induce more frequent proliferative responses in the whole group of HCV patients than in healthy controls. Most of these differences are also significant when interferon responders and non-responders are each compared to the healthy control group. Only for the proliferative response to NS3 of interferon responders this is no longer valid. Although the frequency of proliferative response to peptide pool 5 in healthy controls and HCV patients were not significantly different, they turned out to be so (p&lt;0.03) when only the non-responders were compared to the control subjects. All other differences-did not reach the p&lt;0.05 level.  
     Example 5  
     Fine Specificity of the Recognition of the ECV Core Region by PBMC from Clinical Responders: T Cell Epitome Localization in the Core Carboxyterminal Region  
     [0211] Since peptide pools 2 and 3 elicited proliferative responses in a large fraction of HCV patients, we have examined which peptides from these pools were inducing these responses. The stimulatory capacity of single peptides on PBMC&#39;s from healthy control subjects was tested as well. Twenty-three proliferation assays were performed with PBMC&#39;s from 17 control subjects. Peptides core C17, core C21 and core C31 were recognized by 2, 1 and 1 subject or 12%, 6% and 6% of subjects, respectively. PBMC&#39;s were prepared from 11 HCV patients that responded to interferon therapy. Eight subjects had displayed a proliferative response to either one or both peptide pools 2 and 3, whereas 3 patients had not. Nineteen assays were performed. The scoring system for positive reactions was as described in example 4. Table 6 summarizes the results of these 19 assays and demonstrates the consistency of the assay results. Indeed, PBMC&#39;s from the patients that had not reacted to the peptide pools did not proliferate upon stimulation with any of the individual peptides. The PBMC&#39;s from the patients that had displayed a proliferative response before, also reacted upon stimulation with one or several peptides from these pools. At least one and up to five of these peptides were recognized by these patients. The most immunogenic region of the HCV core sequence seems to be located between amino acids 109 and 176. Peptides C27 (AA 157-176), recognized by 6 of the 8 proliferative responders, turns out to be the most immunodominant one, followed by C25 which is recognized by 5 patients, and C23 and C19 which are recognized by 3 subjects.  
     Example 6  
     [0212] The fine specificity of the lymphoproliferative responses was tested again with new samples, the majority of which was obtained from other patients than those analyzed in example S. Five patients (two αIFN responders and three αIFN non-responders) and 16 normal controls were examined. Table 7 shows the results of the assays performed in chronic hepatitis C patients. The highest LPR observed in both αIFN responders tested was towards aa positions: 73-92 (C13); 109-128 (C19); 121-140 (C21); 145-164 (C25); 157-176 (C27). Only aa residues 121-140 (C21) and 133-152 (C23) elicited a high PLR in two ΔIFN non-responders. Therefore, the use of peptides C13, C19, C25 and/or C27 in prophylactic or therapeutic vaccine compositions may be particularly advantageous.  
     REFERENCES  
     [0213] Maertens, G., Ducatteeuw, A., Stuyver, L., Vandeponseele, P., Venneman, A., Wyseur, A., Bosman, F., Heijtink, R. &amp; de Martynoff, G. (1994) Low prevalence of anti-El antibodies reactive to recombinant type 1b E1 envelope protein in type 2, 3, and 4 sera, but high prevalence in subtypes 1a and 1b. In: Viral Hepatitis and Liver Disease, Proceedings of the International Symposium on Viral Hepatitis and Liver Disease (Eds. Nishioka, K., Suzuki, H., Mishiro, S., and Oda, T.), pp 314-316, Springer-Verlag Tokyo.  
     [0214] Simmonds, P., Rose, K. A., Graham, S., Chan, S.-W., McOmish, F., Dow, B. C., Follett, E. A. C., Yap, P. L., &amp; Marsden, H. (1993b) Mapping of serotype-specific, immunodominant epitopes in the NS4 region of hepatitis C virus (HCV): Use of type-specific peptides to serologically discriminate infections with HCV type 1, 2, and 3 . J. Clin. Microbiol.  31, 1493-1503.  
     [0215] Simmonds, P., Holmes, E. C., Cha, T.-A., Chan, S.-W., McOmish, F., Irvine, B., Beall, E., Yap, P. L., Kolberg, J., &amp; Urdea, M. S. (1993c)  J. Gen. Virol.  74, 2391-2399.  
     [0216] Stuyver, L., Van Arnhem, W., Wyseur, A. &amp; Maertens, G. (1994) Cloning and phylogenetic analysis of the Core, E2, and NS3/4 regions of hepatitis C virus type 5a. Biochem. Biophys. Res. Comm. 202, 1308-1314.  
     [0217] Simmonds, P., Alberti, A., Alter, H., Bonino, F., Bradley, D. W., Bréchot, C., Brouwer, J., Chan, S.-W., Chayama K., Chen, D.-S., Choo, Q.-L., Colombo, M., Cuypers, T., Date, T., Dusheiko, G., Esteban, J. I., Fay, O., Hadziyannis, S., Han, J., Hatzakis, A., Holmes, E. C., Hotta, H., Houghton, M., Irvine, B., Kohara, M., Kolberg, J. A., Kuo, G., Lau, J. Y. N., Lelie, P. N., Maertens. G., Mcomish, F., Miyamura, T., Mizokami, M., Nomoto, A., Prince A. M., Reesink, H. W., Rice, C., Roggendorf, M., Schalm, S., Shikata, T., Shimotohno, K., Stuyver. L., Trépo, C., Weiner, A., Yap, P. L. &amp; Urdea, M. S. (1994) A proposed system for the nomenclature of hepatitis C virus genotypes.  Hepatology  19, 1321-1324.  
     [0218] Stuyver, L., Van Arnhem, W., Wyseur, A., DeLeys, R. &amp; Maertens, G. (1993a) Analysis of the putative E1 envelope and NS4a epitope regions of HCV type 3. Biochem. Biophys. Res. Corm. 192, 635-641.  
     [0219] Stuyver, L., Rossau, R., Wyseur, A., Duhamel, M., Vanderborght, B., Van Heuverswyn, H. &amp; Maertens, G. (1993b) Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J. Gen Virol. 74, 1093-1102.  
     [0220] Stuyver, L., Wyseur, A., Van Arnhem, W., Rossau, R., Delaporte, E., Dazza, M.-C., Van Doorn, L.-J., Kleter, B. &amp; Maertens, G. (1994a) The use of a line probe assay as a tool to detect new types or subtypes of hepatitis C virus. In: Viral Hepatitis and Liver Disease, Proceedings of the International Symposium on Viral Hepatitis and Liver Disease (Eds. Nishioka, K., Suzuki, H., Mishiro, S., and Oda, T.), pp 317-319, Springer-Verlag Tokyo. Stuyver, L., Van Arnhem, W., Wyseur, A. &amp; Maertens, G. (1994b) Cloning and Phylogenetic analysis of the Core, E2, and NS3/4 regions of the hepatitis C virus type 5a. Biochem. Biophys. Res. Comm. 202, 1308-1314.  
     [0221] Stuyver, L., Van Arnhem, W., Wyseur, A., Hernandez, F., Delaporte, E., &amp; Maertens, G. (1994c) Classification of hepatitis C viruses based on phylogenetics analysis of the E1 and NS5B regions and identification of 5 new subtype. Proc. Natl. Acad. Sci. USA 91, in press.  
     [0222] Knauf M, Bell DP, Hirtzer P, Luo Z, Young J, Katre N (1988) Relationship of effective molecular size to systemic clearance in rate of recombinant interleukin-2 chemically modified with water-soluble polymers. J Biol. Chem.263: 15064-15070.  
     [0223] Poznansky M, Juliano R (1984) Biological approaches to the controlled delivery of drugs: a critical review. Pharmacol Rev.36: 277-336.  
     [0224] Szoka F Jr, Papahadjopoulos D (1980) Comparative properties and methods of preparation of lipid vesicles (liposomes) Annu-Rev-Biophys-Bioeng 9: 467-508.  
     [0225] Aurameas et al., Scand J Immunol, Vol. 8, Suppl. 7, 7-23 (1978).  
     [0226] Botarelli P, Brunetto M, Minutello M, Calvo P, Unutmaz D, Weiner A, Choo Q, Shuster J, Kuo G, Bonino F, Houghton M, Abrignani S (1993) T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 104: 580-587.  
     [0227] Bukh J, Purcell R, Miller R (1992). Sequence analysis of the 5′ noncoding region of hepatitis C virus. Proc Natl Acad Sci USA 89:4942-4946.  
     [0228] Cha T, Beal E, Irvine B, Kolberg J, Chien D, Kuo G, Urdea M (1992) At least five related, but distinct, hepatitis C viral genotypes exist. Proc Natl Acad Sci USA 89:7144-7148.  
     [0229] Chan S, Simmonds P, McOmish F, Yap P, Mitchell R, Dow B, Follett E (1991) Serological responses to infection with three different types of hepatitis C virus. Lancet 338:1991.  
     [0230] Chan S, McOmish F, Holmes E, Dow B, Peutherer J, Follett E, Yap P, Simmonds P (1992) Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants. J Gen Virol 73:1131-1141.  
     [0231] Choo Q, Richman K, Han J, Berger K, Lee C, Dong C, Gallegos C, Coit D, Medina-Selby A, Barr P, Weiner A, Bradley D, Kuo G, Houghton M (1991) Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA 88:2451-2455.  
     [0232] Davies G, Balard L, Schiffer E (1989) Treatment of chronic hepatitis with recombinant interferon alpha: a multicenter radomnized, controlled trial. N Engl Med 321: 1501-1506.  
     [0233] Erlanger, Method of Enzymology, 70: 85 (1980).  
     [0234] Gabizon A, Dagan A, Goren D, Barenholz Y, Fuks Z (1982) Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res 42: 4734-4739.  
     [0235] Hoofnagle J, Lullen K, Jones D (1986) Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon., N Engl J Med 315: 1575-1578.  
     [0236] Kato N. Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimotohno K (1990) Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-m hepatitis. Proc Natl Acad Sci USA 87: 9524-9528.  
     [0237] Koziel M, Dudley D, Wong J, Dienstag J. Houghton M, Ralston R, Walker B (1992). Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunology 149: 3339-3344.  
     [0238] Minutello M, Pileri P, Unutmaz D, Censini S, Kuo G, Houghton M, Brunetto M, Bonino F, Abrignani S (1993). Compartimentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of Hepatitis C Virus in patients with Chronic hepatitis C. J Exp Med 178: 17-25.  
     [0239] Mori S, Kato N, Yagyu A, Tanaka T, Ikeda Y, Petchclai E, Chiewsilp P, Kurimura T, Shimotohno K (1992) A new type c; hepatitis C virus in patients in Thailand. Biochem Biophys Res Comm 183: 334-342.  
     [0240] Okamoto H, Okada S, Sugiyama Y, Yotsumoto S, Tanaka T, Yoshizawa H, Tsuda F, Miyakawa Y, Mayumi M (1990). The 5′ terminal sequence of the hepatitis C virus genome. Jap J Exp Med 60: 167-177  
     [0241] Okamoto H, Okada S, Sugiyama Y, Kurai K, Iizuka H, Machida A, Miyakawa Y, Mayumi M (1991) Nucleotide sequence of the genoric RNA of hepatitis C virus isolated from a human carrier: comparison with reported isolates for conserved and divergent regions. J Gen Virol 72: 2697-2704.  
     [0242] Okamoto H, Kurai K, Okada S, Yamamoto K, Lizuka H, Tanaka T, Fukuda S, Tsuda F, Mishiro S (1992) Full-length sequences of a hepatitis C virus genome having poor homology to reported isolates: comparative study of four distinct genotypes. Virology 188: 331-341.  
     [0243] Rodwell et al., Biotech 3, 889-894 (1985).  
     [0244] Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G (1993) Typing of hepatitis C virus (HCV) isolates and characterization of new (sub)types using a L e Probe Assay. J Gen Virology, 74: 1093-1102.  
     [0245] Essential Immunology,  3rd Ed., by Roit, published by Blackwell Scientific Publications;  Fundamentals of Clinical Immunology,  by Alexander and Good, published by W. B. Saunders;  Immunology,  by Bellanti, published by W. B. Saunders.  
               TABLE 1                          Synthetic peptides used as antigens in the lymphoproliferative assays.                                         HCV       PEPTIDE       AA               REGION   POOL   NAME   AMINO ACID (AA) SEQUENCE   POSITION   SEQ ID NO   SOLVENT                                                 CORE   1   CORE 2    PKPQRKTKRNTNRRP    5-19   1   A               CORE 3    RNTNRRPQDVKFPGGGQIVG   13-32   2   A               CORE 5    PGGGQIVGGVYLLPRRGPRL   25-44   3   B               CORE 9    TRKTSERSQPRGRRQPIPKV   49-68   4   A               CORE 11   RRQPIPKVRRPEGRTWAQPG   61-80   5   A                   2   CORE 13   GRTWAQPGYPWPLYGNEGCG   73-92   6   B               CORE 15   LYGNEGCGWAGWLLSPRGSR    85-104   7   C               CORE 17   LLSPRGSRPSWGPIDPRRRS    97-116   8   A               CORE 19   PIDPRRRSRNLGKVIDTLTC   109-128   9   A               CORE 21   KVIDTLTCGFADLMGYIPLV   121-140   10   D                   3   CORE 23   LMGYIPLVGAPLGGAARALA   133-152   11   A               CORE 25   GGAARALAHGVRVLEDGVNY   145-164   12   A               CORE 27   VLEDGVNYATGNLPGCSFSI   157-176   13   E               CORE 29   LPGCSFSIFLLALLSCLTVP   169-188   14   O               CORE 31   LLSCLTVPASAYQVRNSTGL   181-200   15   C               E1   4   E1-33   QVRNSTGLYHVTNDCPNSSI   193-212   16   O               E1-35   NDCPNSSIVYEAHDAILHTP   205-224   17   C               E1-37   HDAILHTPGCVPCVREGNVS   217-236   18   A               E1-39   CVREGNVSRCWVAMTPTVAT   229-248   19   H               E1-41   AMTPTVATRDGKLPPATQLRR   241-260   20   A                   5   E1-43   LPATQLRRHIDLLVGSATLC   253-272   21   H               E1-45   LVGSATLCSALYVGDLCGSV   265-284   22   E               E1-49   QLFTFSPRRHWTTQGCNCSI   289-308   23   H               E1-51   TQGCNCSIYPGHTTGHRMAW   301-320   24   B               E1-53   ITGHRMAWDMMMNWSPTAAL   313-332   25   H                   6   E1-55   NWSPTAALVMAQLLRIPQAI   325-344   26   H               E1-57   LLRIPQAILDMIAGAHWGVL   337-356   27   H               E1-59   AGAHWGVLAGIAYFSMVGNW   349-368   28   I               E1-63   VVLLLFAGVDAETTVSGGQA   373-392   29   E               E2/NS1   7   NS1-3*   LNCNESLNTGWWLAGLIYQHK   427-446   30   C               NS1-1*   AGLIYQHKFNSSGCPERLAS   439-458   31   B               NS1-1    GCPERLASCRPLTDFDQGWG   451-470   32   B               NS1-3    TDFDQGWGPISYANGSGPDQ   463-482   33   A               NS1-5    ANGSGPDQRPYCWHYPPKPC   475-494   34   A                   8   NS1-7    WHYPPKPCGIVPAKSVCGPV   487-506   35   B               NS1-9    AKSVCGPVYCFTPSPVVVGT   499-518   36   O               NS1-11   PSPVVVGTTDRSGAPTYSWG   511-530   37   C               NS1-13   GAPTYSWGENDTDVFVLNNT   523-542   38   E               NS1-17   GNWFGCTWMNSTGFTKVCGA   547-566   39   O               NS1-19   GFTKVCGAPPVCIGGAGNNT   559-578   40   A                   9   NS1-21   IGGAGNNTLHCPIDCFRKHP   571-590   41   A               NS1-23   TDCFRKHPDATYSRCGSGPW   583-602   42   A               NS1-25   SRCGSGPWITPRCLVDYPYR   595-614   43   B               NS1-27   CLVDYPYRLWHYPCTINYII   607-626   44   C               NS1-29   PCTINYTIFKIRMYVGGVEH   619-638   45   A               NS1-7*   SGLVSLFTPGAKQNIQLINT   397-416   46   C               NS1-5*   QNIQLINTNGSWHINSTALN   409-428   47   C                                                                                    
     [0246]               TABLE 2                          General data from HCV patients.                                                 Patient   Gender   Age   AP Diagnosis   Source   Duration (Years)   Genotype   IFN Scheme   ALT before therapy                         CLINICAL RESPONDERS                                                 604   F   30   CAH: mod   IVDA   10   1b   2   150       607   M   39   CPH   Unknown   2   1b   1   182       608   M   61   CAH: mild   Transfusion   7   3a   1   196       610   F   27   Non spec   Unknown   2   1b   2   219       614   M   56   CAH: mild   Transfusion   10   1b   2   425       615   M   71   CAH: mod   Unknown   2   1b   1   201       616   F   52   Non spec   Transfusion   5   1b   1   152       618   F   37   CPH   Needle stick   5   1b   2    60       621   M   48   CAH: mod   Unknown   8   1b   1    63       624   M   31   CPH   Needle stick   15   1b   2   158       626   F   34   CAH: sev   Transfusion   6   3a   2   168       630   M   30   CPH   Needle stick   5   1b   2    9       632   M   57   CPH   Unknown   1   4a or 5a   2   359       633   F   30   CAH: mod   Transfusion   2   1b   2   292       634   F   67   CAH: mod   Unknown   32   1b   2   481       635   F   47   prob cirrh   Transfusion   14   1b   2   100       636   F   54   CAH: mod   Unknown   7   5a   1    90       639   F   62   CAH   Transfusion   32   1b   1    79                 CLINICAL NON-RESPONDERS                                                 601   M   32   CAH: mod   Transfusion   3   1b   2   141       602   M   66   CAH: mod   Transfusion   3   1b   1   349       603   M   45   CAH: sev   Transfusion   17   1b   2   157       606   F   53   CAH: mod   Unknown   2   1b   1   299       611   M   51   CPH   Transfusion   7   1b   1   195       613   F   38   CAH: mod   IVDA   17   3a   1   178       617   M   71   CAH: sev   Transfusion   3   1b   1   447       620   M   67   CAH: mod   Unknown   2   1b   1   138       622   M   40   CAH: sev   Transfusion   11   1b   1   291       625   M   70   CAH: mod   Unknown   1   1b   1   134       627   M   44   CAH: mod   IVDA   8   3a   1   254       629   F   61   Cirrh   Transfusion   11   1b   1   179       631   M   69   CPH   Unknown   5   1b   2   358       637   F   59   Cirrh   Unknown   5   1b   2   118                                                    
     [0247]               TABLE 3                          Antibody reactivities to 6 HCV antigens       of the Line Immuno-Assay in 32 chronic HCV patients.       CLINICAL RESPONDERS                                                 Patient   Weeks   Genotype   NS4   NS5   C1   C2   C3   C4                                                         604   −6   1b   3   3   2   2   −   −           90       3   3   3   3   −   2       607   −11   1b   2   3   2   −   −   −           84       3   3   3   −   −   −       608   −6   3a   −   3   −   −   −   −       610   −6   1b   3   −   2   3   −   −       614   30   1b   3   3   2   2   −   −           60       2   3   3   3   −   −       615   −2   1b   3   −   −   2   −   −       616   −6   1b   3   −   2   3   2   2       618   −6   1b   −   −   −   3   −   −           54       −   −   −   2   −   −       621   −3   1b   3   3   2   −   −   −           30       3   3   2   −   −   −       624   −5   1b   3   3   2   2   −   −           20       3   3   2   3   2   2       626   2   3a   −   2   2   3   −   −           20       2   2   3   3   −   2       630   −12   1b   3   −   2   2   −   −           8       3   −   2   2   −   −       632   −6   4a or 5a   −   3   2   3   2   2           8       −   3   2   3   2   2       633   −6   1b   3   3   −   2   −   2                                            
     [0248]               TABLE 4                          T-cell recognition of 12 HCV antigens in 32 chronic hepatitis C patients under alpha-interferon therapy.                                                                             Patient   Genotype   N°. Assays   Time of assays   P1   P2   P3   P4   P5   P6   P7   P8   P9   NS1-7*   NS1-5*   NS3                         CLINICAL RESPONDERS                                                                             604   1b   2   w90-108       +   +   +   +   +           +   +   +   +       607   1b   2   w84-120       +           +               +   ND   ND   ND       608   3a   2   w90-108       +   +       610   1b   1   w84       614   1b   4   w60-108                                           +       615   1b   2   w66-84   +   +   +   +   +                           +       616   1b   3   w78-108                                           +       618   1b   4   w54-84   +   +                                       +       621   1b   4   w30-60           +                           +   +       624   1b   9   w20-90       626   3a   9   w16-60       +   +                           +       630   1b   6   w8-75       632   4a or 5a   8   w4-54       +   +       633   1b   11   w0-48       634   1b   3   w0-24       +                                   +   +       635   1b   7   w-6-54       636   5a   1   w24       +   +                               +       639   1b   4   w-3-19   +   +   +                           +   +                 CLINICAL NON-RESPONDERS                                                                             601   1b   4   w90-140       +           +   +           +           +       602   1b   2   w96-108   +   +   +   +                   +           +       603   1b   2   w78-93       +   +   +   +                           +       606   1b   3   w84-96       +           +                           +       611   1b   2   w66-84   +   +           +       613   3a   8   w60-96                                               +       617   1b   5   w60-108       620   1b   3   w42-66                                   +           +       622   1b   3   w30-54                   +                           +       625   1b   4   w20-66       +   +                       +       627   3a   3   w16-24       +                           +       629   1b   2   w20-48   +   +       +   +       +       +           +       631   1b   5   w4-w16       637   1b   7   w-6-16           +                                            
     [0249]               TABLE 5                          Antigens recognized by 6 control subjects       displaying significant * lymphoproliferation responses.                                                                     SUBJECTS   N° ASSAYS   P1   P2   P3   P4   P5   P6   P7   P8   P9   NS1-7*   NS1-5*   NS3               CAE   3                                       +               IDS   1       +                                       +       LCE   1                                           +       MVH   1       +       +   +               +       +       PDG   2               +       RDB   2       +                            
     [0250]               TABLE 6                          The lymphoproliferative responses to peptide pools are consistent with lymphoproliferative responses to single peptides fr.                         SINGLE PEPTIDES                                     PEPTIDE POOLS       P2   P3                                                                                 Patient   N° assays   Pool 2   Pool 3   N° assays   C13   C15   C17   C19   C21   C23   C25   C27   C29   C31                                                                                         LPR TO   604   2   +   +   1   −   −   −   −   −   +   −   −   −   −       POOLS   615   2   +   +   1   −   −   −   −   −   +   −   +   −   −       2   618   4   +   −   1   −   −   −   −   −   −   +   +   −   −       AND/OR   621   4   −   +   1   −   −   −   −   −   −   +   +   −   −       3   626   9   +   +   5   −   −   −   −   −   −   +   +   −   −           632   8   +   +   4   −   −   −   +   +   +   +   +   −   −           634   2   +   −   1   −   −   −   +   −   −   −   +   −   −           639   4   +   +   2   −   −   −   +   −   −   +   +   −   +       NO LPR   614   3   −   −   1   −   −   −   −   −   −   −   −   −   −       TO POOLS   616   3   −   −   1   −   −   −   −   −   −   −   −   −   −       2 AND 3   633   1   −   −   1   −   −   −   −   −   −   −   −   −   −                    
     [0251]               TABLE 7                          Fine specificity of T-cell recognition of P2 and P3 Core individual peptides.                                     Clinical                       response       P2 peptides   P3 peptides                                                                         Patient N°   to αIFN a     Week b     Blank e     TT d     C13 e     C15   C17   C19   C21   C23   C25   C27   C29   C31                                                                                 626   R   14    750   14.5   4.4   —   —   —   3.3   —   6     8.2   —   —       636   R   28   1032   3.6   6.3   —   —   7.1   —   —   9.7   5.8   —   —       620   NR   20   5047   4.1   ND f     ND   ND   ND   ND   4.1   —   —   —   —       627   NR   54    928   19.1   —   —   —   —   3.6   —   —   —   —   —       637   NR   45   2370   4.2   —   —   —   —   —   —   —   —   —   —                                                                    
     [0252] 
    
     
       
         1 
         
           
             286  
           
           
             1  
             15  
             PRT  
             hepatitis C virus  
           
            1 

Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn Arg Arg Pro 
1               5                   10                  15 

 
           
             2  
             20  
             PRT  
             hepatitis C virus  
           
            2 

Arg Asn Thr Asn Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly 
1               5                   10                  15 

Gln Ile Val Gly 
            20 

 
           
             3  
             20  
             PRT  
             hepatitis C virus  
           
            3 

Pro Gly Gly Gly Gln Ile Val Gly Gly Val Tyr Leu Leu Pro Arg Arg 
1               5                   10                  15 

Gly Pro Arg Leu 
            20 

 
           
             4  
             20  
             PRT  
             hepatitis C virus  
           
            4 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
1               5                   10                  15 

Ile Pro Lys Val 
            20 

 
           
             5  
             20  
             PRT  
             hepatitis C virus  
           
            5 

Arg Arg Gln Pro Ile Pro Lys Val Arg Arg Pro Glu Gly Arg Thr Trp 
1               5                   10                  15 

Ala Gln Pro Gly 
            20 

 
           
             6  
             20  
             PRT  
             hepatitis C virus  
           
            6 

Gly Arg Thr Trp Ala Gln Pro Gly Tyr Pro Trp Pro Leu Tyr Gly Asn 
1               5                   10                  15 

Glu Gly Cys Gly 
            20 

 
           
             7  
             20  
             PRT  
             hepatitis C virus  
           
            7 

Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp Leu Leu Ser Pro 
1               5                   10                  15 

Arg Gly Ser Arg 
            20 

 
           
             8  
             20  
             PRT  
             hepatitis C virus  
           
            8 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 
1               5                   10                  15 

Arg Arg Arg Ser 
            20 

 
           
             9  
             20  
             PRT  
             hepatitis C virus  
           
            9 

Pro Thr Asp Pro Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp 
1               5                   10                  15 

Thr Leu Thr Cys 
            20 

 
           
             10  
             20  
             PRT  
             hepatitis C virus  
           
            10 

Lys Val Ile Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu Met Gly Tyr 
1               5                   10                  15 

Ile Pro Leu Val 
            20 

 
           
             11  
             20  
             PRT  
             hepatitis C virus  
           
            11 

Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala 
1               5                   10                  15 

Arg Ala Leu Ala 
            20 

 
           
             12  
             20  
             PRT  
             hepatitis C virus  
           
            12 

Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 
1               5                   10                  15 

Gly Val Asn Tyr 
            20 

 
           
             13  
             20  
             PRT  
             hepatitis C virus  
           
            13 

Val Leu Glu Asp Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys 
1               5                   10                  15 

Ser Phe Ser Ile 
            20 

 
           
             14  
             20  
             PRT  
             hepatitis C virus  
           
            14 

Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys 
1               5                   10                  15 

Leu Thr Val Pro 
            20 

 
           
             15  
             20  
             PRT  
             hepatitis C virus  
           
            15 

Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr Gln Val Arg Asn 
1               5                   10                  15 

Ser Thr Gly Leu 
            20 

 
           
             16  
             20  
             PRT  
             hepatitis C virus  
           
            16 

Gln Val Arg Asn Ser Thr Gly Leu Tyr His Val Thr Asn Asp Cys Pro 
1               5                   10                  15 

Asn Ser Ser Ile 
            20 

 
           
             17  
             20  
             PRT  
             hepatitis C virus  
           
            17 

Asn Asp Cys Pro Asn Ser Ser Ile Val Tyr Glu Ala His Asp Ala Ile 
1               5                   10                  15 

Leu His Thr Pro 
            20 

 
           
             18  
             20  
             PRT  
             hepatitis C virus  
           
            18 

His Asp Ala Ile Leu His Thr Pro Gly Cys Val Pro Cys Val Arg Glu 
1               5                   10                  15 

Gly Asn Val Ser 
            20 

 
           
             19  
             20  
             PRT  
             hepatitis C virus  
           
            19 

Cys Val Arg Glu Gly Asn Val Ser Arg Cys Trp Val Ala Met Thr Pro 
1               5                   10                  15 

Thr Val Ala Thr 
            20 

 
           
             20  
             21  
             PRT  
             hepatitis C virus  
           
            20 

Ala Met Thr Pro Thr Val Ala Thr Arg Asp Gly Lys Leu Pro Pro Ala 
1               5                   10                  15 

Thr Gln Leu Arg Arg 
            20 

 
           
             21  
             20  
             PRT  
             hepatitis C virus  
           
            21 

Leu Pro Ala Thr Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser 
1               5                   10                  15 

Ala Thr Leu Cys 
            20 

 
           
             22  
             20  
             PRT  
             hepatitis C virus  
           
            22 

Leu Val Gly Ser Ala Thr Leu Cys Ser Ala Leu Tyr Val Gly Asp Leu 
1               5                   10                  15 

Cys Gly Ser Val 
            20 

 
           
             23  
             20  
             PRT  
             hepatitis C virus  
           
            23 

Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Gly Cys 
1               5                   10                  15 

Asn Cys Ser Ile 
            20 

 
           
             24  
             20  
             PRT  
             hepatitis C virus  
           
            24 

Thr Gln Gly Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His 
1               5                   10                  15 

Arg Met Ala Trp 
            20 

 
           
             25  
             20  
             PRT  
             hepatitis C virus  
           
            25 

Ile Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn Trp Ser Pro 
1               5                   10                  15 

Thr Ala Ala Leu 
            20 

 
           
             26  
             20  
             PRT  
             hepatitis C virus  
           
            26 

Asn Trp Ser Pro Thr Ala Ala Leu Val Met Ala Gln Leu Leu Arg Ile 
1               5                   10                  15 

Pro Gln Ala Ile 
            20 

 
           
             27  
             20  
             PRT  
             hepatitis C virus  
           
            27 

Leu Leu Arg Ile Pro Gln Ala Ile Leu Asp Met Ile Ala Gly Ala His 
1               5                   10                  15 

Trp Gly Val Leu 
            20 

 
           
             28  
             20  
             PRT  
             hepatitis C virus  
           
            28 

Ala Gly Ala His Trp Gly Val Leu Ala Gly Ile Ala Tyr Phe Ser Met 
1               5                   10                  15 

Val Gly Asn Trp 
            20 

 
           
             29  
             20  
             PRT  
             hepatitis C virus  
           
            29 

Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Glu Thr Ile Val Ser 
1               5                   10                  15 

Gly Gly Gln Ala 
            20 

 
           
             30  
             21  
             PRT  
             hepatitis C virus  
           
            30 

Leu Asn Cys Asn Glu Ser Leu Asn Thr Gly Trp Trp Leu Ala Gly Leu 
1               5                   10                  15 

Ile Tyr Gln His Lys 
            20 

 
           
             31  
             20  
             PRT  
             hepatitis C virus  
           
            31 

Ala Gly Leu Ile Tyr Gln His Lys Phe Asn Ser Ser Gly Cys Pro Glu 
1               5                   10                  15 

Arg Leu Ala Ser 
            20 

 
           
             32  
             20  
             PRT  
             hepatitis C virus  
           
            32 

Gly Cys Pro Glu Arg Leu Ala Ser Cys Arg Pro Leu Thr Asp Phe Asp 
1               5                   10                  15 

Gln Gly Trp Gly 
            20 

 
           
             33  
             20  
             PRT  
             hepatitis C virus  
           
            33 

Thr Asp Phe Asp Gln Gly Trp Gly Pro Ile Ser Tyr Ala Asn Gly Ser 
1               5                   10                  15 

Gly Pro Asp Gln 
            20 

 
           
             34  
             20  
             PRT  
             hepatitis C virus  
           
            34 

Ala Asn Gly Ser Gly Pro Asp Gln Arg Pro Tyr Cys Trp His Tyr Pro 
1               5                   10                  15 

Pro Lys Pro Cys 
            20 

 
           
             35  
             20  
             PRT  
             hepatitis C virus  
           
            35 

Trp His Tyr Pro Pro Lys Pro Cys Gly Ile Val Pro Ala Lys Ser Val 
1               5                   10                  15 

Cys Gly Pro Val 
            20 

 
           
             36  
             20  
             PRT  
             hepatitis C virus  
           
            36 

Ala Lys Ser Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser Pro Val 
1               5                   10                  15 

Val Val Gly Thr 
            20 

 
           
             37  
             20  
             PRT  
             hepatitis C virus  
           
            37 

Pro Ser Pro Val Val Val Gly Thr Thr Asp Arg Ser Gly Ala Pro Thr 
1               5                   10                  15 

Tyr Ser Trp Gly 
            20 

 
           
             38  
             20  
             PRT  
             hepatitis C virus  
           
            38 

Gly Ala Pro Thr Tyr Ser Trp Gly Glu Asn Asp Thr Asp Val Phe Val 
1               5                   10                  15 

Leu Asn Asn Thr 
            20 

 
           
             39  
             20  
             PRT  
             hepatitis C virus  
           
            39 

Gly Asn Trp Phe Gly Cys Thr Trp Met Asn Ser Thr Gly Phe Thr Lys 
1               5                   10                  15 

Val Cys Gly Ala 
            20 

 
           
             40  
             20  
             PRT  
             hepatitis C virus  
           
            40 

Gly Phe Thr Lys Val Cys Gly Ala Pro Pro Val Cys Ile Gly Gly Ala 
1               5                   10                  15 

Gly Asn Asn Thr 
            20 

 
           
             41  
             20  
             PRT  
             hepatitis C virus  
           
            41 

Ile Gly Gly Ala Gly Asn Asn Thr Leu His Cys Pro Thr Asp Cys Phe 
1               5                   10                  15 

Arg Lys His Pro 
            20 

 
           
             42  
             20  
             PRT  
             hepatitis C virus  
           
            42 

Thr Asp Cys Phe Arg Lys His Pro Asp Ala Thr Tyr Ser Arg Cys Gly 
1               5                   10                  15 

Ser Gly Pro Trp 
            20 

 
           
             43  
             20  
             PRT  
             hepatitis C virus  
           
            43 

Ser Arg Cys Gly Ser Gly Pro Trp Ile Thr Pro Arg Cys Leu Val Asp 
1               5                   10                  15 

Tyr Pro Tyr Arg 
            20 

 
           
             44  
             20  
             PRT  
             hepatitis C virus  
           
            44 

Cys Leu Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Ile 
1               5                   10                  15 

Asn Tyr Thr Ile 
            20 

 
           
             45  
             20  
             PRT  
             hepatitis C virus  
           
            45 

Pro Cys Thr Ile Asn Tyr Thr Ile Phe Lys Ile Arg Met Tyr Val Gly 
1               5                   10                  15 

Gly Val Glu His 
            20 

 
           
             46  
             20  
             PRT  
             hepatitis C virus  
           
            46 

Ser Gly Leu Val Ser Leu Phe Thr Pro Gly Ala Lys Gln Asn Ile Gln 
1               5                   10                  15 

Leu Ile Asn Thr 
            20 

 
           
             47  
             20  
             PRT  
             hepatitis C virus  
           
            47 

Gln Asn Ile Gln Leu Ile Asn Thr Asn Gly Ser Trp His Ile Asn Ser 
1               5                   10                  15 

Thr Ala Leu Asn 
            20 

 
           
             48  
             68  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)  
               Xaa is Pro or Gln  
             
           
            48 

Xaa Xaa Asp Pro Arg Xaa Xaa Ser Arg Asn Xaa Gly Xaa Val Ile Asp 
1               5                   10                  15 

Thr Xaa Thr Cys Gly Xaa Ala Asp Leu Xaa Xaa Tyr Ile Pro Xaa Xaa 
            20                  25                  30 

Gly Xaa Pro Xaa Gly Gly Xaa Xaa Xaa Xaa Leu Xaa His Gly Val Arg 
        35                  40                  45 

Xaa Xaa Xaa Asp Gly Xaa Asn Xaa Xaa Thr Gly Asn Xaa Pro Gly Cys 
    50                  55                  60 

Ser Phe Ser Ile 
65 

 
           
             49  
             32  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)..(1)  
               Xaa is Ser, Ala, Gln, Leu, Asn, Tyr, Arg or His  
             
           
            49 

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Xaa Xaa Gln Xaa Xaa Xaa 
1               5                   10                  15 

Leu Xaa Asn Xaa Asn Gly Ser Trp His Xaa Asn Xaa Thr Ala Leu Asn 
            20                  25                  30 

 
           
             50  
             44  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (2)..(2)  
               Xaa is Met or Ile  
             
           
            50 

Leu Xaa Xaa Tyr Ile Pro Xaa Xaa Gly Xaa Pro Xaa Gly Gly Xaa Xaa 
1               5                   10                  15 

Xaa Xaa Leu Xaa His Gly Val Arg Xaa Xaa Xaa Asp Gly Xaa Asn Xaa 
            20                  25                  30 

Xaa Thr Gly Asn Xaa Pro Gly Cys Ser Phe Ser Ile 
        35                  40 

 
           
             51  
             20  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)..(1)  
               Xaa is Val, Ala or Leu  
             
           
            51 

Xaa Xaa Xaa Asp Gly Xaa Asn Xaa Xaa Thr Gly Asn Xaa Pro Gly Cys 
1               5                   10                  15 

Ser Phe Ser Ile 
            20 

 
           
             52  
             20  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (3)..(3)  
               Xaa is Ala or Val  
             
           
            52 

Gly Gly Xaa Xaa Xaa Xaa Leu Xaa His Gly Val Arg Xaa Xaa Xaa Asp 
1               5                   10                  15 

Gly Xaa Asn Xaa 
            20 

 
           
             53  
             20  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (2)..(2)  
               Xaa is Met or Ile  
             
           
            53 

Leu Xaa Xaa Tyr Ile Pro Xaa Xaa Gly Xaa Pro Xaa Gly Gly Xaa Xaa 
1               5                   10                  15 

Xaa Xaa Leu Xaa 
            20 

 
           
             54  
             20  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)..(1)  
               Xaa is Pro or Gln  
             
           
            54 

Xaa Xaa Asp Pro Arg Xaa Xaa Ser Arg Asn Xaa Gly Xaa Val Ile Asp 
1               5                   10                  15 

Thr Xaa Thr Cys 
            20 

 
           
             55  
             20  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)..(1)  
               Xaa is Ser, Ala, Gln, Leu, Asn, Tyr, Arg or His  
             
           
            55 

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Xaa Xaa Gln Xaa Xaa Xaa 
1               5                   10                  15 

Leu Xaa Asn Xaa 
            20 

 
           
             56  
             20  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (2)..(2)  
               Xaa is Asn, Lys, Asp or Arg  
             
           
            56 

Gln Xaa Xaa Xaa Leu Xaa Asn Xaa Asn Gly Ser Trp His Xaa Asn Xaa 
1               5                   10                  15 

Thr Ala Leu Asn 
            20 

 
           
             57  
             278  
             PRT  
             hepatitis C virus  
           
            57 

Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu Ser Met Glu Thr 
1               5                   10                  15 

Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val 
            20                  25                  30 

Pro Gln Thr Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly 
        35                  40                  45 

Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val 
    50                  55                  60 

Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr 
65                  70                  75                  80 

Met Ser Lys Ala His Gly Val Asp Pro Asn Ile Arg Thr Gly Val Arg 
                85                  90                  95 

Thr Ile Thr Thr Gly Ala Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe 
            100                 105                 110 

Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys 
        115                 120                 125 

Asp Glu Cys His Ser Ile Asp Ser Thr Ser Ile Leu Gly Ile Gly Thr 
    130                 135                 140 

Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala 
145                 150                 155                 160 

Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu 
                165                 170                 175 

Glu Val Ala Leu Ser Ser Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala 
            180                 185                 190 

Ile Pro Ile Glu Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His 
        195                 200                 205 

Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Ser Gly Phe Gly 
    210                 215                 220 

Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro 
225                 230                 235                 240 

Thr Ser Gly Asp Val Val Val Val Ala Thr Asp Ala Leu Met Thr Gly 
                245                 250                 255 

Phe Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr 
            260                 265                 270 

Gln Thr Val Asp Phe Ser 
        275 

 
           
             58  
             104  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (2)..(2)  
               Xaa is Arg or Lys  
             
           
            58 

Gly Xaa Xaa Trp Xaa Xaa Pro Gly Xaa Pro Trp Pro Leu Tyr Xaa Asn 
1               5                   10                  15 

Xaa Gly Xaa Gly Xaa Ala Gly Trp Leu Leu Ser Pro Arg Gly Ser Arg 
            20                  25                  30 

Pro Xaa Trp Gly Xaa Xaa Asp Pro Arg Xaa Xaa Ser Arg Asn Xaa Gly 
        35                  40                  45 

Xaa Val Ile Asp Thr Xaa Thr Cys Gly Xaa Ala Asp Leu Xaa Xaa Tyr 
    50                  55                  60 

Ile Pro Xaa Xaa Gly Xaa Pro Xaa Gly Gly Xaa Xaa Xaa Xaa Leu Xaa 
65                  70                  75                  80 

His Gly Val Arg Xaa Xaa Xaa Asp Gly Xaa Asn Xaa Xaa Thr Gly Asn 
                85                  90                  95 

Xaa Pro Gly Cys Ser Phe Ser Ile 
            100 

 
           
             59  
             76  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (2)..(2)  
               Xaa is Arg or Lys  
             
           
            59 

Gly Xaa Xaa Trp Xaa Xaa Pro Gly Xaa Pro Trp Pro Leu Tyr Xaa Asn 
1               5                   10                  15 

Xaa Gly Xaa Gly Xaa Ala Gly Trp Leu Leu Ser Pro Arg Gly Ser Arg 
            20                  25                  30 

Pro Xaa Trp Gly Xaa Xaa Asp Pro Arg Xaa Xaa Ser Arg Asn Xaa Gly 
        35                  40                  45 

Xaa Val Ile Asp Thr Xaa Thr Cys Gly Xaa Ala Asp Leu Xaa Xaa Tyr 
    50                  55                  60 

Ile Pro Xaa Xaa Gly Xaa Pro Xaa Gly Gly Xaa Xaa 
65                  70                  75 

 
           
             60  
             15  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)..(1)  
               Xaa is Val or Ile  
             
           
            60 

Xaa Asn Xaa Xaa Thr Gly Asn Xaa Pro Gly Cys Ser Phe Ser Ile 
1               5                   10                  15 

 
           
             61  
             16  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (2)..(2)  
               Xaa is Phe or Leu  
             
           
            61 

Gly Xaa Ala Asp Leu Xaa Xaa Tyr Ile Pro Xaa Xaa Gly Xaa Pro Xaa 
1               5                   10                  15 

 
           
             62  
             15  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (2)..(2)  
               Xaa is Met or Ile  
             
           
            62 

Leu Xaa Xaa Tyr Ile Pro Xaa Xaa Gly Xaa Pro Xaa Gly Gly Xaa 
1               5                   10                  15 

 
           
             63  
             14  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)..(1)  
               Xaa is Met or Ile  
             
           
            63 

Xaa Xaa Tyr Ile Pro Xaa Xaa Gly Xaa Pro Xaa Gly Gly Xaa 
1               5                   10 

 
           
             64  
             9  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (4)..(4)  
               Xaa is Leu, Val or Ile  
             
           
            64 

Tyr Ile Pro Xaa Xaa Gly Xaa Pro Xaa 
1               5 

 
           
             65  
             8  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (3)..(3)  
               Xaa is Leu, Val or Ile  
             
           
            65 

Ile Pro Xaa Xaa Gly Xaa Pro Xaa 
1               5 

 
           
             66  
             9  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)..(1)  
               Xaa is Leu, Val or Ile  
             
           
            66 

Xaa Xaa Gly Xaa Pro Xaa Gly Gly Xaa 
1               5 

 
           
             67  
             44  
             PRT  
             hepatitis C virus  
           
            67 

Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala 
1               5                   10                  15 

Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly Val Asn Tyr 
            20                  25                  30 

Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
        35                  40 

 
           
             68  
             8  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)..(1)  
               Xaa is Val or Leu  
             
           
            68 

Xaa Gly Xaa Pro Xaa Gly Gly Xaa 
1               5 

 
           
             69  
             8  
             PRT  
             hepatitis C virus  
           
            69 

Leu Met Gly Tyr Ile Pro Leu Val 
1               5 

 
           
             70  
             7  
             PRT  
             hepatitis C virus  
           
            70 

Met Gly Tyr Ile Pro Leu Val 
1               5 

 
           
             71  
             9  
             PRT  
             hepatitis C virus  
           
            71 

Tyr Ile Pro Leu Val Gly Ala Pro Leu 
1               5 

 
           
             72  
             8  
             PRT  
             hepatitis C virus  
           
            72 

Ile Pro Leu Val Gly Ala Pro Leu 
1               5 

 
           
             73  
             20  
             PRT  
             hepatitis C virus  
           
            73 

Val Leu Glu Asp Ile Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys 
1               5                   10                  15 

Ser Phe Ser Ile 
            20 

 
           
             74  
             9  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (2)..(2)  
               Xaa is Val or Ile  
             
           
            74 

Gly Xaa Asn Xaa Xaa Thr Gly Asn Xaa 
1               5 

 
           
             75  
             8  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)..(1)  
               Xaa is Val or Ile  
             
           
            75 

Xaa Asn Xaa Xaa Thr Gly Asn Xaa 
1               5 

 
           
             76  
             9  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (2)..(2)  
               Xaa is Leu or Ile  
             
           
            76 

Asn Xaa Pro Gly Cys Ser Phe Ser Ile 
1               5 

 
           
             77  
             8  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)..(1)  
               Xaa is Leu or Ile  
             
           
            77 

Xaa Pro Gly Cys Ser Phe Ser Ile 
1               5 

 
           
             78  
             9  
             PRT  
             hepatitis C virus  
           
            78 

Gly Val Asn Tyr Ala Thr Gly Asn Leu 
1               5 

 
           
             79  
             9  
             PRT  
             hepatitis C virus  
           
            79 

Gly Val Asn Tyr Ala Thr Gly Asn Leu 
1               5 

 
           
             80  
             9  
             PRT  
             hepatitis C virus  
           
            80 

Asn Leu Pro Gly Cys Ser Phe Ser Ile 
1               5 

 
           
             81  
             8  
             PRT  
             hepatitis C virus  
           
            81 

Leu Pro Gly Cys Ser Phe Ser Ile 
1               5 

 
           
             82  
             9  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)..(1)  
               Xaa is Ala, Thr or Glu  
             
           
            82 

Xaa Leu Xaa His Gly Val Arg Xaa Xaa 
1               5 

 
           
             83  
             8  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (2)..(2)  
               Xaa is Ala or Glu  
             
           
            83 

Leu Xaa His Gly Val Arg Xaa Xaa 
1               5 

 
           
             84  
             9  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (4)..(4)  
               Xaa is Val, Ala or Leu  
             
           
            84 

Gly Val Arg Xaa Xaa Xaa Asp Gly Xaa 
1               5 

 
           
             85  
             8  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (3)..(3)  
               Xaa is Val, Ala or Leu  
             
           
            85 

Val Arg Xaa Xaa Xaa Asp Gly Xaa 
1               5 

 
           
             86  
             9  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (2)..(2)  
               Xaa is Val, Ala or Leu  
             
           
            86 

Arg Xaa Xaa Xaa Asp Gly Xaa Asn Xaa 
1               5 

 
           
             87  
             8  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)..(1)  
               Xaa is Val, Ala or Leu  
             
           
            87 

Xaa Xaa Xaa Asp Gly Xaa Asn Xaa 
1               5 

 
           
             88  
             9  
             PRT  
             hepatitis C virus  
           
            88 

Ala Leu Ala His Gly Val Arg Val Leu 
1               5 

 
           
             89  
             8  
             PRT  
             hepatitis C virus  
           
            89 

Leu Ala His Gly Val Arg Val Leu 
1               5 

 
           
             90  
             8  
             PRT  
             hepatitis C virus  
           
            90 

Val Arg Val Leu Glu Asp Gly Val 
1               5 

 
           
             91  
             7  
             PRT  
             hepatitis C virus  
           
            91 

Arg Val Leu Glu Asp Gly Val 
1               5 

 
           
             92  
             8  
             PRT  
             hepatitis C virus  
           
            92 

Val Leu Glu Asp Gly Val Asn Tyr 
1               5 

 
           
             93  
             7  
             PRT  
             hepatitis C virus  
           
            93 

Leu Glu Asp Gly Val Asn Tyr 
1               5 

 
           
             94  
             9  
             PRT  
             hepatitis C virus  
           
            94 

Leu Val Gly Ala Pro Leu Gly Gly Ala 
1               5 

 
           
             95  
             8  
             PRT  
             hepatitis C virus  
           
            95 

Val Gly Ala Pro Leu Gly Gly Ala 
1               5 

 
           
             96  
             9  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (2)..(2)  
               Xaa is Leu, Val or Phe  
             
           
            96 

Asn Xaa Gly Xaa Val Ile Asp Thr Xaa 
1               5 

 
           
             97  
             8  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)..(1)  
               Xaa is Leu, Val or Phe  
             
           
            97 

Xaa Gly Xaa Val Ile Asp Thr Xaa 
1               5 

 
           
             98  
             9  
             PRT  
             hepatitis C virus  
           
            98 

Asn Leu Gly Lys Val Ile Asp Thr Leu 
1               5 

 
           
             99  
             20  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (2)..(2)  
               Xaa is Arg or Lys  
             
           
            99 

Gly Xaa Xaa Trp Xaa Xaa Pro Gly Xaa Pro Trp Pro Leu Tyr Xaa Asn 
1               5                   10                  15 

Xaa Gly Xaa Gly 
            20 

 
           
             100  
             9  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)..(1)  
               Xaa is Ala, Ser or Thr  
             
           
            100 

Xaa Trp Xaa Xaa Pro Gly Xaa Pro Trp 
1               5 

 
           
             101  
             8  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (2)..(2)  
               Xaa is Ala or Gly  
             
           
            101 

Trp Xaa Xaa Pro Gly Xaa Pro Trp 
1               5 

 
           
             102  
             9  
             PRT  
             hepatitis C virus  
           
            102 

Thr Trp Ala Gln Pro Gly Tyr Pro Trp 
1               5 

 
           
             103  
             8  
             PRT  
             hepatitis C virus  
           
            103 

Trp Ala Gln Pro Gly Tyr Pro Trp 
1               5 

 
           
             104  
             147  
             PRT  
             hepatitis C virus  
           
            104 

Thr Pro Thr Val Ala Thr Thr Arg Asp Gly Lys Leu Pro Ala Thr Gln 
1               5                   10                  15 

Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr Leu Cys Ser 
            20                  25                  30 

Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Val Gln Leu Phe Thr Phe 
        35                  40                  45 

Ser Pro Arg Arg His Trp Thr Thr Gln Gly Cys Asn Cys Ser Ile Tyr 
    50                  55                  60 

Pro Gly His Ile Thr Gly His Arg Met Ala Trp Asp Met Met Met Asn 
65                  70                  75                  80 

Trp Ser Pro Thr Ala Ala Leu Val Met Ala Gln Leu Leu Arg Ile Pro 
                85                  90                  95 

Gln Ala Ile Leu Asp Met Ile Ala Gly Ala His Trp Gly Val Leu Ala 
            100                 105                 110 

Gly Ile Ala Tyr Phe Ser Met Val Gly Asn Trp Ala Lys Val Leu Val 
        115                 120                 125 

Val Leu Leu Leu Phe Ala Gly Val Asp Ala Glu Thr Ile Val Ser Gly 
    130                 135                 140 

Gly Gln Ala 
145 

 
           
             105  
             18  
             PRT  
             hepatitis C virus  
           
            105 

Thr Pro Thr Val Ala Thr Thr Arg Asp Gly Lys Leu Pro Ala Thr Gln 
1               5                   10                  15 

Leu Arg 

 
           
             106  
             76  
             PRT  
             hepatitis C virus  
           
            106 

Leu Pro Ala Thr Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser 
1               5                   10                  15 

Ala Thr Leu Cys Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Val 
            20                  25                  30 

Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Gly Cys 
        35                  40                  45 

Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala Trp 
    50                  55                  60 

Asp Met Met Met Asn Trp Ser Pro Thr Ala Ala Leu 
65                  70                  75 

 
           
             107  
             69  
             PRT  
             hepatitis C virus  
           
            107 

Met Asn Trp Ser Pro Thr Ala Ala Leu Val Met Ala Gln Leu Leu Arg 
1               5                   10                  15 

Ile Pro Gln Ala Ile Leu Asp Met Ile Ala Gly Ala His Trp Gly Val 
            20                  25                  30 

Leu Ala Gly Ile Ala Tyr Phe Ser Met Val Gly Asn Trp Ala Lys Val 
        35                  40                  45 

Leu Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Glu Thr Ile Val 
    50                  55                  60 

Ser Gly Gly Gln Ala 
65 

 
           
             108  
             70  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (2)..(2)  
               Xaa is Gly or Arg  
             
           
            108 

Ile Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Leu Xaa Cys Pro Thr Asp 
1               5                   10                  15 

Cys Phe Arg Lys Xaa Pro Xaa Xaa Thr Tyr Xaa Xaa Cys Gly Xaa Gly 
            20                  25                  30 

Pro Xaa Xaa Thr Pro Arg Cys Xaa Xaa Asp Tyr Pro Tyr Arg Leu Trp 
        35                  40                  45 

His Tyr Pro Cys Thr Xaa Asn Xaa Xaa Xaa Phe Lys Xaa Arg Met Xaa 
    50                  55                  60 

Val Gly Gly Val Glu His 
65                  70 

 
           
             109  
             9  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)..(1)  
               Xaa is Gln, Ser or Tyr  
             
           
            109 

Xaa Leu Xaa Asn Xaa Asn Gly Ser Trp 
1               5 

 
           
             110  
             8  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (2)..(2)  
               Xaa is Ile or Val  
             
           
            110 

Leu Xaa Asn Xaa Asn Gly Ser Trp 
1               5 

 
           
             111  
             9  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (4)..(4)  
               Xaa is Leu or Ile  
             
           
            111 

Ser Trp His Xaa Asn Xaa Thr Ala Leu 
1               5 

 
           
             112  
             8  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (3)..(3)  
               Xaa is Leu or Ile  
             
           
            112 

Trp His Xaa Asn Xaa Thr Ala Leu 
1               5 

 
           
             113  
             9  
             PRT  
             hepatitis C virus  
           
            113 

Gln Leu Ile Asn Thr Asn Gly Ser Trp 
1               5 

 
           
             114  
             8  
             PRT  
             hepatitis C virus  
           
            114 

Leu Ile Asn Thr Asn Gly Ser Trp 
1               5 

 
           
             115  
             9  
             PRT  
             hepatitis C virus  
           
            115 

Ser Trp His Ile Asn Ser Thr Ala Leu 
1               5 

 
           
             116  
             8  
             PRT  
             hepatitis C virus  
           
            116 

Trp His Ile Asn Ser Thr Ala Leu 
1               5 

 
           
             117  
             8  
             PRT  
             hepatitis C virus  
           
            117 

Leu Gly Lys Val Ile Asp Thr Leu 
1               5 

 
           
             118  
             21  
             PRT  
             hepatitis C virus  
           
            118 

Gly Gly Val Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu 
1               5                   10                  15 

Asp Gly Val Asn Tyr 
            20 

 
           
             119  
             11  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)..(1)  
               Xaa is Thr or Ser  
             
           
            119 

Xaa Xaa Xaa Leu Xaa Cys Pro Thr Asp Cys Phe 
1               5                   10 

 
           
             120  
             9  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (4)..(4)  
               Xaa is His or Tyr  
             
           
            120 

Phe Arg Lys Xaa Pro Xaa Xaa Thr Tyr 
1               5 

 
           
             121  
             8  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)..(1)  
               Xaa is Trp or Leu  
             
           
            121 

Xaa Xaa Thr Pro Arg Cys Xaa Xaa 
1               5 

 
           
             122  
             8  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)..(1)  
               Xaa is Leu, Met or Ile  
             
           
            122 

Xaa Xaa Asp Tyr Pro Tyr Arg Leu 
1               5 

 
           
             123  
             8  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)..(1)  
               Xaa is Val or Ile  
             
           
            123 

Xaa Asp Tyr Pro Tyr Arg Leu Trp 
1               5 

 
           
             124  
             8  
             PRT  
             hepatitis C virus  
           
            124 

Tyr Pro Tyr Arg Leu Trp His Tyr 
1               5 

 
           
             125  
             8  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (8)..(8)  
               Xaa is Ile, Val, Phe or Leu  
             
           
            125 

Leu Trp His Tyr Pro Cys Thr Xaa 
1               5 

 
           
             126  
             8  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)..(1)  
               Xaa is Ile, Val, Phe or Leu  
             
           
            126 

Xaa Asn Xaa Xaa Xaa Phe Lys Xaa 
1               5 

 
           
             127  
             8  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)..(1)  
               Xaa is Tyr or Phe  
             
           
            127 

Xaa Xaa Xaa Phe Lys Xaa Arg Met 
1               5 

 
           
             128  
             8  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)..(1)  
               Xaa is Ile or Val  
             
           
            128 

Xaa Phe Lys Xaa Arg Met Xaa Val 
1               5 

 
           
             129  
             8  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)..(1)  
               Xaa is Ile, Val or Ala  
             
           
            129 

Xaa Arg Met Xaa Val Gly Gly Val 
1               5 

 
           
             130  
             22  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (2)..(2)  
               Xaa is Gly or Arg  
             
           
            130 

Ile Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Leu Xaa Cys Pro Thr Asp 
1               5                   10                  15 

Cys Phe Arg Lys Xaa Pro 
            20 

 
           
             131  
             20  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (7)..(7)  
               Xaa is His or Tyr  
             
           
            131 

Thr Asp Cys Phe Arg Lys Xaa Pro Xaa Xaa Thr Tyr Xaa Xaa Cys Gly 
1               5                   10                  15 

Xaa Gly Pro Xaa 
            20 

 
           
             132  
             20  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)..(1)  
               Xaa is Ser, Thr, Ile or Leu  
             
           
            132 

Xaa Xaa Cys Gly Xaa Gly Pro Xaa Xaa Thr Pro Arg Cys Xaa Xaa Asp 
1               5                   10                  15 

Tyr Pro Tyr Arg 
            20 

 
           
             133  
             20  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (2)..(2)  
               Xaa is Leu, Met or Ile  
             
           
            133 

Cys Xaa Xaa Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr Xaa 
1               5                   10                  15 

Asn Xaa Xaa Xaa 
            20 

 
           
             134  
             20  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (4)..(4)  
               Xaa is Ile, Val, Phe or Leu  
             
           
            134 

Pro Cys Thr Xaa Asn Xaa Xaa Xaa Phe Lys Xaa Arg Met Xaa Val Gly 
1               5                   10                  15 

Gly Val Glu His 
            20 

 
           
             135  
             8  
             PRT  
             hepatitis C virus  
           
            135 

Val Ala Lys Ala Val Asp Phe Val 
1               5 

 
           
             136  
             8  
             PRT  
             hepatitis C virus  
           
            136 

Val Ala Lys Ala Val Asp Phe Ile 
1               5 

 
           
             137  
             8  
             PRT  
             hepatitis C virus  
           
            137 

Val Glu Ser Met Glu Thr Thr Met 
1               5 

 
           
             138  
             8  
             PRT  
             hepatitis C virus  
           
            138 

Ala Val Pro Gln Thr Phe Gln Val 
1               5 

 
           
             139  
             8  
             PRT  
             hepatitis C virus  
           
            139 

Tyr Ala Ala Gln Gly Tyr Lys Val 
1               5 

 
           
             140  
             9  
             PRT  
             hepatitis C virus  
           
            140 

Val Leu Val Leu Asn Pro Ser Val Ala 
1               5 

 
           
             141  
             8  
             PRT  
             hepatitis C virus  
           
            141 

Tyr Met Ser Lys Ala His Gly Val 
1               5 

 
           
             142  
             8  
             PRT  
             hepatitis C virus  
           
            142 

Ile Arg Thr Gly Val Arg Thr Ile 
1               5 

 
           
             143  
             8  
             PRT  
             hepatitis C virus  
           
            143 

Tyr Ser Thr Tyr Gly Lys Phe Leu 
1               5 

 
           
             144  
             8  
             PRT  
             hepatitis C virus  
           
            144 

Ile Leu Gly Ile Gly Thr Val Leu 
1               5 

 
           
             145  
             8  
             PRT  
             hepatitis C virus  
           
            145 

Val Thr Val Pro His Pro Asn Ile 
1               5 

 
           
             146  
             8  
             PRT  
             hepatitis C virus  
           
            146 

Ile Pro Phe Tyr Gly Lys Ala Ile 
1               5 

 
           
             147  
             8  
             PRT  
             hepatitis C virus  
           
            147 

Phe Tyr Gly Lys Ala Ile Pro Ile 
1               5 

 
           
             148  
             8  
             PRT  
             hepatitis C virus  
           
            148 

Val Ile Lys Gly Gly Arg His Leu 
1               5 

 
           
             149  
             8  
             PRT  
             hepatitis C virus  
           
            149 

Ile Lys Gly Gly Arg His Leu Ile 
1               5 

 
           
             150  
             8  
             PRT  
             hepatitis C virus  
           
            150 

Phe Cys His Ser Lys Lys Lys Cys 
1               5 

 
           
             151  
             8  
             PRT  
             hepatitis C virus  
           
            151 

Cys Asp Glu Leu Ala Ala Lys Leu 
1               5 

 
           
             152  
             9  
             PRT  
             hepatitis C virus  
           
            152 

Leu Ala Ala Lys Leu Ser Gly Phe Gly 
1               5 

 
           
             153  
             8  
             PRT  
             hepatitis C virus  
           
            153 

Ser Gly Phe Gly Ile Asn Ala Val 
1               5 

 
           
             154  
             8  
             PRT  
             hepatitis C virus  
           
            154 

Phe Gly Ile Asn Ala Val Ala Tyr 
1               5 

 
           
             155  
             8  
             PRT  
             hepatitis C virus  
           
            155 

Tyr Arg Gly Leu Asp Val Ser Val 
1               5 

 
           
             156  
             8  
             PRT  
             hepatitis C virus  
           
            156 

Val Ile Pro Thr Ser Gly Asp Val 
1               5 

 
           
             157  
             8  
             PRT  
             hepatitis C virus  
           
            157 

Ile Pro Thr Ser Gly Asp Val Val 
1               5 

 
           
             158  
             8  
             PRT  
             hepatitis C virus  
           
            158 

Val Val Val Ala Thr Asp Ala Leu 
1               5 

 
           
             159  
             8  
             PRT  
             hepatitis C virus  
           
            159 

Val Val Ala Thr Asp Ala Leu Met 
1               5 

 
           
             160  
             8  
             PRT  
             hepatitis C virus  
           
            160 

Met Thr Gly Phe Thr Gly Asp Phe 
1               5 

 
           
             161  
             8  
             PRT  
             hepatitis C virus  
           
            161 

Phe Thr Gly Asp Phe Asp Ser Val 
1               5 

 
           
             162  
             8  
             PRT  
             hepatitis C virus  
           
            162 

Val Ile Asp Cys Asn Thr Cys Val 
1               5 

 
           
             163  
             9  
             PRT  
             hepatitis C virus  
           
            163 

Ala Leu Met Gly Tyr Ile Pro Leu Val 
1               5 

 
           
             164  
             43  
             PRT  
             hepatitis C virus  
           
            164 

Tyr Gln Val Arg Asn Ser Thr Gly Leu Tyr His Val Thr Asn Asp Cys 
1               5                   10                  15 

Pro Asn Ser Ser Ile Val Tyr Glu Ala His Asp Ala Ile Leu His Thr 
            20                  25                  30 

Pro Gly Cys Val Pro Cys Val Arg Glu Gly Asn 
        35                  40 

 
           
             165  
             42  
             PRT  
             hepatitis C virus  
           
            165 

Gln Val Arg Asn Ser Thr Gly Leu Tyr His Val Thr Asn Asp Cys Pro 
1               5                   10                  15 

Asn Ser Ser Ile Val Tyr Glu Ala His Asp Ala Ile Leu His Thr Pro 
            20                  25                  30 

Gly Cys Val Pro Cys Val Arg Glu Gly Asn 
        35                  40 

 
           
             166  
             10  
             PRT  
             hepatitis C virus  
           
            166 

Lys Leu Val Ala Leu Gly Ile Asn Ala Val 
1               5                   10 

 
           
             167  
             8  
             PRT  
             hepatitis C virus  
           
            167 

Ala Ser Arg Cys Trp Val Ala Met 
1               5 

 
           
             168  
             13  
             PRT  
             hepatitis C virus  
           
            168 

Leu Met Ala Leu Thr Leu Ser Pro Tyr Tyr Lys Arg Tyr 
1               5                   10 

 
           
             169  
             13  
             PRT  
             hepatitis C virus  
           
            169 

Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp Gly 
1               5                   10 

 
           
             170  
             7  
             PRT  
             hepatitis C virus  
           
            170 

Arg Met Ala Trp Asp Met Met 
1               5 

 
           
             171  
             9  
             PRT  
             hepatitis C virus  
           
            171 

Pro Thr Asp Cys Phe Arg Lys His Pro 
1               5 

 
           
             172  
             7  
             PRT  
             hepatitis C virus  
           
            172 

Tyr Pro Tyr Arg Leu Trp His 
1               5 

 
           
             173  
             7  
             PRT  
             hepatitis C virus  
           
            173 

Gly Lys Ser Thr Lys Val Pro 
1               5 

 
           
             174  
             6  
             PRT  
             hepatitis C virus  
           
            174 

Pro Ser Val Ala Ala Thr 
1               5 

 
           
             175  
             9  
             PRT  
             hepatitis C virus  
           
            175 

Ile Gly Thr Val Leu Asp Gln Ala Glu 
1               5 

 
           
             176  
             6  
             PRT  
             hepatitis C virus  
           
            176 

Ala Val Ala Tyr Tyr Arg 
1               5 

 
           
             177  
             9  
             PRT  
             hepatitis C virus  
           
            177 

Thr Gly Asp Phe Asp Ser Val Ile Asp 
1               5 

 
           
             178  
             278  
             PRT  
             hepatitis C virus  
           
            178 

Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu Ser Met Glu Thr 
1               5                   10                  15 

Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val 
            20                  25                  30 

Pro Gln Thr Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly 
        35                  40                  45 

Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val 
    50                  55                  60 

Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr 
65                  70                  75                  80 

Met Ser Lys Ala His Gly Val Asp Pro Asn Ile Arg Thr Gly Val Arg 
                85                  90                  95 

Thr Ile Thr Thr Gly Ala Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe 
            100                 105                 110 

Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys 
        115                 120                 125 

Asp Glu Cys His Ser Ile Asp Ser Thr Ser Ile Leu Gly Ile Gly Thr 
    130                 135                 140 

Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala 
145                 150                 155                 160 

Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu 
                165                 170                 175 

Glu Val Ala Leu Ser Ser Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala 
            180                 185                 190 

Ile Pro Ile Glu Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His 
        195                 200                 205 

Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Ser Gly Phe Gly 
    210                 215                 220 

Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro 
225                 230                 235                 240 

Thr Ser Gly Asp Val Val Val Val Ala Thr Asp Ala Leu Met Thr Gly 
                245                 250                 255 

Phe Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr 
            260                 265                 270 

Gln Thr Val Asp Phe Ser 
        275 

 
           
             179  
             450  
             PRT  
             hepatitis C virus  
           
            179 

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 
            100                 105                 110 

Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 
        115                 120                 125 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 
    130                 135                 140 

Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 
145                 150                 155                 160 

Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
                165                 170                 175 

Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr 
            180                 185                 190 

Gln Val Arg Asn Ser Ser Gly Leu Tyr His Val Thr Asn Asp Cys Pro 
        195                 200                 205 

Asn Ser Ser Val Val Tyr Glu Ala Ala Asp Ala Ile Leu His Thr Pro 
    210                 215                 220 

Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ala Ser Arg Cys Trp Val 
225                 230                 235                 240 

Ala Val Thr Pro Thr Val Ala Thr Arg Asp Gly Lys Leu Pro Thr Thr 
                245                 250                 255 

Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr Leu Cys 
            260                 265                 270 

Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Gly 
        275                 280                 285 

Gln Leu Phe Thr Phe Ser Pro Arg His His Trp Thr Thr Gln Asp Cys 
    290                 295                 300 

Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala Trp 
305                 310                 315                 320 

Asn Met Met Met Asn Trp Ser Pro Thr Ala Ala Leu Val Val Ala Gln 
                325                 330                 335 

Leu Leu Arg Ile Pro Gln Ala Ile Met Asp Met Ile Ala Gly Ala His 
            340                 345                 350 

Trp Gly Val Leu Ala Gly Ile Lys Tyr Phe Ser Met Val Gly Asn Trp 
        355                 360                 365 

Ala Lys Val Leu Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Glu 
    370                 375                 380 

Thr His Val Thr Gly Gly Asn Ala Gly Arg Thr Thr Ala Gly Leu Val 
385                 390                 395                 400 

Gly Leu Leu Thr Pro Gly Ala Lys Gln Asn Ile Gln Leu Ile Asn Thr 
                405                 410                 415 

Asn Gly Ser Trp His Ile Asn Ser Thr Ala Leu Asn Cys Asn Glu Ser 
            420                 425                 430 

Leu Asn Thr Gly Trp Leu Ala Gly Leu Phe Tyr Gln His Lys Phe Asn 
        435                 440                 445 

Ser Ser 
    450 

 
           
             180  
             450  
             PRT  
             hepatitis C virus  
           
            180 

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 
            100                 105                 110 

Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 
        115                 120                 125 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 
    130                 135                 140 

Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 
145                 150                 155                 160 

Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
                165                 170                 175 

Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr 
            180                 185                 190 

Gln Val Arg Asn Ser Thr Gly Leu Tyr His Val Thr Asn Asp Cys Pro 
        195                 200                 205 

Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Ala Ile Leu His Thr Pro 
    210                 215                 220 

Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ala Ser Arg Cys Trp Val 
225                 230                 235                 240 

Ala Met Thr Pro Thr Val Ala Thr Arg Asp Gly Lys Leu Pro Ala Thr 
                245                 250                 255 

Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr Leu Cys 
            260                 265                 270 

Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Gly 
        275                 280                 285 

Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Gly Cys 
    290                 295                 300 

Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala Trp 
305                 310                 315                 320 

Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Met Ala Gln 
                325                 330                 335 

Leu Leu Arg Ile Pro Gln Ala Ile Leu Asp Met Ile Ala Gly Ala His 
            340                 345                 350 

Trp Gly Val Leu Ala Gly Ile Ala Tyr Phe Ser Met Val Gly Asn Trp 
        355                 360                 365 

Ala Lys Val Leu Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Glu 
    370                 375                 380 

Thr His Val Thr Gly Gly Ser Ala Gly His Thr Val Ser Gly Phe Val 
385                 390                 395                 400 

Ser Leu Leu Ala Pro Gly Ala Lys Gln Asn Val Gln Leu Ile Asn Thr 
                405                 410                 415 

Asn Gly Ser Trp His Leu Asn Ser Thr Ala Leu Asn Cys Asn Asp Ser 
            420                 425                 430 

Leu Asn Thr Gly Trp Leu Ala Gly Leu Phe Tyr His His Lys Phe Asn 
        435                 440                 445 

Ser Ser 
    450 

 
           
             181  
             450  
             PRT  
             hepatitis C virus  
           
            181 

Met Ser Thr Ile Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Val Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 
            100                 105                 110 

Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 
        115                 120                 125 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 
    130                 135                 140 

Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 
145                 150                 155                 160 

Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
                165                 170                 175 

Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr 
            180                 185                 190 

Gln Val Arg Asn Ser Thr Gly Leu Tyr His Val Thr Asn Asp Cys Pro 
        195                 200                 205 

Asn Ser Ser Ile Val Tyr Glu Ala His Asp Ala Ile Leu His Thr Pro 
    210                 215                 220 

Gly Cys Val Pro Cys Val Arg Glu Gly Asn Val Ser Arg Cys Trp Val 
225                 230                 235                 240 

Ala Met Thr Pro Thr Val Ala Thr Arg Asp Gly Lys Leu Pro Ala Thr 
                245                 250                 255 

Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr Leu Cys 
            260                 265                 270 

Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Ile Gly 
        275                 280                 285 

Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Gly Cys 
    290                 295                 300 

Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala Trp 
305                 310                 315                 320 

Asp Met Met Met Asn Trp Ser Pro Thr Ala Ala Leu Val Met Ala Gln 
                325                 330                 335 

Leu Leu Arg Ile Pro Gln Ala Ile Leu Asp Met Ile Ala Gly Ala His 
            340                 345                 350 

Trp Gly Val Leu Ala Gly Ile Ala Tyr Phe Ser Met Val Gly Asn Trp 
        355                 360                 365 

Ala Lys Val Leu Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Glu 
    370                 375                 380 

Thr Ile Val Ser Gly Gly Gln Ala Ala Arg Ala Met Ser Gly Leu Val 
385                 390                 395                 400 

Ser Leu Phe Thr Pro Gly Ala Lys Gln Asn Ile Gln Leu Ile Asn Thr 
                405                 410                 415 

Asn Gly Ser Trp His Ile Asn Ser Thr Ala Leu Asn Cys Asn Glu Ser 
            420                 425                 430 

Leu Asn Thr Gly Trp Leu Ala Gly Leu Ile Tyr Gln His Lys Phe Asn 
        435                 440                 445 

Ser Ser 
    450 

 
           
             182  
             181  
             PRT  
             hepatitis C virus  
           
            182 

Thr Cys Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala 
1               5                   10                  15 

Pro Leu Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu 
            20                  25                  30 

Glu Asp Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe 
        35                  40                  45 

Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser 
    50                  55                  60 

Ala Tyr Gln Val Arg Asn Ser Ser Gly Leu Tyr His Val Thr Asn Asp 
65                  70                  75                  80 

Cys Pro Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Ala Ile Leu His 
                85                  90                  95 

Thr Pro Gly Cys Val Pro Cys His Arg Glu Gly Val Ala Ser Arg Cys 
            100                 105                 110 

Trp Val Ala Met Thr Pro Thr Val Ala Thr Arg Asp Gly Lys Leu Thr 
        115                 120                 125 

Ala Thr Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr 
    130                 135                 140 

Leu Cys Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu 
145                 150                 155                 160 

Val Gly Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln 
                165                 170                 175 

Gly Cys Asn Cys Ser 
            180 

 
           
             183  
             192  
             PRT  
             hepatitis C virus  
           
            183 

Thr Cys Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala 
1               5                   10                  15 

Pro Leu Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu 
            20                  25                  30 

Glu Asp Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe 
        35                  40                  45 

Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser 
    50                  55                  60 

Ala His Gln Val Arg Asn Ser Thr Gly Leu Tyr His Val Thr Asn Asp 
65                  70                  75                  80 

Cys Pro Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Ala Ile Leu His 
                85                  90                  95 

Thr Pro Gly Cys Val Pro Cys His Arg Glu Gly Val Ala Ser Arg Cys 
            100                 105                 110 

Trp Val Val Met Thr Pro Thr Val Ala Thr Arg Asp Gly Lys Leu Thr 
        115                 120                 125 

Ala Thr Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr 
    130                 135                 140 

Leu Cys Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu 
145                 150                 155                 160 

Val Gly Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln 
                165                 170                 175 

Gly Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met 
            180                 185                 190 

 
           
             184  
             191  
             PRT  
             hepatitis C virus  
           
            184 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 
1               5                   10                  15 

Gly Gly Arg Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 
            20                  25                  30 

Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
        35                  40                  45 

Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr 
    50                  55                  60 

Gln Val Arg Asn Ser Thr Gly Leu Tyr His Val Thr Asn Asp Cys Pro 
65                  70                  75                  80 

Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Ala Ile Leu His Ala Pro 
                85                  90                  95 

Gly Cys Val Pro Cys Val Arg Asp Gly Val Ala Ser Arg Cys Trp Val 
            100                 105                 110 

Val Met Thr Pro Thr Val Ala Lys Arg Asp Gly Lys Leu Thr Ala Thr 
        115                 120                 125 

Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr Leu Cys 
    130                 135                 140 

Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ile Val Phe Leu Val Gly 
145                 150                 155                 160 

Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Asp Cys 
                165                 170                 175 

Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala 
            180                 185                 190 

 
           
             185  
             191  
             PRT  
             hepatitis C virus  
           
            185 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 
1               5                   10                  15 

Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 
            20                  25                  30 

Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
        35                  40                  45 

Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr 
    50                  55                  60 

Gln Val Arg Asn Ser Ser Gly Ile Tyr His Val Thr Asn Asp Cys Pro 
65                  70                  75                  80 

Asn Ser Ser Ile Val Tyr Glu Thr Ala Asp Thr Ile Leu His Ser Pro 
                85                  90                  95 

Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ala Lys Arg Cys Trp Pro 
            100                 105                 110 

Val Ala Thr Pro Thr Val Ala Thr Arg Asp Asn Lys Leu Pro Ala Thr 
        115                 120                 125 

Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr Leu Cys 
    130                 135                 140 

Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Gly 
145                 150                 155                 160 

Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln Asp Cys 
                165                 170                 175 

Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala 
            180                 185                 190 

 
           
             186  
             192  
             PRT  
             hepatitis C virus  
           
            186 

Thr Cys Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala 
1               5                   10                  15 

Pro Leu Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu 
            20                  25                  30 

Glu Asp Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe 
        35                  40                  45 

Ser Leu Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser 
    50                  55                  60 

Ala Tyr Gln Val Arg Asn Ser Thr Gly Leu Tyr His Val Thr Asn Asp 
65                  70                  75                  80 

Cys Pro Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Ala Ile Leu His 
                85                  90                  95 

Ala Pro Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ala Ser Arg Cys 
            100                 105                 110 

Trp Val Ala Met Thr Pro Thr Val Ala Thr Arg Asp Arg Lys Leu Thr 
        115                 120                 125 

Ala Thr Gln Leu Arg Arg His Ile Asp Leu Leu Val Gly Ser Ala Thr 
    130                 135                 140 

Leu Cys Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ile Val Phe Leu 
145                 150                 155                 160 

Val Gly Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp Thr Thr Gln 
                165                 170                 175 

Gly Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met 
            180                 185                 190 

 
           
             187  
             450  
             PRT  
             hepatitis C virus  
           
            187 

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Met Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 
            100                 105                 110 

Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 
        115                 120                 125 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 
    130                 135                 140 

Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 
145                 150                 155                 160 

Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
                165                 170                 175 

Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Ile Pro Ala Ser Ala Tyr 
            180                 185                 190 

Glu Val Arg Asn Val Ser Gly Ile Tyr His Val Thr Asn Asp Cys Ser 
        195                 200                 205 

Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro 
    210                 215                 220 

Gly Cys Val Pro Cys Val Arg Glu Ser Asn Phe Ser Arg Cys Trp Val 
225                 230                 235                 240 

Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Ser Ser Ile Pro Thr Thr 
                245                 250                 255 

Thr Ile Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Ala Leu Cys 
            260                 265                 270 

Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser 
        275                 280                 285 

Gln Leu Phe Thr Phe Ser Pro Arg Arg Tyr Glu Thr Val Gln Asp Cys 
    290                 295                 300 

Asn Cys Ser Ile Tyr Pro Gly His Val Ser Gly His Arg Met Ala Trp 
305                 310                 315                 320 

Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln 
                325                 330                 335 

Leu Leu Arg Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala His 
            340                 345                 350 

Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp 
        355                 360                 365 

Ala Lys Val Leu Ile Val Met Leu Leu Phe Ala Gly Val Asp Gly His 
    370                 375                 380 

Thr His Val Thr Gly Gly Arg Val Ala Ser Ser Thr Gln Ser Leu Val 
385                 390                 395                 400 

Ser Trp Leu Ser Gln Gly Pro Ser Gln Lys Ile Gln Leu Val Asn Thr 
                405                 410                 415 

Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser 
            420                 425                 430 

Leu Gln Thr Gly Phe Ile Ala Ala Leu Phe Tyr Ala His Arg Phe Asn 
        435                 440                 445 

Ala Ser 
    450 

 
           
             188  
             450  
             PRT  
             hepatitis C virus  
           
            188 

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Trp Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Ala Trp Ala Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Leu Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 
            100                 105                 110 

Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 
        115                 120                 125 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 
    130                 135                 140 

Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 
145                 150                 155                 160 

Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
                165                 170                 175 

Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Ile Pro Ala Ser Ala Tyr 
            180                 185                 190 

Glu Val Arg Asn Val Ser Gly Ile Tyr His Val Thr Asn Asp Cys Ser 
        195                 200                 205 

Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro 
    210                 215                 220 

Gly Cys Val Pro Cys Val Arg Glu Asp Asn Ser Ser Arg Cys Trp Val 
225                 230                 235                 240 

Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Ala Ser Val Pro Thr Thr 
                245                 250                 255 

Thr Ile Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys 
            260                 265                 270 

Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser 
        275                 280                 285 

Gln Leu Phe Thr Phe Ser Pro Arg Arg His Glu Thr Val Gln Asp Cys 
    290                 295                 300 

Asn Cys Ser Ile Tyr Pro Gly His Leu Ser Gly His Arg Met Ala Trp 
305                 310                 315                 320 

Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln 
                325                 330                 335 

Leu Leu Arg Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala His 
            340                 345                 350 

Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp 
        355                 360                 365 

Ala Lys Val Leu Ile Val Ala Leu Leu Phe Ala Gly Val Asp Gly Glu 
    370                 375                 380 

Thr Tyr Thr Ser Gly Gly Ala Ala Ser His Thr Thr Ser Thr Leu Ala 
385                 390                 395                 400 

Ser Leu Phe Ser Pro Gly Ala Ser Gln Arg Ile Gln Leu Val Asn Thr 
                405                 410                 415 

Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser 
            420                 425                 430 

Leu His Thr Gly Phe Leu Ala Ala Leu Phe Tyr Thr His Arg Phe Asn 
        435                 440                 445 

Ser Ser 
    450 

 
           
             189  
             450  
             PRT  
             hepatitis C virus  
           
            189 

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Ala Arg Gln Pro Glu Gly Arg Ala Trp Ala Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Leu Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 
            100                 105                 110 

Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 
        115                 120                 125 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 
    130                 135                 140 

Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 
145                 150                 155                 160 

Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
                165                 170                 175 

Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Ile Pro Ala Ser Ala Tyr 
            180                 185                 190 

Glu Val Arg Asn Val Ser Gly Ile Tyr His Val Thr Asn Asp Cys Ser 
        195                 200                 205 

Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Val Ile Met His Thr Pro 
    210                 215                 220 

Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ser Ser Arg Cys Trp Val 
225                 230                 235                 240 

Ala Leu Thr Pro Thr Leu Ala Ala Arg Asp Ala Ser Val Pro Thr Thr 
                245                 250                 255 

Thr Ile Arg Arg His Val Asp Leu Leu Val Gly Thr Ala Ala Phe Cys 
            260                 265                 270 

Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Ile Phe Leu Val Ser 
        275                 280                 285 

Gln Leu Phe Thr Phe Ser Pro Arg Arg His Glu Thr Val Gln Asp Cys 
    290                 295                 300 

Asn Cys Ser Ile Tyr Pro Gly His Val Ser Gly His Arg Met Ala Trp 
305                 310                 315                 320 

Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln 
                325                 330                 335 

Leu Leu Arg Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala His 
            340                 345                 350 

Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp 
        355                 360                 365 

Ala Lys Val Leu Ile Val Ala Leu Leu Phe Ala Gly Val Asp Gly Ala 
    370                 375                 380 

Thr Tyr Thr Ser Gly Gly Val Ala Gly Arg Thr Thr Ser Gly Phe Thr 
385                 390                 395                 400 

Ser Leu Phe Ser Ser Gly Ala Ser Gln Lys Ile Gln Leu Val Asn Thr 
                405                 410                 415 

Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser 
            420                 425                 430 

Leu His Thr Gly Phe Leu Ala Ala Leu Phe Tyr Thr His Lys Phe Asn 
        435                 440                 445 

Ser Ser 
    450 

 
           
             190  
             450  
             PRT  
             hepatitis C virus  
           
            190 

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Phe Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 
            100                 105                 110 

Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 
        115                 120                 125 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 
    130                 135                 140 

Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 
145                 150                 155                 160 

Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
                165                 170                 175 

Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Thr Pro Ala Ser Ala Tyr 
            180                 185                 190 

Glu Val Arg Asn Val Ser Gly Ile Tyr His Val Thr Asn Asp Cys Ser 
        195                 200                 205 

Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Leu Ile Met His Thr Pro 
    210                 215                 220 

Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ser Ser Arg Cys Trp Val 
225                 230                 235                 240 

Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Ala Thr Ile Pro Thr Ala 
                245                 250                 255 

Thr Val Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Ala Phe Ser 
            260                 265                 270 

Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser 
        275                 280                 285 

Gln Leu Phe Thr Phe Ser Pro Arg Arg Tyr Glu Thr Ile Gln Asp Cys 
    290                 295                 300 

Asn Cys Ser Ile Tyr Pro Gly His Val Thr Gly His Arg Met Ala Trp 
305                 310                 315                 320 

Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln 
                325                 330                 335 

Leu Leu Arg Ile Pro Gln Ala Val Met Asp Met Val Val Gly Ala His 
            340                 345                 350 

Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ala Met Val Gly Asn Trp 
        355                 360                 365 

Ala Lys Val Leu Ile Val Met Leu Leu Phe Ala Gly Val Asp Gly Asp 
    370                 375                 380 

Thr Tyr Ala Ser Gly Gly Ala Gln Gly Arg Ser Thr Leu Gly Phe Thr 
385                 390                 395                 400 

Ser Leu Phe Thr Pro Gly Ala Ser Gln Lys Ile Gln Leu Ile Asn Thr 
                405                 410                 415 

Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser 
            420                 425                 430 

Leu Asn Thr Gly Phe Leu Ala Ala Leu Phe Tyr Thr His Arg Phe Asn 
        435                 440                 445 

Ala Ser 
    450 

 
           
             191  
             450  
             PRT  
             hepatitis C virus  
           
            191 

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Tyr 
1               5                   10                  15 

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Val Leu Pro Arg Arg Gly Pro Thr Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Ala Trp Ala Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Leu Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 
            100                 105                 110 

Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 
        115                 120                 125 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 
    130                 135                 140 

Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 
145                 150                 155                 160 

Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
                165                 170                 175 

Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Ile Pro Ala Ser Ala Tyr 
            180                 185                 190 

Gln Val Arg Asn Ala Ser Gly Leu Tyr His Val Thr Asn Asp Cys Ser 
        195                 200                 205 

Asn Ser Ser Ile Val Tyr Glu Ala Ala Gly Met Ile Met His Thr Pro 
    210                 215                 220 

Gly Cys Val Pro Cys Val Arg Glu Asn Asn Ala Ser Arg Cys Trp Val 
225                 230                 235                 240 

Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Thr Ser Ile Pro Thr Thr 
                245                 250                 255 

Thr Ile Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys 
            260                 265                 270 

Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser 
        275                 280                 285 

Gln Leu Phe Thr Phe Ser Pro Arg Arg Tyr Glu Thr Val Gln Asp Cys 
    290                 295                 300 

Asn Cys Ser Ile Tyr Pro Gly His Val Ser Gly His Arg Met Ala Trp 
305                 310                 315                 320 

Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln 
                325                 330                 335 

Leu Leu Arg Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala His 
            340                 345                 350 

Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp 
        355                 360                 365 

Ala Lys Val Leu Ile Val Met Leu Leu Phe Ala Gly Val Asp Gly Val 
    370                 375                 380 

Thr Tyr Thr Thr Gly Gly Ser Gln Ala Arg His Thr Gln Ser Val Thr 
385                 390                 395                 400 

Ser Phe Phe Thr Gln Gly Pro Ala Gln Arg Ile Gln Leu Ile Asn Thr 
                405                 410                 415 

Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Glu Ser 
            420                 425                 430 

Leu Asn Thr Gly Phe Phe Ala Ala Leu Phe Tyr Ala His Lys Phe Asn 
        435                 440                 445 

Ser Ser 
    450 

 
           
             192  
             450  
             PRT  
             hepatitis C virus  
           
            192 

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Tyr 
1               5                   10                  15 

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Val Leu Pro Arg Arg Gly Pro Thr Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Ala Trp Ala Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Leu Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 
            100                 105                 110 

Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 
        115                 120                 125 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 
    130                 135                 140 

Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 
145                 150                 155                 160 

Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
                165                 170                 175 

Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Ile Pro Ala Ser Ala Tyr 
            180                 185                 190 

Gln Val Arg Asn Arg Ser Gly Leu Tyr His Val Thr Asn Asp Cys Ser 
        195                 200                 205 

Asn Ser Ser Ile Val Tyr Glu Ala Ala Gly Met Ile Met His Thr Pro 
    210                 215                 220 

Gly Cys Val Pro Cys Val Arg Glu Asn Asn Val Ser Arg Cys Trp Val 
225                 230                 235                 240 

Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Thr Ser Ile Pro Thr Thr 
                245                 250                 255 

Thr Ile Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys 
            260                 265                 270 

Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser 
        275                 280                 285 

Gln Leu Phe Thr Phe Ser Pro Arg Arg Tyr Glu Thr Val Gln Asp Cys 
    290                 295                 300 

Asn Cys Ser Ile Tyr Pro Gly His Val Ser Gly His Arg Met Ala Trp 
305                 310                 315                 320 

Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln 
                325                 330                 335 

Leu Leu Arg Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala His 
            340                 345                 350 

Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp 
        355                 360                 365 

Ala Lys Val Leu Ile Val Met Leu Leu Phe Ala Gly Val Asp Gly Val 
    370                 375                 380 

Thr Tyr Thr Thr Gly Gly Ser Gln Ala Arg His Thr Gln Gly Val Ala 
385                 390                 395                 400 

Ser Phe Phe Thr Pro Gly Pro Ala Gln Lys Ile Gln Leu Ile Asn Thr 
                405                 410                 415 

Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Glu Ser 
            420                 425                 430 

Leu Asn Thr Gly Phe Phe Ala Ala Leu Phe Tyr Ala His Lys Phe Asn 
        435                 440                 445 

Ser Ser 
    450 

 
           
             193  
             450  
             PRT  
             hepatitis C virus  
           
            193 

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Pro Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Thr Trp Ala Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Leu Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 
            100                 105                 110 

Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 
        115                 120                 125 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 
    130                 135                 140 

Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 
145                 150                 155                 160 

Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
                165                 170                 175 

Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Thr Pro Ala Ser Ala Tyr 
            180                 185                 190 

Glu Val His Asn Val Ser Gly Ile Tyr His Val Thr Asn Asp Cys Ser 
        195                 200                 205 

Asn Ala Ser Ile Val Tyr Glu Ala Ala Asp Leu Ile Met His Thr Pro 
    210                 215                 220 

Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ser Ser Arg Cys Trp Val 
225                 230                 235                 240 

Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Val Thr Ile Pro Thr Thr 
                245                 250                 255 

Thr Ile Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys 
            260                 265                 270 

Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser 
        275                 280                 285 

Gln Leu Phe Thr Phe Ser Pro Arg Arg His Val Thr Leu Gln Asp Cys 
    290                 295                 300 

Asn Cys Ser Ile Tyr Pro Gly His Val Ser Gly His Arg Met Ala Trp 
305                 310                 315                 320 

Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln 
                325                 330                 335 

Leu Leu Arg Ile Pro Gln Ala Val Val Asp Met Val Ala Gly Ala His 
            340                 345                 350 

Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Ala Gly Asn Trp 
        355                 360                 365 

Ala Lys Val Leu Ile Val Met Leu Leu Phe Ala Gly Val Asp Gly Asp 
    370                 375                 380 

Thr His Val Thr Gly Gly Ala Gln Ala Lys Thr Thr Asn Arg Leu Val 
385                 390                 395                 400 

Ser Met Phe Ala Ser Gly Pro Ser Gln Lys Ile Gln Leu Ile Asn Thr 
                405                 410                 415 

Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser 
            420                 425                 430 

Leu Gln Thr Gly Phe Leu Ala Ala Leu Phe Tyr Thr His Ser Phe Asn 
        435                 440                 445 

Ser Ser 
    450 

 
           
             194  
             450  
             PRT  
             hepatitis C virus  
           
            194 

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Ala Arg Gln Pro Glu Gly Arg Ala Trp Ala Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Leu Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Tyr Gly Ser Arg Pro Arg Trp Gly Pro Thr Asp Pro 
            100                 105                 110 

Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 
        115                 120                 125 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 
    130                 135                 140 

Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 
145                 150                 155                 160 

Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
                165                 170                 175 

Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Val Ser Thr Tyr 
            180                 185                 190 

Glu Val Arg Asn Val Ser Gly Val Tyr His Val Thr Asn Asp Cys Ser 
        195                 200                 205 

Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro 
    210                 215                 220 

Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ser Ser Arg Cys Trp Val 
225                 230                 235                 240 

Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Ser Ser Ile Pro Thr Thr 
                245                 250                 255 

Thr Ile Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Ala Leu Cys 
            260                 265                 270 

Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser 
        275                 280                 285 

Gln Leu Phe Thr Phe Ser Pro Arg Arg Tyr Glu Thr Val Gln Asp Cys 
    290                 295                 300 

Asn Cys Ser Leu Tyr Pro Gly His Val Ser Gly His Arg Met Ala Trp 
305                 310                 315                 320 

Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln 
                325                 330                 335 

Leu Leu Arg Ile Pro Gln Ala Val Val Asp Met Val Val Gly Ala His 
            340                 345                 350 

Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp 
        355                 360                 365 

Ala Lys Val Leu Ile Val Met Leu Leu Phe Ala Gly Val Asp Gly Thr 
    370                 375                 380 

Thr Tyr Val Ser Val Gly His Ala Ser Gln Thr Thr Arg Arg Val Ala 
385                 390                 395                 400 

Ser Phe Phe Ser Pro Gly Ser Ala Gln Lys Ile Gln Leu Val Asn Thr 
                405                 410                 415 

Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Glu Ser 
            420                 425                 430 

Ile Asn Thr Gly Phe Phe Ala Ala Leu Phe Tyr Val Lys Lys Phe Asn 
        435                 440                 445 

Ser Ser 
    450 

 
           
             195  
             450  
             PRT  
             hepatitis C virus  
           
            195 

Met Ser Thr Asn Gly Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Trp Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Ala Arg Gln Pro Glu Gly Arg Ala Trp Ala Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Leu Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Val Ser Pro Arg Gly Ser Arg Pro Asn Trp Gly Pro Thr Asp Pro 
            100                 105                 110 

Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 
        115                 120                 125 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 
    130                 135                 140 

Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 
145                 150                 155                 160 

Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
                165                 170                 175 

Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Ile Pro Ala Ser Ala Tyr 
            180                 185                 190 

Glu Val His Asn Val Ser Gly Ile Tyr His Val Thr Asn Asp Cys Ser 
        195                 200                 205 

Asn Ser Ser Ile Val Tyr Glu Ala Ala Asp Met Ile Met His Thr Pro 
    210                 215                 220 

Gly Cys Val Pro Cys Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Val 
225                 230                 235                 240 

Ala Leu Thr Pro Thr Leu Ala Ala Arg Asn Asn Ser Val Pro Thr Ala 
                245                 250                 255 

Thr Ile Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys 
            260                 265                 270 

Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Ser 
        275                 280                 285 

Gln Leu Phe Thr Phe Ser Pro Arg Arg Tyr Glu Thr Val Gln Asp Cys 
    290                 295                 300 

Asn Cys Ser Ile Tyr Pro Gly His Val Thr Gly His Arg Met Ala Trp 
305                 310                 315                 320 

Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ser Gln 
                325                 330                 335 

Leu Leu Arg Ile Pro Gln Ala Val Val Asp Met Val Gly Gly Ala His 
            340                 345                 350 

Trp Gly Val Leu Ala Gly Leu Ala Tyr Tyr Ser Met Val Gly Asn Trp 
        355                 360                 365 

Ala Lys Val Leu Ile Val Met Leu Leu Phe Ala Gly Val Asp Gly Ser 
    370                 375                 380 

Thr Ile Val Ser Gly Gly Thr Val Ala Arg Thr Thr His Ser Leu Ala 
385                 390                 395                 400 

Ser Leu Phe Thr Gln Gly Ala Ser Gln Lys Ile Gln Leu Ile Asn Thr 
                405                 410                 415 

Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser 
            420                 425                 430 

Leu Gln Thr Gly Phe Leu Ala Ser Leu Phe Tyr Ala His Arg Phe Asn 
        435                 440                 445 

Ala Ser 
    450 

 
           
             196  
             258  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (71)..(71)  
               Xaa is any amino acid  
             
           
            196 

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Ala Arg Arg Xaa Glu Gly Arg Ser Trp Ala Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Asn Trp Gly Pro Asp Gly Val 
            100                 105                 110 

Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu 
        115                 120                 125 

Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Xaa Thr Ala His Glu Val 
    130                 135                 140 

Arg Asn Ala Ser Gly Val Tyr His Val Thr Asn Asp Cys Ser Asn Ser 
145                 150                 155                 160 

Ser Ile Ile Tyr Glu Met Asp Gly Met Ile Met His Tyr Pro Gly Cys 
                165                 170                 175 

Val Pro Cys Val Arg Glu Asp Asn His Leu Arg Cys Trp Met Ala Leu 
            180                 185                 190 

Thr Pro Thr Leu Ala Val Lys Xaa Ala Ser Val Pro Thr Xaa Ala Ile 
        195                 200                 205 

Arg Arg His Val Asp Leu Leu Val Gly Xaa Xaa Thr Phe Cys Ser Ala 
    210                 215                 220 

Met Tyr Val Xaa Asp Leu Cys Gly Ser Val Phe Leu Ala Gly Gln Leu 
225                 230                 235                 240 
Phe Thr Phe Ser Pro Arg Met His His Thr Thr Gln Glu Cys Asn Cys 
                245                 250                 255 
Ser Ile 

 
           
             197  
             258  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (75)..(75)  
               Xaa is any amino acid  
             
           
            197 

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Asp Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Ala Arg Gln Ser Asp Gly Arg Xaa Trp Ala Gln Pro Gly 
65                  70                  75                  80 

His Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Asp Gly Val 
            100                 105                 110 

Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu 
        115                 120                 125 

Leu Ala Phe Leu Ser Cys Leu Thr Val Pro Thr Thr Ala His Glu Val 
    130                 135                 140 

Arg Asn Ala Ser Gly Val Tyr His Leu Thr Asn Asp Cys Ser Asn Ser 
145                 150                 155                 160 

Ser Ile Ile Tyr Glu Met Ser Gly Met Ile Leu His Ala Pro Gly Cys 
                165                 170                 175 

Val Pro Cys Val Arg Glu Asn Asn Ser Ser Arg Cys Trp Met Xaa Leu 
            180                 185                 190 

Thr Pro Thr Leu Ala Val Lys Asp Ala Asn Val Pro Thr Ala Ala Ile 
        195                 200                 205 

Arg Arg His Val Asp Leu Leu Val Gly Thr Ala Ala Phe Arg Ser Ala 
    210                 215                 220 

Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Gly Gln Leu 
225                 230                 235                 240 

Phe Thr Phe Ser Pro Arg Leu Tyr His Thr Thr Gln Glu Cys Asn Cys 
                245                 250                 255 

Ser Ile 

 
           
             198  
             74  
             PRT  
             hepatitis C virus  
           
            198 

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Val Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Ala Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Glu Arg Arg Pro Glu Gly Arg 
65                  70 

 
           
             199  
             319  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (152)..(152)  
               Xaa is any amino acid  
             
           
            199 

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Ala Arg Arg Pro Glu Gly Arg Ser Trp Ala Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Ala Asn Glu Gly Cys Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Asn Asp Pro 
            100                 105                 110 

Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 
        115                 120                 125 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Leu 
    130                 135                 140 

Gly Gly Ala Ser Arg Thr Leu Xaa His Gly Val Arg Val Leu Xaa Gly 
145                 150                 155                 160 

Gly Val Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa Gly Cys Ser Xaa Xaa Ile 
                165                 170                 175 

Phe Leu Leu Xaa Leu Leu Ser Cys Leu Thr Val Pro Thr Ser Ala Tyr 
            180                 185                 190 

Glu Val His Ser Thr Thr Asp Gly Tyr His Val Thr Asn Asp Cys Ser 
        195                 200                 205 

Asn Gly Ser Ile Val Tyr Glu Ala Lys Asp Ile Ile Leu His Thr Pro 
    210                 215                 220 

Gly Xaa Val Pro Cys Ile Arg Glu Gly Asn Ile Ser Arg Cys Trp Val 
225                 230                 235                 240 

Pro Leu Thr Pro Thr Leu Ala Ala Arg Ile Ala Asn Ala Pro Ile Asp 
                245                 250                 255 

Glu Val Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Val Phe Cys 
            260                 265                 270 

Ser Ala Met Tyr Ile Gly Asp Leu Cys Gly Gly Val Phe Leu Val Gly 
        275                 280                 285 

Gln Leu Phe Thr Phe Thr Ser Arg Arg His Trp Thr Val Gln Asp Cys 
    290                 295                 300 

Asn Cys Ser Ile Tyr Ser Gly His Ile Thr Gly His Xaa Xaa Xaa 
305                 310                 315 

 
           
             200  
             450  
             PRT  
             hepatitis C virus  
           
            200 

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Asp Arg Arg Ser Thr Gly Lys Ser Trp Gly Lys Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Leu Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Asn Asp Pro 
            100                 105                 110 

Arg His Arg Ser Arg Asn Val Gly Lys Val Ile Asp Thr Leu Thr Cys 
        115                 120                 125 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Val Val Gly Ala Pro Leu 
    130                 135                 140 

Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 
145                 150                 155                 160 

Gly Val Asn Phe Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
                165                 170                 175 

Phe Leu Leu Ala Leu Leu Ser Cys Ile Thr Thr Pro Val Ser Ala Ala 
            180                 185                 190 

Glu Val Lys Asn Ile Ser Thr Gly Tyr Met Val Thr Asn Asp Cys Thr 
        195                 200                 205 

Asn Asp Ser Ile Thr Trp Gln Leu Gln Ala Ala Val Leu His Val Pro 
    210                 215                 220 

Gly Cys Val Pro Cys Glu Lys Val Gly Asn Thr Ser Arg Cys Trp Ile 
225                 230                 235                 240 

Pro Val Ser Pro Asn Val Ala Val Gln Gln Pro Gly Ala Leu Thr Gln 
                245                 250                 255 

Gly Leu Arg Thr His Ile Asp Met Val Val Met Ser Ala Thr Leu Cys 
            260                 265                 270 

Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Gly Val Met Leu Ala Ala 
        275                 280                 285 

Gln Met Phe Ile Val Ser Pro Gln His His Trp Phe Val Gln Asp Cys 
    290                 295                 300 

Asn Cys Ser Ile Tyr Pro Gly Thr Ile Thr Gly His Arg Met Ala Trp 
305                 310                 315                 320 

Asp Met Met Met Asn Trp Ser Pro Thr Ala Thr Met Ile Leu Ala Tyr 
                325                 330                 335 

Ala Met Arg Val Pro Glu Val Ile Ile Asp Ile Ile Gly Gly Ala His 
            340                 345                 350 

Trp Gly Val Met Phe Gly Leu Ala Tyr Phe Ser Met Gln Gly Ala Trp 
        355                 360                 365 

Ala Lys Val Val Val Ile Leu Leu Leu Ala Ala Gly Val Asp Ala Gln 
    370                 375                 380 

Thr His Thr Val Gly Gly Ser Thr Ala His Asn Ala Arg Thr Leu Thr 
385                 390                 395                 400 

Gly Met Phe Ser Leu Gly Ala Arg Gln Lys Ile Gln Leu Ile Asn Thr 
                405                 410                 415 

Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser 
            420                 425                 430 

Leu His Thr Gly Phe Leu Ala Ser Leu Phe Tyr Thr His Ser Phe Asn 
        435                 440                 445 

Ser Ser 
    450 

 
           
             201  
             450  
             PRT  
             hepatitis C virus  
           
            201 

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Asp Arg Arg Ser Thr Gly Lys Ser Trp Gly Lys Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Thr Trp Gly Pro Thr Asp Pro 
            100                 105                 110 

Arg His Arg Ser Arg Asn Leu Gly Arg Val Ile Asp Thr Ile Thr Cys 
        115                 120                 125 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Val Val Gly Ala Pro Val 
    130                 135                 140 

Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 
145                 150                 155                 160 

Gly Ile Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
                165                 170                 175 

Phe Leu Leu Ala Leu Leu Ser Cys Val Thr Val Pro Val Ser Ala Val 
            180                 185                 190 

Glu Val Arg Asn Ile Ser Ser Ser Tyr Tyr Ala Thr Asn Asp Cys Ser 
        195                 200                 205 

Asn Asn Ser Ile Thr Trp Gln Leu Thr Asp Ala Val Leu His Leu Pro 
    210                 215                 220 

Gly Cys Val Pro Cys Glu Asn Asp Asn Gly Thr Leu His Cys Trp Ile 
225                 230                 235                 240 

Gln Val Thr Pro Asn Val Ala Val Lys His Arg Gly Ala Leu Thr Arg 
                245                 250                 255 

Ser Leu Arg Thr His Val Asp Met Ile Val Met Ala Ala Thr Ala Cys 
            260                 265                 270 

Ser Ala Leu Tyr Val Gly Asp Val Cys Gly Ala Val Met Ile Leu Ser 
        275                 280                 285 

Gln Ala Phe Met Val Ser Pro Gln Arg His Asn Phe Thr Gln Glu Cys 
    290                 295                 300 

Asn Cys Ser Ile Tyr Gln Gly His Ile Thr Gly His Arg Met Ala Trp 
305                 310                 315                 320 

Asp Met Met Leu Ser Trp Ser Pro Thr Leu Thr Met Ile Leu Ala Tyr 
                325                 330                 335 

Ala Ala Arg Val Pro Glu Leu Val Leu Glu Ile Ile Phe Gly Gly His 
            340                 345                 350 

Trp Gly Val Val Phe Gly Leu Ala Tyr Phe Ser Met Gln Gly Ala Trp 
        355                 360                 365 

Ala Lys Val Ile Ala Ile Leu Leu Leu Val Ala Gly Val Asp Ala Thr 
    370                 375                 380 

Thr Tyr Ser Ser Gly Gln Glu Ala Gly Arg Thr Val Ala Gly Phe Ala 
385                 390                 395                 400 

Gly Leu Phe Thr Thr Gly Ala Lys Gln Asn Leu Tyr Leu Ile Asn Thr 
                405                 410                 415 

Asn Gly Ser Trp His Ile Asn Arg Thr Ala Leu Asn Cys Asn Asp Ser 
            420                 425                 430 

Leu Gln Thr Gly Phe Leu Ala Ser Leu Phe Tyr Thr His Lys Phe Asn 
        435                 440                 445 

Ser Ser 
    450 

 
           
             202  
             319  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (319)..(319)  
               Xaa is any amino acid  
             
           
            202 

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Asp Arg Arg Thr Thr Gly Lys Ser Trp Gly Arg Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Leu Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 
            100                 105                 110 

Arg His Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 
        115                 120                 125 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Val Val Gly Ala Pro Val 
    130                 135                 140 

Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 
145                 150                 155                 160 

Gly Ile Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
                165                 170                 175 

Phe Leu Ser Ala Leu Leu Ser Cys Ile Ser Val Pro Val Ser Ala Val 
            180                 185                 190 

Glu Val Lys Asn Thr Ser Thr Ser Tyr Met Val Thr Asn Asp Cys Ser 
        195                 200                 205 

Asn Ser Ser Ile Val Trp Gln Leu Glu Gly Ala Val Leu His Thr Pro 
    210                 215                 220 

Gly Cys Val Pro Cys Glu Gln Ile Gly Asn Ala Ser Arg Cys Trp Val 
225                 230                 235                 240 

Pro Val Ser Pro Asn Val Ala Ile Arg Gln Pro Gly Thr Leu Thr Lys 
                245                 250                 255 

Gly Leu Arg Ala His Val Asp Val Ile Val Met Ser Ala Thr Leu Cys 
            260                 265                 270 

Ser Ala Leu Tyr Val Gly Asp Val Cys Gly Ala Leu Met Ile Ala Ala 
        275                 280                 285 

Gln Ala Val Ile Ala Ser Pro Gln Arg His Thr Phe Val Gln Glu Cys 
    290                 295                 300 

Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Xaa 
305                 310                 315 

 
           
             203  
             193  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (5)..(5)  
               Xaa is any amino acid  
             
           
            203 

Thr Cys Gly Phe Xaa Asp Leu Met Gly Tyr Ile Pro Val Val Gly Ala 
1               5                   10                  15 

Pro Xaa Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Val Leu 
            20                  25                  30 

Glu Asp Gly Ile Xaa Tyr Ala Thr Gly Asn Met Pro Gly Cys Ser Phe 
        35                  40                  45 

Ser Ile Phe Leu Leu Ala Leu Leu Ser Xaa Ile Ser Val Pro Val Ser 
    50                  55                  60 

Ala Xaa Glu Val Arg Asn Thr Ser Thr Leu Tyr Met Val Thr Asn Asp 
65                  70                  75                  80 

Cys Ser Asn Ser Ser Ile Val Trp Gln Leu Glu Gly Ala Val Xaa His 
                85                  90                  95 

Ile Pro Gly Cys Val Pro Cys Glu Trp Thr Asn Thr Thr Pro Arg Cys 
            100                 105                 110 

Trp Val Pro Val Ser Pro Xaa Val Ala Ile Arg Gln Pro Gly Ala Leu 
        115                 120                 125 

Thr Lys Gly Leu Arg Ala His Ile Asp Val Ile Val Met Ser Ala Thr 
    130                 135                 140 

Leu Cys Ser Ala Leu Tyr Val Gly Asp Val Cys Gly Ala Leu Met Ile 
145                 150                 155                 160 

Ala Ala Gln Ala Val Val Ala Ser Pro Gln Arg His Xaa Phe Val Gln 
                165                 170                 175 

Glu Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met 
            180                 185                 190 

Xaa 

 
           
             204  
             304  
             PRT  
             hepatitis C virus  
           
            204 

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Asp Arg Arg Pro Thr Gly Lys Ser Trp Gly Lys Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Leu Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Thr Asp Pro 
            100                 105                 110 

Arg His Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 
        115                 120                 125 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Val Val Gly Ala Pro Val 
    130                 135                 140 

Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 
145                 150                 155                 160 

Gly Ile Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
                165                 170                 175 

Phe Leu Leu Ala Leu Leu Ser Cys Ile Thr Val Pro Val Ser Gly Leu 
            180                 185                 190 

Gln Val Lys Asn Thr Ser Ser Ser Tyr Met Val Thr Asn Asp Cys Gln 
        195                 200                 205 

Asn Ser Ser Ile Val Trp Gln Leu Arg Asp Ala Val Leu His Val Pro 
    210                 215                 220 

Gly Cys Val Pro Cys Glu Glu Lys Gly Asn Ile Ser Arg Cys Trp Ile 
225                 230                 235                 240 

Pro Val Ser Pro Asn Ile Ala Val Ser Gln Pro Gly Ala Leu Thr Lys 
                245                 250                 255 

Gly Leu Arg Thr His Ile Asp Thr Ile Ile Ala Ser Ala Thr Phe Cys 
            260                 265                 270 

Ser Ala Leu Tyr Ile Gly Asp Leu Cys Gly Ala Val Met Val Gln Asp 
        275                 280                 285 

Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Ala 
    290                 295                 300 

 
           
             205  
             277  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (70)..(70)  
               Xaa is any amino acid  
             
           
            205 

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Asp Arg Xaa Ala Thr Gly Arg Ser Trp Gly Arg Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Leu Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Leu Ala Xaa Gly 
            100                 105                 110 

Val Arg Val Leu Glu Asp Gly Ile Asn Tyr Xaa Thr Gly Asn Leu Pro 
        115                 120                 125 

Gly Cys Ser Phe Ser Ile Phe Xaa Leu Ala Leu Leu Ser Cys Val Thr 
    130                 135                 140 

Val Pro Val Ser Xaa Val Glu Val Lys Asn Thr Ser Gln Ala Tyr Met 
145                 150                 155                 160 

Ala Thr Asn Asp Cys Ser Asn Asn Ser Ile Val Trp Gln Leu Xaa Asp 
                165                 170                 175 

Ala Val Leu His Val Pro Gly Cys Val Pro Cys Glu Asn Ser Ser Gly 
            180                 185                 190 

Arg Phe His Cys Trp Ile Pro Ile Ser Pro Asn Ile Ala Val Ser Lys 
        195                 200                 205 

Pro Gly Ala Leu Thr Lys Gly Leu Arg Ala Arg Ile Asp Ala Val Val 
    210                 215                 220 

Met Ser Ala Thr Leu Cys Ser Ala Leu Tyr Val Gly Asp Val Cys Gly 
225                 230                 235                 240 

Ala Val Met Ile Ala Ala Gln Ala Phe Ile Val Ala Pro Lys Arg His 
                245                 250                 255 

Tyr Phe Val Gln Glu Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr 
            260                 265                 270 

Gly His Arg Met Ala 
        275 

 
           
             206  
             319  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (131)..(131)  
               Xaa is any amino acid  
             
           
            206 

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Pro Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Asp Arg Arg Ala Thr Gly Lys Ser Trp Gly Arg Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Leu Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Asn Asp Pro 
            100                 105                 110 

Arg His Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 
        115                 120                 125 

Gly Phe Xaa Asp Leu Met Gly Tyr Ile Pro Val Val Gly Ala Pro Val 
    130                 135                 140 

Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 
145                 150                 155                 160 

Gly Ile Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
                165                 170                 175 

Phe Leu Leu Ala Leu Leu Ser Cys Ile Thr Val Pro Val Ser Ala Ile 
            180                 185                 190 

Gln Val Lys Asn Asn Ser His Phe Tyr Met Ala Thr Asn Asp Cys Ala 
        195                 200                 205 

Asn Asp Ser Ile Val Trp Gln Leu Arg Asp Ala Val Leu His Val Pro 
    210                 215                 220 

Gly Cys Val Pro Cys Glu Arg Ser Gly Asn Arg Thr Phe Cys Trp Thr 
225                 230                 235                 240 

Ala Val Ser Pro Asn Val Ala Val Ser Arg Pro Gly Ala Leu Thr Arg 
                245                 250                 255 

Gly Leu Arg Ala His Ile Asp Thr Ile Val Met Ser Ala Thr Leu Cys 
            260                 265                 270 

Ser Ala Leu Tyr Ile Gly Asp Leu Cys Gly Ala Val Met Ile Ala Ala 
        275                 280                 285 

Gln Val Ala Val Val Ser Pro Gln Tyr His Thr Phe Val Gln Glu Cys 
    290                 295                 300 

Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His Arg Met Xaa 
305                 310                 315 

 
           
             207  
             187  
             PRT  
             hepatitis C virus  
           
            207 

Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Val Gly Gly Val Ala 
1               5                   10                  15 

Arg Ala Leu Ala His Gly Val Arg Ala Leu Glu Asp Gly Ile Asn Phe 
            20                  25                  30 

Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala 
        35                  40                  45 

Leu Phe Ser Cys Leu Ile His Pro Ala Ala Ser Leu Glu Trp Arg Asn 
    50                  55                  60 

Thr Ser Gly Leu Tyr Val Leu Thr Asn Asp Cys Ser Asn Ser Ser Ile 
65                  70                  75                  80 

Val Tyr Glu Ala Asp Asp Val Ile Leu His Thr Pro Gly Cys Val Pro 
                85                  90                  95 

Cys Val Gln Asp Gly Asn Thr Ser Ala Cys Trp Thr Pro Val Thr Pro 
            100                 105                 110 

Thr Val Ala Val Arg Tyr Val Gly Ala Thr Thr Ala Ser Ile Arg Arg 
        115                 120                 125 

His Val Asp Met Leu Val Gly Ala Ala Thr Met Cys Ser Ala Leu Tyr 
    130                 135                 140 

Val Gly Asp Met Cys Gly Ala Val Phe Leu Val Gly Gln Ala Phe Thr 
145                 150                 155                 160 

Phe Arg Pro Arg Arg His Gln Thr Val Gln Thr Cys Asn Cys Ser Leu 
                165                 170                 175 

Tyr Pro Gly His Leu Ser Gly His Arg Met Ala 
            180                 185 

 
           
             208  
             187  
             PRT  
             hepatitis C virus  
           
            208 

Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Val Gly Gly Val Ala 
1               5                   10                  15 

Arg Ala Leu Ala His Gly Val Arg Ala Leu Glu Asp Gly Ile Asn Phe 
            20                  25                  30 

Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala 
        35                  40                  45 

Leu Phe Ser Cys Leu Ile His Pro Ala Ala Gly Leu Glu Trp Arg Asn 
    50                  55                  60 

Thr Ser Gly Leu Tyr Val Leu Thr Asn Asp Cys Ser Asn Ser Ser Ile 
65                  70                  75                  80 

Val Tyr Glu Ala Asp Asp Val Ile Leu His Ala Pro Gly Cys Val Pro 
                85                  90                  95 

Cys Val Gln Asp Gly Asn Thr Ser Thr Cys Trp Thr Pro Val Thr Pro 
            100                 105                 110 

Thr Val Ala Val Arg Tyr Val Gly Ala Thr Thr Ala Ser Ile Arg Ser 
        115                 120                 125 

His Val Asp Leu Leu Val Gly Ala Ala Thr Met Cys Ser Ala Leu Tyr 
    130                 135                 140 

Val Gly Asp Met Cys Gly Ala Val Phe Leu Val Gly Gln Ala Phe Thr 
145                 150                 155                 160 

Phe Arg Pro Arg Arg His Gln Thr Val Gln Thr Cys Asn Cys Ser Leu 
                165                 170                 175 

Tyr Pro Gly His Leu Ser Gly His Arg Met Ala 
            180                 185 

 
           
             209  
             187  
             PRT  
             hepatitis C virus  
           
            209 

Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Val Gly Gly Val Ala 
1               5                   10                  15 

Arg Ala Leu Ala His Gly Val Arg Ala Leu Glu Asp Gly Ile Asn Phe 
            20                  25                  30 

Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala 
        35                  40                  45 

Leu Phe Ser Cys Leu Ile His Pro Ala Ala Ser Leu Glu Trp Arg Asn 
    50                  55                  60 

Thr Ser Gly Leu Tyr Val Leu Thr Asn Asp Cys Ser Asn Ser Ser Ile 
65                  70                  75                  80 

Val Tyr Glu Ala Asp Asp Val Ile Leu His Thr Pro Gly Ile Val Pro 
                85                  90                  95 

Cys Val Gln Asp Gly Asn Thr Ser Thr Cys Trp Thr Pro Val Thr Pro 
            100                 105                 110 

Thr Val Ala Val Lys Tyr Val Gly Ala Thr Thr Ala Ser Ile Arg Ser 
        115                 120                 125 

His Val Asp Leu Leu Val Gly Ala Ala Thr Met Cys Ser Ala Leu Tyr 
    130                 135                 140 

Val Gly Asp Met Cys Gly Ala Val Phe Leu Val Gly Gln Ala Phe Thr 
145                 150                 155                 160 

Phe Arg Pro Arg Arg His Gln Thr Val Gln Thr Cys Asn Cys Ser Leu 
                165                 170                 175 

Tyr Pro Gly His Leu Ser Gly His Arg Met Ala 
            180                 185 

 
           
             210  
             193  
             PRT  
             hepatitis C virus  
           
            210 

Thr Cys Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala 
1               5                   10                  15 

Pro Val Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Ala Leu 
            20                  25                  30 

Glu Asp Gly Ile Asn Phe Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe 
        35                  40                  45 

Ser Ile Phe Leu Leu Ala Leu Phe Ser Cys Leu Ile His Pro Ala Ala 
    50                  55                  60 

Ser Leu Glu Trp Arg Asn Thr Ser Gly Leu Tyr Val Leu Thr Asn Asp 
65                  70                  75                  80 

Cys Ser Asn Ser Ser Ile Val Tyr Glu Ala Asp Asp Val Ile Leu His 
                85                  90                  95 

Thr Pro Gly Cys Val Pro Cys Val Gln Asp Gly Asn Thr Ser Thr Cys 
            100                 105                 110 

Trp Thr Pro Val Thr Pro Thr Val Ala Val Arg Tyr Val Gly Ala Thr 
        115                 120                 125 

Thr Ala Ser Ile Arg Ser His Val Asp Leu Leu Val Gly Ala Ala Thr 
    130                 135                 140 

Met Cys Ser Ala Leu Tyr Val Gly Asp Met Cys Gly Ala Val Phe Leu 
145                 150                 155                 160 

Val Gly Gln Ala Phe Thr Phe Arg Pro Arg Arg His Gln Thr Val Gln 
                165                 170                 175 

Thr Cys Asn Cys Ser Leu Tyr Pro Gly His Leu Ser Gly His Arg Met 
            180                 185                 190 

Ala 

 
           
             211  
             319  
             PRT  
             hepatitis C virus  
           
            211 

Met Ser Thr Leu Pro Lys Pro Gln Arg Gln Thr Lys Arg Asn Thr Leu 
1               5                   10                  15 

Arg Arg Pro Gln Asn Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Val Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Val Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Lys Gln Arg His Leu 
    50                  55                  60 

Ile Pro Lys Ala Arg Ser Arg Glu Gly Arg Ser Trp Ala Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Lys Gly Cys Gly Leu Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Asn Asp Pro 
            100                 105                 110 

Arg Arg Arg Ser Arg Asn Phe Gly Lys Val Ile Asp Thr Leu Thr Cys 
        115                 120                 125 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Val 
    130                 135                 140 

Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Ala Leu Gly Asp 
145                 150                 155                 160 

Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
                165                 170                 175 

Phe Leu Leu Ala Leu Phe Ser Cys Leu Thr Cys Pro Ala Ser Gly Leu 
            180                 185                 190 

Glu Tyr Thr Asn Thr Ser Gly Leu Tyr Val Leu Thr Asn Asp Cys Ser 
        195                 200                 205 

Asn Gly Ser Ile Val Tyr Glu Ala Glu Asp Val Ile Leu His Leu Pro 
    210                 215                 220 

Gly Cys Val Pro Cys Val Thr Thr Gly Asn Gln Ser Ser Cys Trp Thr 
225                 230                 235                 240 

Thr Val Ser Thr Thr Val Ala Val Arg Thr Leu Gly Val Thr Thr Ala 
                245                 250                 255 

Ser Ile Arg Thr His Val Asp Met Leu Val Gly Ala Arg Gln Leu Cys 
            260                 265                 270 

Ser Ala Leu Tyr Val Gly Asp Ala Phe Gly Ala Val Phe Leu Val Gly 
        275                 280                 285 

Gln Ala Phe Thr Phe Arg Pro Arg Arg His Thr Thr Val Gln Thr Cys 
    290                 295                 300 

Asn Cys Ser Ile Tyr Pro Gly His Val Ser Gly His Arg Met Ala 
305                 310                 315 

 
           
             212  
             193  
             PRT  
             hepatitis C virus  
           
            212 

Thr Cys Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala 
1               5                   10                  15 

Pro Val Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Ala Val 
            20                  25                  30 

Glu Asp Gly Ile Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe 
        35                  40                  45 

Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser 
    50                  55                  60 

Ala Glu His Tyr Arg Asn Ala Ser Gly Ile Tyr His Ile Thr Asn Asp 
65                  70                  75                  80 

Cys Pro Asn Ser Ser Val Val Tyr Glu Thr Asp His His Ile Leu His 
                85                  90                  95 

Leu Pro Gly Cys Val Pro Cys Val Arg Ala Gly Asn Val Ser Arg Cys 
            100                 105                 110 

Trp Thr Pro Val Thr Pro Thr Val Ala Ala Val Ser Met Asp Ala Pro 
        115                 120                 125 

Leu Glu Ser Phe Arg Arg His Val Asp Leu Met Val Gly Ala Ala Thr 
    130                 135                 140 

Val Cys Ser Val Leu Tyr Val Gly Asp Leu Cys Gly Gly Ala Phe Leu 
145                 150                 155                 160 

Val Gly Gln Met Phe Thr Phe Gln Pro Arg Arg His Trp Thr Thr Gln 
                165                 170                 175 

Asp Cys Asn Cys Ser Ile Tyr Thr Gly His Ile Thr Gly His Arg Met 
            180                 185                 190 

Ala 

 
           
             213  
             193  
             PRT  
             hepatitis C virus  
           
            213 

Thr Cys Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala 
1               5                   10                  15 

Pro Val Gly Gly Val Ala Arg Ala Leu Glu His Gly Val Arg Ala Val 
            20                  25                  30 

Glu Asp Gly Ile Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe 
        35                  40                  45 

Ser Ile Ser Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Thr Ser 
    50                  55                  60 

Ala Val Asn Tyr Arg Asn Ala Ser Gly Val Tyr His Ile Thr Asn Asp 
65                  70                  75                  80 

Cys Pro Asn Ser Ser Ile Val Tyr Glu Ala Asp Tyr His Ile Leu His 
                85                  90                  95 

Leu Pro Gly Leu Val Pro Cys Val Arg Val Gly Asn Gln Ser Arg Cys 
            100                 105                 110 

Trp Val Ala Leu Thr Pro Thr Val Ala Ala Pro Tyr Val Gly Ala Pro 
        115                 120                 125 

Leu Glu Ser Leu Arg Ser His Val Asp Leu Met Val Gly Ala Ala Thr 
    130                 135                 140 

Val Cys Ser Ala Leu Tyr Ile Gly Asp Leu Cys Gly Gly Val Phe Leu 
145                 150                 155                 160 

Val Gly Gln Met Phe Ser Phe Gln Pro Arg Arg His Trp Thr Thr Gln 
                165                 170                 175 

Asp Cys Asn Cys Ser Ile Tyr Ala Gly His Val Thr Gly His Arg Met 
            180                 185                 190 

Ala 

 
           
             214  
             193  
             PRT  
             hepatitis C virus  
           
            214 

Thr Cys Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala 
1               5                   10                  15 

Pro Val Gly Gly Val Ala Arg Ala Leu Glu His Gly Val Arg Ala Val 
            20                  25                  30 

Glu Asp Gly Ile Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe 
        35                  40                  45 

Ser Ile Tyr Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Thr Ser 
    50                  55                  60 

Ala Ile His Tyr Arg Asn Ala Ser Gly Val Tyr His Val Thr Asn Asp 
65                  70                  75                  80 

Cys Pro Asn Ser Ser Ile Val Tyr Glu Ala Asp His His Ile Leu His 
                85                  90                  95 

Leu Pro Gly Leu Val Pro Cys Val Arg Val Gly Asn Gln Ser Arg Cys 
            100                 105                 110 

Trp Val Ala Leu Ser Pro Thr Val Ala Ala Pro Tyr Ile Gly Ala Pro 
        115                 120                 125 

Val Glu Ser Phe Arg Arg His Val Asp Met Met Val Gly Ala Ala Thr 
    130                 135                 140 

Val Cys Ser Ala Leu Tyr Ile Gly Asp Leu Cys Gly Gly Val Phe Leu 
145                 150                 155                 160 

Val Gly Gln Met Phe Ser Phe Arg Pro Arg Arg His Trp Thr Thr Gln 
                165                 170                 175 

Asp Cys Asn Cys Ser Ile Tyr Ala Gly His Ile Thr Gly His Gly Met 
            180                 185                 190 

Ala 

 
           
             215  
             193  
             PRT  
             hepatitis C virus  
           
            215 

Thr Cys Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala 
1               5                   10                  15 

Pro Val Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Ala Val 
            20                  25                  30 

Glu Asp Gly Ile Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe 
        35                  40                  45 

Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Thr Ser 
    50                  55                  60 

Ala Val Asn Tyr Arg Asn Ala Ser Gly Ile Tyr His Ile Thr Asn Asp 
65                  70                  75                  80 

Cys Pro Asn Ser Ser Ile Val Tyr Glu Thr Glu His His Ile Leu His 
                85                  90                  95 

Leu Pro Gly Leu Val Pro Cys Val Arg Val Gly Asn Gln Ser Arg Cys 
            100                 105                 110 

Trp Val Ala Leu Thr Pro Thr Val Ala Ala Pro Tyr Ile Gly Ala Pro 
        115                 120                 125 

Leu Glu Ser Leu Arg Ser His Val Asp Leu Met Val Gly Ala Ala Thr 
    130                 135                 140 

Ala Cys Ser Ala Leu Tyr Ile Gly Asp Leu Cys Gly Gly Val Phe Leu 
145                 150                 155                 160 

Val Gly Gln Met Phe Ser Phe Gln Pro Arg Arg His Trp Thr Thr Gln 
                165                 170                 175 

Asp Cys Asn Cys Ser Ile Tyr Ala Gly His Val Thr Gly His Arg Met 
            180                 185                 190 

Ala 

 
           
             216  
             24  
             PRT  
             hepatitis C virus  
           
            216 

Thr Cys Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala 
1               5                   10                  15 

Pro Val Gly Gly Val Ala Arg Ala 
            20 

 
           
             217  
             319  
             PRT  
             hepatitis C virus  
           
            217 

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Met Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Ala Arg Gln Leu Glu Gly Arg Ser Trp Ala Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Asn Asp Pro 
            100                 105                 110 

Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 
        115                 120                 125 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Val Val Gly Ala Pro Val 
    130                 135                 140 

Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Leu Leu Glu Asp 
145                 150                 155                 160 

Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
                165                 170                 175 

Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Tyr 
            180                 185                 190 

Asn Tyr Arg Asn Ser Ser Gly Val Tyr His Val Thr Asn Asp Cys Pro 
        195                 200                 205 

Asn Ser Ser Ile Val Tyr Glu Thr Asp Tyr His Ile Leu His Leu Pro 
    210                 215                 220 

Gly Cys Val Pro Cys Val Arg Glu Gly Asn Lys Ser Thr Cys Trp Val 
225                 230                 235                 240 

Ser Leu Thr Pro Thr Val Ala Ala Gln His Leu Asn Ala Pro Leu Glu 
                245                 250                 255 

Ser Leu Arg Arg His Val Asp Leu Met Val Gly Gly Ala Thr Leu Cys 
            260                 265                 270 

Ser Ala Leu Tyr Ile Gly Asp Val Cys Gly Gly Val Phe Leu Val Gly 
        275                 280                 285 

Gln Leu Phe Thr Phe Gln Pro Arg Arg His Trp Thr Thr Gln Asp Cys 
    290                 295                 300 

Asn Cys Ser Ile Tyr Thr Gly His Ile Thr Gly His Arg Met Ala 
305                 310                 315 

 
           
             218  
             319  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (102)..(102)  
               Xaa is any amino acid  
             
           
            218 

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Met Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Ala Arg Arg Thr Glu Gly Arg Ser Trp Ala Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Xaa Ser Arg Xaa Ser Trp Gly Pro Asn Asp Pro 
            100                 105                 110 

Arg Xaa Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 
        115                 120                 125 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Val 
    130                 135                 140 

Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Ala Val Glu Asp 
145                 150                 155                 160 

Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
                165                 170                 175 

Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Thr Ser Ala Val 
            180                 185                 190 

Asn Tyr Arg Asn Ala Ser Gly Ile Tyr His Ile Thr Asn Asp Cys Pro 
        195                 200                 205 

Asn Ala Ser Ile Val Tyr Glu Thr Glu Asn His Ile Leu His Leu Pro 
    210                 215                 220 

Gly Cys Val Pro Cys Val Arg Thr Gly Asn Gln Ser Arg Cys Trp Val 
225                 230                 235                 240 

Ala Leu Thr Pro Thr Val Ala Ser Pro Tyr Ala Gly Ala Pro Leu Glu 
                245                 250                 255 

Pro Leu Arg Arg His Val Asp Leu Met Val Gly Ala Ala Thr Met Cys 
            260                 265                 270 

Ser Ala Leu Tyr Ile Gly Asp Leu Cys Gly Gly Leu Phe Leu Val Gly 
        275                 280                 285 

Gln Met Phe Thr Phe Gln Pro Arg Arg His Trp Thr Thr Gln Asp Cys 
    290                 295                 300 

Asn Cys Ser Ile Tyr Thr Gly His Ile Thr Gly His Arg Met Ala 
305                 310                 315 

 
           
             219  
             319  
             PRT  
             hepatitis C virus  
           
            219 

Met Ser Thr Asn Pro Lys Leu Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Met Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Ala Arg Arg Ser Glu Gly Arg Ser Trp Ala Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Asn Asp Pro 
            100                 105                 110 

Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 
        115                 120                 125 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala Pro Val 
    130                 135                 140 

Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Ala Val Glu Asp 
145                 150                 155                 160 

Gly Ile Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
                165                 170                 175 

Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Gly Val 
            180                 185                 190 

Asn Tyr Arg Asn Ala Ser Gly Val Tyr His Ile Thr Asn Asp Cys Pro 
        195                 200                 205 

Asn Ala Ser Ile Val Tyr Glu Thr Asp Asn His Ile Leu His Leu Pro 
    210                 215                 220 

Gly Cys Val Pro Cys Val Lys Thr Gly Asn Gln Ser Arg Cys Trp Val 
225                 230                 235                 240 

Ala Leu Thr Pro Thr Val Ala Ser Pro Tyr Val Gly Ala Pro Leu Glu 
                245                 250                 255 

Pro Leu Arg Arg His Val Asp Leu Met Val Gly Ala Ala Thr Val Cys 
            260                 265                 270 

Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Gly Leu Phe Leu Val Gly 
        275                 280                 285 

Gln Met Phe Thr Phe Gln Pro Arg Arg His Trp Thr Thr Gln Asp Cys 
    290                 295                 300 

Asn Cys Ser Ile Tyr Ala Gly His Ile Thr Gly His Arg Met Ala 
305                 310                 315 

 
           
             220  
             193  
             PRT  
             hepatitis C virus  
           
            220 

Thr Cys Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala 
1               5                   10                  15 

Pro Val Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Ala Val 
            20                  25                  30 

Glu Asp Gly Ile Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe 
        35                  40                  45 

Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser 
    50                  55                  60 

Ala Val His Tyr His Asn Thr Ser Gly Ile Tyr His Leu Thr Asn Asp 
65                  70                  75                  80 

Cys Pro Asn Ser Ser Ile Val Phe Glu Ala Val His His Ile Leu His 
                85                  90                  95 

Leu Pro Gly Cys Val Pro Cys Val Arg Thr Gly Asn Gln Ser Arg Cys 
            100                 105                 110 

Trp Val Ala Leu Thr Pro Thr Leu Ala Ala Pro Tyr Leu Gly Ala Pro 
        115                 120                 125 

Leu Glu Ser Met Arg Arg His Val Asp Leu Met Val Gly Thr Ala Thr 
    130                 135                 140 

Leu Cys Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Gly Ile Phe Leu 
145                 150                 155                 160 

Ala Gly Gln Met Phe Thr Phe Arg Pro Arg Leu His Trp Thr Thr Gln 
                165                 170                 175 

Glu Cys Asn Cys Ser Thr Tyr Pro Gly His Ile Thr Gly His Arg Met 
            180                 185                 190 

Ala 

 
           
             221  
             193  
             PRT  
             hepatitis C virus  
           
            221 

Thr Cys Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala 
1               5                   10                  15 

Pro Val Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Ala Val 
            20                  25                  30 

Glu Asp Gly Ile Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe 
        35                  40                  45 

Ser Ile Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser 
    50                  55                  60 

Ala Gln His Tyr Arg Asn Ile Ser Gly Ile Tyr His Val Thr Asn Asp 
65                  70                  75                  80 

Cys Pro Asn Ser Ser Ile Val Tyr Glu Ala Asp His His Ile Met His 
                85                  90                  95 

Leu Pro Gly Cys Val Pro Cys Val Arg Thr Gly Asn Thr Ser Arg Cys 
            100                 105                 110 

Trp Val Pro Leu Thr Pro Thr Val Ala Ala Pro Tyr Val Gly Ala Pro 
        115                 120                 125 

Leu Glu Ser Met Arg Arg His Val Asp Leu Met Val Gly Ala Ala Thr 
    130                 135                 140 

Val Cys Ser Ala Leu Tyr Ile Gly Asp Leu Cys Gly Gly Val Phe Leu 
145                 150                 155                 160 

Val Gly Gln Met Phe Thr Phe Arg Pro Arg Arg His Trp Thr Thr Gln 
                165                 170                 175 

Asp Cys Asn Cys Ser Ile Tyr Asp Gly His Ile Thr Gly His Arg Met 
            180                 185                 190 

Ala 

 
           
             222  
             193  
             PRT  
             hepatitis C virus  
           
            222 

Thr Cys Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala 
1               5                   10                  15 

Pro Val Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Ala Val 
            20                  25                  30 

Glu Asp Gly Ile Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe 
        35                  40                  45 

Ser Ile Phe Leu Leu Val Leu Leu Ser Arg Leu Thr Val Pro Ala Ser 
    50                  55                  60 

Ala Gln His Tyr Arg Asn Ala Ser Gly Ile Tyr His Val Thr Asn Asp 
65                  70                  75                  80 

Cys Pro Asn Ser Ser Ile Val Tyr Glu Ala Asp His His Ile Met His 
                85                  90                  95 

Leu Pro Gly Cys Val Pro Cys Val Arg Thr Gly Asn Val Ser Arg Cys 
            100                 105                 110 

Trp Ile Pro Leu Thr Pro Thr Val Ala Val Pro Tyr Leu Gly Ala Pro 
        115                 120                 125 

Leu Thr Ser Val Arg Gln His Val Asp Leu Met Val Gly Ala Ala Thr 
    130                 135                 140 

Leu Cys Ser Ala Leu Tyr Ile Gly Asp His Cys Gly Gly Val Phe Leu 
145                 150                 155                 160 

Ala Gly Gln Met Val Ser Phe Gln Pro Arg Arg His Trp Thr Thr Gln 
                165                 170                 175 

Asp Cys Asn Cys Ser Ile Tyr Val Gly His Ile Thr Gly His Arg Met 
            180                 185                 190 

Ala 

 
           
             223  
             193  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (24)..(24)  
               Xaa is any amino acid  
             
           
            223 

Thr Cys Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala 
1               5                   10                  15 

Pro Val Gly Gly Val Ala Arg Xaa Leu Ala His Gly Val Arg Ala Leu 
            20                  25                  30 

Glu Asp Gly Ile Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe 
        35                  40                  45 

Ser Ile Ser Leu Leu Glu Leu Leu Ser Cys Leu Thr Val Pro Ala Ser 
    50                  55                  60 

Ala Ile His Tyr Arg Asn Ala Ser Asp Gly Tyr Tyr Ile Thr Asn Asp 
65                  70                  75                  80 

Cys Pro Asn Ser Ser Ile Val Tyr Glu Ala Glu Asn His Ile Leu His 
                85                  90                  95 

Leu Pro Gly Ile Val Pro Cys Val Lys Thr Gly Asn Gln Ser Arg Cys 
            100                 105                 110 

Trp Val Ala Leu Thr Pro Thr Leu Ala Ala Pro His Leu Arg Ala Pro 
        115                 120                 125 

Leu Ser Ser Leu Arg Ala His Val Asp Leu Met Val Gly Ala Ala Thr 
    130                 135                 140 

Ala Cys Ser Ala Phe Tyr Ile Gly Asp Leu Cys Gly Gly Val Phe Leu 
145                 150                 155                 160 

Ala Gly Gln Leu Phe Thr Ile Arg Pro Arg Ile His Glu Thr Thr Gln 
                165                 170                 175 

Asp Cys Asn Cys Ser Ile Tyr Ser Gly His Ile Thr Gly Xaa Xaa Xaa 
            180                 185                 190 

Xaa 

 
           
             224  
             193  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (51)..(51)  
               Xaa is any amino acid  
             
           
            224 

Ala Cys Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Ala 
1               5                   10                  15 

Pro Val Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Ala Val 
            20                  25                  30 

Glu Asp Gly Ile Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe 
        35                  40                  45 

Ser Ile Xaa Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser 
    50                  55                  60 

Ala Gln His Tyr Arg Asn Val Ser Gly Ile Tyr His Val Thr Asn Asp 
65                  70                  75                  80 

Cys Pro Asn Ser Ser Ile Val Tyr Glu Ala Asp His His Ile Met His 
                85                  90                  95 

Leu Pro Gly Ile Val Pro Cys Val Arg Thr Gly Asn Val Ser Arg Cys 
            100                 105                 110 

Trp Val Ser Leu Thr Pro Thr Val Ala Ala Pro Tyr Leu Gly Ala Pro 
        115                 120                 125 

Leu Thr Ser Leu Arg Arg His Val Asp Leu Met Val Gly Ala Ala Thr 
    130                 135                 140 

Leu Cys Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Gly Val Phe Leu 
145                 150                 155                 160 

Val Gly Gln Met Phe Thr Phe Gln Pro Arg Arg His Trp Thr Thr Gln 
                165                 170                 175 

Asp Cys Asn Cys Ser Ile Tyr Val Gly His Ile Thr Gly His Arg Met 
            180                 185                 190 

Ala 

 
           
             225  
             117  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (95)..(95)  
               Xaa is any amino acid  
             
           
            225 

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Met Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Ala Arg Arg Ser Glu Gly Arg Ser Trp Ala Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Xaa Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser Trp Gly Pro Asn Asp Pro 
            100                 105                 110 

Arg Arg Arg Ser Arg 
        115 

 
           
             226  
             319  
             PRT  
             hepatitis C virus  
           
            226 

Met Ser Thr Asn Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Met Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Ala Arg Gln Pro Thr Gly Arg Ser Trp Gly Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Ala Asn Glu Gly Leu Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Asn Trp Gly Pro Asn Asp Pro 
            100                 105                 110 

Arg Arg Lys Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 
        115                 120                 125 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Gly Gly Pro Ile 
    130                 135                 140 

Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Val Leu Glu Asp 
145                 150                 155                 160 

Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
                165                 170                 175 

Phe Ile Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala Val 
            180                 185                 190 

Pro Tyr Arg Asn Ala Ser Gly Ile Tyr His Val Thr Asn Asp Cys Pro 
        195                 200                 205 

Asn Ser Ser Ile Val Tyr Glu Ala Asp Asn Leu Ile Leu His Ala Pro 
    210                 215                 220 

Gly Cys Val Pro Cys Val Met Thr Gly Asn Val Ser Arg Cys Trp Val 
225                 230                 235                 240 

Gln Ile Thr Pro Thr Leu Ser Ala Pro Ser Leu Gly Ala Val Thr Ala 
                245                 250                 255 

Pro Leu Arg Arg Ala Val Asp Tyr Leu Ala Gly Gly Ala Ala Leu Cys 
            260                 265                 270 

Ser Ala Leu Tyr Val Gly Asp Ala Cys Gly Ala Leu Phe Leu Val Gly 
        275                 280                 285 

Gln Met Phe Thr Tyr Arg Pro Arg Gln His Ala Thr Val Gln Asn Cys 
    290                 295                 300 

Asn Cys Ser Ile Tyr Ser Gly His Val Thr Gly His Arg Met Ala 
305                 310                 315 

 
           
             227  
             193  
             PRT  
             hepatitis C virus  
           
            227 

Thr Cys Gly Phe Ala Asp Leu Val Gly Tyr Ile Pro Leu Val Gly Gly 
1               5                   10                  15 

Pro Val Gly Gly Val Ala Arg Ala Leu Ala His Gly Val Arg Val Leu 
            20                  25                  30 

Glu Asp Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe 
        35                  40                  45 

Ser Ile Phe Ile Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser 
    50                  55                  60 

Ala Val Pro Tyr Arg Asn Ala Ser Gly Ile Tyr His Val Thr Asn Asp 
65                  70                  75                  80 

Cys Pro Asn Ser Ser Ile Val Tyr Glu Ala Asp Asp Leu Ile Leu His 
                85                  90                  95 

Ala Pro Gly Cys Val Pro Cys Val Arg Lys Asp Asn Val Ser Arg Cys 
            100                 105                 110 

Trp Val Gln Ile Thr Pro Thr Leu Ser Ala Pro Ser Phe Gly Ala Val 
        115                 120                 125 

Thr Ala Pro Leu Arg Arg Ala Val Asp Tyr Leu Val Gly Gly Ala Ala 
    130                 135                 140 

Leu Cys Ser Ala Leu Tyr Val Gly Asp Ala Cys Gly Ala Leu Phe Leu 
145                 150                 155                 160 

Val Gly Gln Met Phe Thr Tyr Arg Pro Arg Gln His Ala Thr Val Gln 
                165                 170                 175 

Asp Cys Asn Cys Ser Ile Tyr Ser Gly His Val Thr Gly His Gln Met 
            180                 185                 190 

Ala 

 
           
             228  
             319  
             PRT  
             hepatitis C virus  
           
            228 

Met Ser Thr Leu Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Thr Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Ala Arg Gln Pro Gln Gly Arg His Trp Ala Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro His Trp Gly Pro Asn Asp Pro 
            100                 105                 110 

Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 
        115                 120                 125 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Val Val Gly Ala Pro Leu 
    130                 135                 140 

Gly Gly Val Ala Ala Ala Leu Ala His Gly Val Arg Ala Ile Glu Asp 
145                 150                 155                 160 

Gly Ile Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
                165                 170                 175 

Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Thr Pro Ala Ser Ala Leu 
            180                 185                 190 

Thr Tyr Gly Asn Ser Ser Gly Leu Tyr His Leu Thr Asn Asp Cys Pro 
        195                 200                 205 

Asn Ser Ser Ile Val Leu Glu Ala Asp Ala Met Ile Leu His Leu Pro 
    210                 215                 220 

Gly Cys Leu Pro Cys Val Arg Val Asp Asp Arg Ser Thr Cys Trp His 
225                 230                 235                 240 

Ala Val Thr Pro Thr Leu Ala Ile Pro Asn Ala Ser Thr Pro Ala Thr 
                245                 250                 255 

Gly Phe Arg Arg His Val Asp Leu Leu Ala Gly Ala Ala Val Val Cys 
            260                 265                 270 

Ser Ser Leu Tyr Ile Gly Asp Leu Cys Gly Ser Leu Phe Leu Ala Gly 
        275                 280                 285 

Gln Leu Phe Thr Phe Gln Pro Arg Arg His Trp Thr Val Gln Asp Cys 
    290                 295                 300 

Asn Cys Ser Ile Tyr Thr Gly His Val Thr Gly His Arg Met Ala 
305                 310                 315 

 
           
             229  
             319  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (128)..(129)  
               Xaa is any amino acid  
             
           
            229 

Met Ser Thr Leu Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Met Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Val Arg Gln Pro Thr Gly Arg Ser Trp Gly Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Asn Trp Gly Pro Asn Asp Pro 
            100                 105                 110 

Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Xaa 
        115                 120                 125 

Xaa Leu Ala Asp Leu Met Gly Tyr Ile Pro Val Leu Gly Gly Pro Leu 
    130                 135                 140 

Gly Gly Val Ala Ala Ala Leu Ala His Gly Val Arg Ala Ile Glu Asp 
145                 150                 155                 160 

Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
                165                 170                 175 

Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Thr Pro Ala Ser Ala Ile 
            180                 185                 190 

Gln Val Lys Asn Ala Ser Gly Ile Tyr His Leu Thr Asn Asp Cys Ser 
        195                 200                 205 

Asn Asn Ser Ile Val Phe Glu Ala Glu Thr Met Ile Leu His Leu Pro 
    210                 215                 220 

Gly Cys Val Pro Cys Ile Lys Ala Gly Asn Glu Ser Arg Cys Trp Leu 
225                 230                 235                 240 

Pro Val Ser Pro Thr Leu Ala Val Pro Asn Ser Ser Val Pro Ile His 
                245                 250                 255 

Gly Phe Arg Arg His Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys 
            260                 265                 270 

Ser Ala Met Tyr Ile Gly Asp Leu Cys Gly Ser Ile Ile Leu Val Gly 
        275                 280                 285 

Gln Leu Phe Thr Phe Arg Pro Lys Tyr His Gln Val Thr Gln Asp Cys 
    290                 295                 300 

Asn Cys Ser Xaa Asn Xaa Gly His Val Thr Gly His Arg Met Ala 
305                 310                 315 

 
           
             230  
             319  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (144)..(144)  
               Xaa is any amino acid  
             
           
            230 

Met Ser Thr Leu Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Ile 
1               5                   10                  15 

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Val Arg His Gln Thr Gly Arg Thr Trp Ala Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Asn Trp Gly Pro Asn Asp Pro 
            100                 105                 110 

Arg Arg Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 
        115                 120                 125 

Gly Phe Ala Asp Leu Met Gly Tyr Ile Pro Val Val Gly Ala Pro Xaa 
    130                 135                 140 

Gly Gly Val Ala Xaa Ala Leu Ala His Gly Val Xaa Xaa Ile Glu Asp 
145                 150                 155                 160 

Xaa Val Asn Tyr Ala Thr Xaa Asn Leu Pro Xaa Xaa Ser Xaa Ser Ile 
                165                 170                 175 

Xaa Leu Leu Ala Leu Leu Ser Cys Leu Thr Thr Pro Ala Ser Ala Ala 
            180                 185                 190 

His Tyr Thr Asn Lys Ser Gly Leu Tyr His Leu Thr Asn Asp Cys Pro 
        195                 200                 205 

Asn Ser Ser Ile Val Tyr Glu Ala Glu Thr Leu Ile Leu His Leu Pro 
    210                 215                 220 

Gly Cys Val Pro Cys Val Lys Xaa Xaa Asn Gln Ser Arg Cys Trp Val 
225                 230                 235                 240 

Gln Ala Ser Pro Thr Leu Ala Val Pro Asn Ala Ser Thr Pro Val Thr 
                245                 250                 255 

Gly Phe Arg Lys His Val Asp Ile Met Val Gly Ala Ala Ala Phe Cys 
            260                 265                 270 

Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Gly Leu Phe Leu Val Gly 
        275                 280                 285 

Gln Leu Phe Thr Leu Arg Pro Arg Met His Gln Val Val Gln Glu Cys 
    290                 295                 300 

Asn Cys Ser Ile Tyr Thr Gly His Ile Thr Gly His Arg Met Ala 
305                 310                 315 

 
           
             231  
             319  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (108)..(108)  
               Xaa is any amino acid  
             
           
            231 

Met Ser Thr Leu Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Met Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Ala Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Val Arg Gln Asn Gln Gly Arg Thr Trp Ala Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro Arg Gly Ser Arg Pro Asp Trp Xaa Pro Asn Asp Pro 
            100                 105                 110 

Arg Xaa Arg Ser Arg Asn Leu Gly Lys Val Ile Asp Thr Leu Thr Cys 
        115                 120                 125 

Gly Phe Ala Asp Leu Met Glu Tyr Ile Pro Val Val Gly Ala Pro Leu 
    130                 135                 140 

Gly Gly Val Ala Ala Glu Leu Xaa His Gly Val Arg Ala Ile Glu Asp 
145                 150                 155                 160 

Gly Ile Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile 
                165                 170                 175 

Phe Xaa Leu Ala Leu Leu Ser Cys Leu Thr Thr Pro Ala Ser Ala Leu 
            180                 185                 190 

Asn Tyr Ala Asn Lys Ser Gly Leu Tyr His Leu Thr Asn Asp Cys Pro 
        195                 200                 205 

Asn Ser Ser Ile Val Tyr Glu Ala Asn Gly Met Ile Leu His Leu Pro 
    210                 215                 220 

Gly Cys Val Pro Cys Val Lys Thr Gly Asn Leu Thr Lys Cys Trp Leu 
225                 230                 235                 240 

Ser Ala Ser Pro Thr Leu Ala Val Gln Asn Ala Ser Val Ser Ile Arg 
                245                 250                 255 

Gly Val Arg Glu His Val Asp Leu Leu Val Gly Ala Ala Ala Phe Cys 
            260                 265                 270 

Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Gly Leu Phe Leu Val Gly 
        275                 280                 285 

Gln Leu Phe Thr Phe Arg Pro Arg Met Tyr Glu Ile Ala Gln Asp Cys 
    290                 295                 300 

Asn Cys Ser Ile Tyr Ala Gly His Ile Thr Gly His Arg Met Ala 
305                 310                 315 

 
           
             232  
             100  
             PRT  
             hepatitis C virus  
           
            232 

Met Ser Thr Leu Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Arg Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro Arg Leu Gly Val Arg Ala 
        35                  40                  45 

Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Gly Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Lys Val Arg His Gln Thr Gly Arg Thr Trp Ala Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro 
            100 

 
           
             233  
             100  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (17)..(17)  
               Xaa is any amino acid  
             
           
            233 

Met Ser Thr Leu Pro Lys Pro Gln Arg Lys Thr Lys Arg Asn Thr Asn 
1               5                   10                  15 

Xaa Arg Pro Gln Asp Val Lys Phe Pro Gly Gly Gly Gln Ile Val Gly 
            20                  25                  30 

Gly Val Tyr Val Leu Pro Arg Arg Gly Pro Gln Leu Gly Val Arg Ala 
        35                  40                  45 

Val Arg Lys Thr Ser Glu Arg Ser Gln Pro Arg Ser Arg Arg Gln Pro 
    50                  55                  60 

Ile Pro Arg Ala Arg Arg Thr Glu Gly Arg Ser Trp Ala Gln Pro Gly 
65                  70                  75                  80 

Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly Cys Gly Trp Ala Gly Trp 
                85                  90                  95 

Leu Leu Ser Pro 
            100 

 
           
             234  
             128  
             PRT  
             hepatitis C virus  
           
            234 

Val Glu Val Lys Asp Thr Gly Asp Ser Tyr Met Pro Thr Asn Asp Cys 
1               5                   10                  15 

Ser Asn Ser Ser Ile Val Trp Gln Leu Glu Gly Ala Val Leu His Thr 
            20                  25                  30 

Pro Gly Cys Val Pro Cys Glu Arg Thr Ala Asn Val Ser Arg Cys Trp 
        35                  40                  45 

Val Pro Val Ala Pro Asn Leu Ala Ile Ser Gln Pro Gly Ala Leu Thr 
    50                  55                  60 

Lys Gly Leu Arg Ala His Ile Asp Ile Ile Val Met Ser Ala Thr Val 
65                  70                  75                  80 

Cys Ser Ala Leu Tyr Val Gly Asp Val Cys Gly Ala Leu Met Leu Ala 
                85                  90                  95 

Ala Gln Val Val Val Val Ser Pro Gln His His Thr Phe Val Gln Glu 
            100                 105                 110 

Cys Asn Cys Ser Ile Tyr Pro Gly Arg Ile Thr Gly His Arg Met Ala 
        115                 120                 125 

 
           
             235  
             149  
             PRT  
             hepatitis C virus  
           
            235 

Asp Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser 
1               5                   10                  15 

Ile Phe Leu Leu Ala Leu Leu Ser Cys Val Thr Val Pro Val Ser Ala 
            20                  25                  30 

Val Gln Val Lys Asn Thr Ser Thr Met Tyr Met Ala Thr Asn Asp Cys 
        35                  40                  45 

Ser Asn Asn Ser Ile Ile Trp Gln Met Gln Gly Ala Val Leu His Val 
    50                  55                  60 

Pro Gly Cys Val Pro Cys Glu Leu Gln Gly Asn Lys Ser Arg Cys Trp 
65                  70                  75                  80 

Ile Pro Val Thr Pro Asn Val Ala Val Asn Gln Pro Gly Ala Leu Thr 
                85                  90                  95 

Arg Gly Leu Arg Thr His Ile Asp Thr Ile Val Met Val Ala Thr Leu 
            100                 105                 110 

Cys Ser Ala Leu Tyr Ile Gly Asp Val Cys Gly Ala Val Met Ile Ala 
        115                 120                 125 

Ala Gln Val Val Ile Val Ser Pro Gln His His Asn Phe Ser Gln Asp 
    130                 135                 140 

Cys Asn Cys Ser Ile 
145 

 
           
             236  
             154  
             PRT  
             hepatitis C virus  
           
            236 

Asp Gly Ile Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser 
1               5                   10                  15 

Ile Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala 
            20                  25                  30 

Val Gln Val Lys Asn Thr Ser His Ser Tyr Met Val Thr Asn Asp Cys 
        35                  40                  45 

Ser Asn Ser Ser Ile Val Trp Gln Leu Lys Asp Ala Val Leu His Val 
    50                  55                  60 

Pro Gly Cys Val Pro Cys Glu Arg His Gln Asn Gln Ser Arg Cys Trp 
65                  70                  75                  80 

Ile Pro Val Thr Pro Asn Val Ala Val Ser Gln Pro Gly Ala Leu Thr 
                85                  90                  95 

Arg Gly Leu Arg Thr His Ile Asp Thr Ile Val Ala Ser Ala Thr Val 
            100                 105                 110 

Cys Ser Ala Leu Tyr Val Gly Asp Phe Cys Gly Ala Val Met Leu Val 
        115                 120                 125 

Ser Gln Phe Phe Met Ile Ser Pro Gln His His Ile Phe Val Gln Asp 
    130                 135                 140 

Cys Asn Cys Ser Ile Tyr Pro Gly His Ile 
145                 150 

 
           
             237  
             118  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (95)..(95)  
               Xaa is any amino acid  
             
           
            237 

Asp Gly Ile Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser 
1               5                   10                  15 

Ile Phe Leu Leu Ala Leu Leu Ser Cys Ile Thr Val Pro Val Ser Ala 
            20                  25                  30 

Val Gln Val Ala Asn Arg Ser Gly Ser Tyr Met Val Thr Asn Asp Cys 
        35                  40                  45 

Ser Asn Ser Ser Ile Val Trp Gln Leu Glu Glu Ala Val Leu His Val 
    50                  55                  60 

Pro Gly Cys Val Pro Cys Glu Trp Lys Asp Asn Thr Ser Arg Cys Trp 
65                  70                  75                  80 

Ile Pro Val Thr Pro Asn Ile Ala Val Ser Gln Pro Gly Ala Xaa Thr 
                85                  90                  95 

Lys Gly Leu Arg Thr His Ile Asp Ile Ile Val Ala Ser Ala Thr Phe 
            100                 105                 110 

Cys Ser Ala Leu Tyr Val 
        115 

 
           
             238  
             128  
             PRT  
             hepatitis C virus  
           
            238 

Glu His Tyr Arg Asn Ala Ser Gly Ile Tyr His Ile Thr Asn Asp Cys 
1               5                   10                  15 

Pro Asn Ser Ser Ile Val Tyr Glu Ala Asp His His Ile Leu His Leu 
            20                  25                  30 

Pro Gly Cys Val Pro Cys Val Met Thr Gly Asn Thr Ser Arg Cys Trp 
        35                  40                  45 

Thr Pro Val Thr Pro Thr Val Ala Val Ala His Pro Gly Ala Pro Leu 
    50                  55                  60 

Glu Ser Phe Arg Arg His Val Asp Leu Met Val Gly Ala Ala Thr Leu 
65                  70                  75                  80 

Cys Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Gly Ala Phe Leu Met 
                85                  90                  95 

Gly Gln Met Ile Thr Phe Arg Pro Arg Arg His Trp Thr Thr Gln Glu 
            100                 105                 110 

Cys Asn Cys Ser Ile Tyr Thr Gly His Ile Thr Gly His Arg Met Ala 
        115                 120                 125 

 
           
             239  
             128  
             PRT  
             hepatitis C virus  
           
            239 

Val His Tyr Arg Asn Ala Ser Gly Val Tyr His Val Thr Asn Asp Cys 
1               5                   10                  15 

Pro Asn Thr Ser Ile Val Tyr Glu Thr Glu His His Ile Met His Leu 
            20                  25                  30 

Pro Gly Cys Val Pro Cys Val Arg Thr Glu Asn Thr Ser Arg Cys Trp 
        35                  40                  45 

Val Pro Leu Thr Pro Thr Val Ala Ala Pro Tyr Pro Asn Ala Pro Leu 
    50                  55                  60 

Glu Ser Met Arg Arg His Val Asp Leu Met Val Gly Ala Ala Thr Met 
65                  70                  75                  80 

Cys Ser Ala Phe Tyr Ile Gly Asp Leu Cys Gly Gly Val Phe Leu Val 
                85                  90                  95 

Gly Gln Leu Phe Asp Phe Arg Pro Arg Arg His Trp Thr Thr Gln Asp 
            100                 105                 110 

Cys Asn Cys Ser Ile Tyr Pro Gly His Val Ser Gly His Arg Met Ala 
        115                 120                 125 

 
           
             240  
             128  
             PRT  
             hepatitis C virus  
           
            240 

Val Asn Tyr Arg Asn Ala Ser Gly Val Tyr His Val Thr Asn Asp Cys 
1               5                   10                  15 

Pro Asn Ser Ser Ile Val Tyr Glu Ala Glu His Gln Ile Leu His Leu 
            20                  25                  30 

Pro Gly Leu Val Pro Cys Val Arg Val Gly Asn Gln Ser Arg Cys Trp 
        35                  40                  45 

Val Ala Leu Thr Pro Thr Val Ala Val Ser Tyr Ile Gly Ala Pro Leu 
    50                  55                  60 

Asp Ser Leu Arg Arg His Val Asp Leu Met Val Gly Ala Ala Thr Val 
65                  70                  75                  80 

Cys Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Gly Ala Phe Leu Val 
                85                  90                  95 

Gly Gln Met Phe Ser Phe Gln Pro Arg Arg His Trp Thr Thr Gln Asp 
            100                 105                 110 

Cys Asn Cys Ser Ile Tyr Ala Gly His Ile Thr Gly His Arg Met Ala 
        115                 120                 125 

 
           
             241  
             128  
             PRT  
             hepatitis C virus  
           
            241 

Val Asn Tyr His Asn Ala Ser Gly Val Tyr His Ile Thr Asn Asp Cys 
1               5                   10                  15 

Pro Asn Ser Ser Ile Met Tyr Glu Ala Glu His His Ile Leu His Leu 
            20                  25                  30 

Pro Gly Cys Val Pro Cys Val Arg Glu Gly Asn Gln Ser Arg Cys Trp 
        35                  40                  45 

Val Ala Leu Thr Pro Thr Val Ala Ala Pro Tyr Ile Gly Ala Pro Leu 
    50                  55                  60 

Glu Ser Ile Arg Arg His Val Asp Leu Met Val Gly Ala Ala Thr Val 
65                  70                  75                  80 

Cys Ser Ala Leu Tyr Ile Gly Asp Leu Cys Gly Gly Val Phe Leu Val 
                85                  90                  95 

Gly Gln Met Phe Ser Phe Gln Pro Arg Arg His Trp Thr Thr Gln Asp 
            100                 105                 110 

Cys Asn Cys Ser Ile Tyr Ala Gly His Val Thr Gly His Arg Met Ala 
        115                 120                 125 

 
           
             242  
             169  
             PRT  
             hepatitis C virus  
           
            242 

Leu Ala His Gly Val Arg Ala Val Glu Asp Gly Ile Asn Tyr Ala Thr 
1               5                   10                  15 

Gly Asn Leu Pro Gly Cys Ser Phe Ser Ile Phe Leu Leu Ala Leu Leu 
            20                  25                  30 

Ser Cys Leu Thr Val Pro Ala Ser Ala Val His Tyr His Asn Thr Ser 
        35                  40                  45 

Gly Ile Tyr His Ile Thr Asn Asp Cys Pro Asn Ser Ser Ile Val Phe 
    50                  55                  60 

Glu Ala Glu His His Ile Leu His Leu Pro Gly Cys Val Pro Cys Val 
65                  70                  75                  80 

Arg Thr Gly Asn Gln Ser Arg Cys Trp Ile Ala Leu Thr Pro Thr Leu 
                85                  90                  95 

Ala Ala Pro His Ile Gly Ala Pro Leu Glu Ser Met Arg Arg His Val 
            100                 105                 110 

Asp Leu Met Val Gly Thr Ala Thr Leu Cys Ser Ala Leu Tyr Ile Gly 
        115                 120                 125 

Asp Leu Cys Gly Gly Ile Phe Leu Val Gly Gln Met Phe Asn Phe Arg 
    130                 135                 140 

Pro Arg Leu His Trp Thr Thr Gln Glu Cys Asn Cys Ser Ile Tyr Pro 
145                 150                 155                 160 

Gly His Ile Thr Gly His Arg Met Ala 
                165 

 
           
             243  
             149  
             PRT  
             hepatitis C virus  
           
            243 

Asp Gly Ile Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser 
1               5                   10                  15 

Ile Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala 
            20                  25                  30 

Ile Asn Tyr Arg Asn Thr Ser Gly Ile Tyr His Val Thr Asn Asp Cys 
        35                  40                  45 

Pro Asn Ser Ser Ile Val Tyr Glu Ala Asp His His Ile Leu His Leu 
    50                  55                  60 

Pro Gly Cys Val Pro Cys Val Arg Thr Gly Asn Gln Ser Arg Cys Trp 
65                  70                  75                  80 

Val Ala Leu Thr Pro Thr Val Ala Ala Pro Tyr Ile Gly Ala Pro Leu 
                85                  90                  95 

Glu Ser Leu Arg Ser His Val Asp Leu Met Val Gly Ala Ala Thr Val 
            100                 105                 110 

Cys Ser Ala Leu Tyr Ile Gly Asp Leu Cys Gly Gly Leu Phe Leu Val 
        115                 120                 125 

Gly Gln Met Phe Ser Phe Arg Pro Arg Arg His Trp Thr Ala Gln Asp 
    130                 135                 140 

Cys Asn Cys Ser Ile 
145 

 
           
             244  
             149  
             PRT  
             hepatitis C virus  
           
            244 

Asp Gly Ile Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser 
1               5                   10                  15 

Ile Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala 
            20                  25                  30 

Ile Asn Tyr His Asn Thr Ser Gly Ile Tyr His Ile Thr Asn Asp Cys 
        35                  40                  45 

Pro Asn Ser Ser Ile Val Tyr Glu Ala Asp His His Ile Leu His Leu 
    50                  55                  60 

Pro Gly Cys Val Pro Cys Val Arg Val Gly Asn Gln Ser Ser Cys Trp 
65                  70                  75                  80 

Val Ala Leu Thr Pro Thr Ile Ala Ala Pro Tyr Ile Gly Ala Pro Leu 
                85                  90                  95 

Glu Ser Leu Arg Ser His Val Asp Leu Met Val Gly Ala Ala Thr Val 
            100                 105                 110 

Cys Ser Ala Leu Tyr Ile Gly Asp Leu Cys Gly Gly Ala Phe Leu Val 
        115                 120                 125 

Gly Gln Met Phe Ser Phe Arg Pro Arg Arg His Trp Thr Thr Gln Asp 
    130                 135                 140 

Cys Asn Cys Ser Ile 
145 

 
           
             245  
             149  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (14)..(14)  
               Xaa is any amino acid  
             
           
            245 

Asp Gly Ile Asn Tyr Ala Thr Gly Asn Ile Pro Gly Cys Xaa Phe Ser 
1               5                   10                  15 

Ile Phe Leu Xaa Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala 
            20                  25                  30 

Thr Asn Tyr Arg Asn Val Ser Gly Ile Tyr His Val Thr Asn Asp Cys 
        35                  40                  45 

Pro Asn Ser Ser Ile Val Tyr Glu Ala Asp His His Ile Leu Ala Leu 
    50                  55                  60 

Pro Gly Cys Val Pro Cys Val Arg Val Gly Asn Gln Ser Arg Cys Trp 
65                  70                  75                  80 

Val Ala Leu Thr Pro Thr Val Ala Ala Pro Tyr Thr Ala Ala Pro Leu 
                85                  90                  95 

Glu Ser Leu Arg Ser His Val Asp Leu Met Val Gly Ala Ala Thr Val 
            100                 105                 110 

Cys Ser Ala Leu Tyr Ile Gly Xaa Leu Cys Gly Gly Leu Phe Leu Val 
        115                 120                 125 

Gly Gln Met Phe Ser Xaa Gln Pro Arg Arg His Trp Thr Thr Gln Asp 
    130                 135                 140 

Cys Asn Cys Ser Ile 
145 

 
           
             246  
             149  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (9)..(9)  
               Xaa is any amino acid  
             
           
            246 

Asp Gly Ile Asn Tyr Ala Thr Gly Xaa Leu Pro Gly Cys Ser Phe Ser 
1               5                   10                  15 

Ile Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala 
            20                  25                  30 

Thr Asn Tyr Arg Asn Val Ser Gly Ile Tyr His Val Thr Asn Asp Cys 
        35                  40                  45 

Pro Asn Ser Ser Ile Val Phe Glu Ala Asp His His Ile Leu His Leu 
    50                  55                  60 

Pro Gly Cys Val Pro Cys Val Lys Glu Gly Asn His Ser Arg Cys Trp 
65                  70                  75                  80 

Val Ala Leu Thr Pro Thr Val Ala Ala Pro Tyr Ile Gly Ala Pro Leu 
                85                  90                  95 

Glu Ser Leu Arg Ser His Val Asp Val Met Val Gly Ala Ala Thr Val 
            100                 105                 110 

Cys Ser Ala Leu Tyr Ile Gly Asp Leu Cys Gly Gly Leu Phe Leu Val 
        115                 120                 125 

Gly Gln Met Phe Ser Phe Arg Pro Arg Arg His Trp Thr Thr Gln Glu 
    130                 135                 140 

Cys Asn Cys Ser Ile 
145 

 
           
             247  
             149  
             PRT  
             hepatitis C virus  
           
            247 

Asp Gly Ile Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser 
1               5                   10                  15 

Ile Phe Ile Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala 
            20                  25                  30 

Gln His Tyr Arg Asn Val Ser Gly Ile Tyr His Val Thr Asn Asp Cys 
        35                  40                  45 

Pro Asn Ser Ser Ile Val Tyr Glu Ser Asp His His Ile Leu His Leu 
    50                  55                  60 

Pro Gly Cys Val Pro Cys Val Lys Thr Gly Asn Thr Ser Arg Cys Trp 
65                  70                  75                  80 

Val Ala Leu Thr Pro Thr Val Ala Ala Pro Ile Leu Ser Ala Pro Leu 
                85                  90                  95 

Met Ser Val Arg Arg His Val Asp Leu Met Val Gly Ala Ala Thr Leu 
            100                 105                 110 

Ser Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Gly Ala Phe Leu Val 
        115                 120                 125 

Gly Gln Met Phe Thr Phe Gln Pro Arg Arg His Trp Thr Val Gln Asp 
    130                 135                 140 

Cys Asn Cys Ser Ile 
145 

 
           
             248  
             119  
             PRT  
             hepatitis C virus  
           
            248 

Tyr His Ile Thr Asn Asp Cys Pro Asn Ser Ser Val Val Tyr Glu Thr 
1               5                   10                  15 

Asp His His Ile Leu His Leu Pro Gly Cys Val Pro Cys Val Arg Thr 
            20                  25                  30 

Gly Asn Val Ser Arg Cys Trp Thr Pro Val Thr Pro Thr Val Ala Ala 
        35                  40                  45 

Val Ser Val Asp Ala Pro Leu Glu Ser Phe Arg Arg His Val Asp Leu 
    50                  55                  60 

Met Val Gly Ala Ala Thr Leu Cys Ser Val Leu Tyr Val Gly Asp Leu 
65                  70                  75                  80 

Cys Gly Gly Ala Phe Leu Val Gly Gln Met Phe Thr Phe Gln Pro Arg 
                85                  90                  95 

Arg His Trp Thr Thr Gln Asp Cys Asn Cys Ser Ile Tyr Thr Gly His 
            100                 105                 110 

Ile Thr Gly His Arg Met Ala 
        115 

 
           
             249  
             128  
             PRT  
             hepatitis C virus  
           
            249 

Val Pro Tyr Arg Asn Ala Ser Gly Val Tyr His Val Thr Asn Asp Cys 
1               5                   10                  15 

Pro Asn Ser Ser Ile Val Tyr Glu Ala Asp Asn Leu Ile Leu His Ala 
            20                  25                  30 

Pro Gly Cys Val Pro Cys Val Arg Gln Asp Asn Val Ser Lys Cys Trp 
        35                  40                  45 

Val Gln Ile Thr Pro Thr Leu Ser Ala Pro Asn Leu Gly Ala Val Thr 
    50                  55                  60 

Ala Pro Leu Arg Arg Ala Val Asp Tyr Leu Ala Gly Gly Ala Ala Leu 
65                  70                  75                  80 

Cys Ser Ala Leu Tyr Val Gly Asp Ala Cys Gly Ala Val Phe Leu Val 
                85                  90                  95 

Gly Gln Met Phe Thr Tyr Arg Pro Arg Gln His Thr Thr Val Gln Asp 
            100                 105                 110 

Cys Asn Cys Ser Ile Tyr Ser Gly His Ile Thr Gly His Arg Met Ala 
        115                 120                 125 

 
           
             250  
             68  
             PRT  
             hepatitis C virus  
           
            250 

Ile Gly Gly Ala Gly Asn Asn Thr Leu His Cys Pro Thr Asp Cys Phe 
1               5                   10                  15 

Arg Lys His Pro Asp Ala Thr Tyr Ser Arg Cys Gly Ser Gly Pro Trp 
            20                  25                  30 

Ile Thr Pro Arg Cys Leu Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr 
        35                  40                  45 

Pro Cys Thr Ile Asn Tyr Thr Ile Phe Lys Ile Arg Met Tyr Val Gly 
    50                  55                  60 

Gly Val Glu His 
65 

 
           
             251  
             68  
             PRT  
             hepatitis C virus  
           
            251 

Ile Gly Gly Val Gly Asn Asn Thr Leu Leu Cys Pro Thr Asp Cys Phe 
1               5                   10                  15 

Arg Lys Tyr Pro Glu Ala Thr Tyr Ser Arg Cys Gly Ser Gly Pro Arg 
            20                  25                  30 

Ile Thr Pro Arg Cys Met Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr 
        35                  40                  45 

Pro Cys Thr Ile Asn Tyr Thr Ile Phe Lys Val Arg Met Tyr Val Gly 
    50                  55                  60 

Gly Val Glu His 
65 

 
           
             252  
             68  
             PRT  
             hepatitis C virus  
           
            252 

Ile Gly Gly Gly Gly Asn Asn Thr Leu His Cys Pro Thr Asp Cys Phe 
1               5                   10                  15 

Arg Lys His Pro Glu Ala Thr Tyr Ser Arg Cys Gly Ser Gly Pro Trp 
            20                  25                  30 

Ile Thr Pro Arg Cys Leu Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr 
        35                  40                  45 

Pro Cys Thr Ile Asn Tyr Thr Ile Phe Lys Val Arg Met Tyr Val Gly 
    50                  55                  60 

Gly Val Glu His 
65 

 
           
             253  
             68  
             PRT  
             hepatitis C virus  
           
            253 

Ile Gly Gly Val Gly Asn Asn Thr Leu Val Cys Pro Thr Asp Cys Phe 
1               5                   10                  15 

Arg Lys His Pro Glu Ala Thr Tyr Thr Lys Cys Gly Ser Gly Pro Trp 
            20                  25                  30 

Leu Thr Pro Arg Cys Met Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr 
        35                  40                  45 

Pro Cys Thr Val Asn Phe Thr Val Phe Lys Val Arg Met Tyr Val Gly 
    50                  55                  60 

Gly Val Glu His 
65 

 
           
             254  
             68  
             PRT  
             hepatitis C virus  
           
            254 

Ile Gly Gly Val Gly Asn His Thr Leu Thr Cys Pro Thr Asp Cys Phe 
1               5                   10                  15 

Arg Lys His Pro Glu Ala Thr Tyr Thr Lys Cys Gly Ser Gly Pro Trp 
            20                  25                  30 

Leu Thr Pro Arg Cys Leu Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr 
        35                  40                  45 

Pro Cys Thr Phe Asn Phe Ser Ile Phe Lys Val Arg Met Tyr Val Gly 
    50                  55                  60 

Gly Val Glu His 
65 

 
           
             255  
             68  
             PRT  
             hepatitis C virus  
           
            255 

Ile Gly Gly Val Gly Asn Arg Thr Leu Ile Cys Pro Thr Asp Cys Phe 
1               5                   10                  15 

Arg Lys His Pro Glu Ala Thr Tyr Thr Lys Cys Gly Ser Gly Pro Trp 
            20                  25                  30 

Leu Thr Pro Arg Cys Leu Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr 
        35                  40                  45 

Pro Cys Thr Leu Asn Phe Ser Ile Phe Lys Val Arg Met Tyr Val Gly 
    50                  55                  60 

Gly Val Glu His 
65 

 
           
             256  
             68  
             PRT  
             hepatitis C virus  
           
            256 

Ile Gly Gly Val Gly Asn Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe 
1               5                   10                  15 

Arg Lys His Pro Glu Ala Thr Tyr Thr Arg Cys Gly Ser Gly Pro Trp 
            20                  25                  30 

Leu Thr Pro Arg Cys Leu Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr 
        35                  40                  45 

Pro Cys Thr Val Asn Phe Ala Ile Phe Lys Val Arg Met Tyr Val Gly 
    50                  55                  60 

Gly Val Glu His 
65 

 
           
             257  
             68  
             PRT  
             hepatitis C virus  
           
            257 

Ile Gly Gly Val Gly Asn Leu Thr Leu Thr Cys Pro Thr Asp Cys Phe 
1               5                   10                  15 

Arg Lys His Pro Glu Ala Thr Tyr Thr Lys Cys Gly Ser Gly Pro Trp 
            20                  25                  30 

Leu Thr Pro Arg Cys Ile Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr 
        35                  40                  45 

Pro Cys Thr Val Asn Phe Thr Ile Phe Lys Val Arg Met Tyr Val Gly 
    50                  55                  60 

Gly Val Glu His 
65 

 
           
             258  
             68  
             PRT  
             hepatitis C virus  
           
            258 

Ile Gly Gly Val Gly Asn Leu Thr Leu Thr Cys Pro Thr Asp Cys Phe 
1               5                   10                  15 

Arg Lys His Pro Glu Ala Thr Tyr Thr Lys Cys Gly Ser Gly Pro Trp 
            20                  25                  30 

Leu Thr Pro Arg Cys Ile Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr 
        35                  40                  45 

Pro Cys Thr Val Asn Phe Thr Ile Phe Lys Val Arg Met Tyr Val Gly 
    50                  55                  60 

Gly Val Glu His 
65 

 
           
             259  
             68  
             PRT  
             hepatitis C virus  
           
            259 

Ile Gly Gly Val Gly Asn Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe 
1               5                   10                  15 

Arg Lys His Pro Glu Ala Thr Tyr Thr Lys Cys Gly Ser Gly Pro Trp 
            20                  25                  30 

Leu Thr Pro Arg Cys Met Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr 
        35                  40                  45 

Pro Cys Thr Val Asn Phe Thr Ile Phe Lys Val Arg Met Tyr Val Gly 
    50                  55                  60 

Gly Val Glu His 
65 

 
           
             260  
             68  
             PRT  
             hepatitis C virus  
           
            260 

Ile Gly Gly Ala Gly Asn Asn Thr Leu Thr Cys Pro Thr Asp Cys Phe 
1               5                   10                  15 

Arg Lys His Pro Glu Ala Thr Tyr Thr Lys Cys Gly Ser Gly Pro Trp 
            20                  25                  30 

Leu Thr Pro Arg Cys Met Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr 
        35                  40                  45 

Pro Cys Thr Phe Asn Phe Thr Ile Phe Lys Ile Arg Met Tyr Val Gly 
    50                  55                  60 

Gly Val Glu His 
65 

 
           
             261  
             68  
             PRT  
             hepatitis C virus  
           
            261 

Ile Gly Gly Gly Gly Asn Asn Thr Leu Val Cys Pro Thr Asp Cys Phe 
1               5                   10                  15 

Arg Lys His Pro Glu Ala Thr Tyr Thr Lys Cys Gly Ser Gly Pro Trp 
            20                  25                  30 

Leu Thr Pro Arg Cys Met Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr 
        35                  40                  45 

Pro Cys Thr Val Asn Phe Thr Ile Phe Lys Val Arg Met Tyr Val Gly 
    50                  55                  60 

Gly Val Glu His 
65 

 
           
             262  
             68  
             PRT  
             hepatitis C virus  
           
            262 

Ile Gly Gly Ser Gly Asn Asn Thr Leu Leu Cys Pro Thr Asp Cys Phe 
1               5                   10                  15 

Arg Lys His Pro Asp Ala Thr Tyr Ser Arg Cys Gly Ser Gly Pro Trp 
            20                  25                  30 

Leu Thr Pro Arg Cys Leu Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr 
        35                  40                  45 

Pro Cys Thr Val Asn Tyr Thr Ile Phe Lys Ile Arg Met Phe Val Gly 
    50                  55                  60 

Gly Val Glu His 
65 

 
           
             263  
             70  
             PRT  
             hepatitis C virus  
           
            263 

Ile Arg Ala Asp Phe Asn Ala Ser Met Asp Leu Leu Cys Pro Thr Asp 
1               5                   10                  15 

Cys Phe Arg Lys His Pro Asp Thr Thr Tyr Ile Lys Cys Gly Ser Gly 
            20                  25                  30 

Pro Trp Leu Thr Pro Arg Cys Leu Ile Asp Tyr Pro Tyr Arg Leu Trp 
        35                  40                  45 

His Tyr Pro Cys Thr Val Asn Tyr Thr Ile Phe Lys Ile Arg Met Tyr 
    50                  55                  60 

Val Gly Gly Val Glu His 
65                  70 

 
           
             264  
             70  
             PRT  
             hepatitis C virus  
           
            264 

Ile Arg Lys Asp Tyr Asn Ser Thr Ile Asp Leu Leu Cys Pro Thr Asp 
1               5                   10                  15 

Cys Phe Arg Lys His Pro Asp Ala Thr Tyr Leu Lys Cys Gly Ala Gly 
            20                  25                  30 

Pro Trp Leu Thr Pro Arg Cys Leu Val Asp Tyr Pro Tyr Arg Leu Trp 
        35                  40                  45 

His Tyr Pro Cys Thr Val Asn Phe Thr Ile Phe Lys Ala Arg Met Tyr 
    50                  55                  60 

Val Gly Gly Val Glu His 
65                  70 

 
           
             265  
             278  
             PRT  
             hepatitis C virus  
           
            265 

Gly Val Ala Lys Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr 
1               5                   10                  15 

Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Val Val 
            20                  25                  30 

Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly 
        35                  40                  45 

Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val 
    50                  55                  60 

Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr 
65                  70                  75                  80 

Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg 
                85                  90                  95 

Thr Ile Thr Thr Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe 
            100                 105                 110 

Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys 
        115                 120                 125 

Asp Glu Cys His Ser Thr Asp Ala Thr Ser Ile Leu Gly Ile Gly Thr 
    130                 135                 140 

Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala 
145                 150                 155                 160 

Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu 
                165                 170                 175 

Glu Val Ala Leu Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala 
            180                 185                 190 

Ile Pro Leu Glu Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His 
        195                 200                 205 

Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly 
    210                 215                 220 

Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro 
225                 230                 235                 240 

Thr Ser Gly Asp Val Val Val Val Ala Thr Asp Ala Leu Met Thr Gly 
                245                 250                 255 

Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr 
            260                 265                 270 

Gln Thr Val Asp Phe Ser 
        275 

 
           
             266  
             278  
             PRT  
             hepatitis C virus  
           
            266 

Gly Val Ala Lys Ala Val Asp Phe Ile Pro Val Glu Asn Leu Glu Thr 
1               5                   10                  15 

Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val 
            20                  25                  30 

Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly 
        35                  40                  45 

Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Lys Gly Tyr Lys Val 
    50                  55                  60 

Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr 
65                  70                  75                  80 

Met Ser Lys Ala His Gly Val Asp Pro Asn Ile Arg Thr Gly Val Arg 
                85                  90                  95 

Thr Ile Thr Thr Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe 
            100                 105                 110 

Leu Ala Asp Ala Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys 
        115                 120                 125 

Asp Glu Cys His Ser Thr Asp Ala Thr Ser Ile Ser Gly Ile Gly Thr 
    130                 135                 140 

Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala 
145                 150                 155                 160 

Thr Ala Thr Pro Pro Gly Ser Val Thr Val Ser His Pro Asn Ile Glu 
                165                 170                 175 

Glu Val Ala Leu Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala 
            180                 185                 190 

Ile Pro Leu Glu Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His 
        195                 200                 205 

Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly 
    210                 215                 220 

Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro 
225                 230                 235                 240 

Thr Ser Gly Asp Val Val Val Val Ser Thr Asp Ala Leu Met Thr Gly 
                245                 250                 255 

Phe Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr 
            260                 265                 270 

Gln Thr Val Asp Phe Ser 
        275 

 
           
             267  
             278  
             PRT  
             hepatitis C virus  
           
            267 

Gly Val Ala Lys Ala Val Asp Phe Ile Pro Val Glu Ser Leu Glu Thr 
1               5                   10                  15 

Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val 
            20                  25                  30 

Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly 
        35                  40                  45 

Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val 
    50                  55                  60 

Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr 
65                  70                  75                  80 

Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg 
                85                  90                  95 

Thr Ile Thr Thr Gly Ser Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe 
            100                 105                 110 

Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys 
        115                 120                 125 

Asp Glu Cys His Ser Thr Asp Ala Thr Ser Val Leu Gly Ile Gly Thr 
    130                 135                 140 

Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala 
145                 150                 155                 160 

Thr Ala Thr Pro Pro Gly Ser Ile Thr Val Pro His Ala Asn Ile Glu 
                165                 170                 175 

Glu Val Ala Leu Ser Thr Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala 
            180                 185                 190 

Ile Pro Leu Glu Ala Ile Lys Gly Gly Arg His Leu Ile Phe Cys His 
        195                 200                 205 

Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Val Ala Leu Gly 
    210                 215                 220 

Val Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro 
225                 230                 235                 240 

Thr Ser Gly Asp Val Val Val Val Ala Thr Asp Ala Leu Met Thr Gly 
                245                 250                 255 

Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr 
            260                 265                 270 

Gln Thr Val Asp Phe Ser 
        275 

 
           
             268  
             278  
             PRT  
             hepatitis C virus  
           
            268 

Gly Val Ala Lys Ala Val Asp Phe Ile Pro Val Glu Ser Met Glu Thr 
1               5                   10                  15 

Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val 
            20                  25                  30 

Pro Gln Thr Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly 
        35                  40                  45 

Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val 
    50                  55                  60 

Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr 
65                  70                  75                  80 

Met Ser Lys Ala His Gly Ile Glu Pro Asn Ile Arg Thr Gly Val Arg 
                85                  90                  95 

Thr Ile Thr Thr Gly Gly Pro Ile Thr Tyr Ser Thr Tyr Cys Lys Phe 
            100                 105                 110 

Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys 
        115                 120                 125 

Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu Gly Ile Gly Thr 
    130                 135                 140 

Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala 
145                 150                 155                 160 

Thr Ala Thr Pro Pro Gly Ser Ile Thr Val Pro His Pro Asn Ile Glu 
                165                 170                 175 

Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala 
            180                 185                 190 

Ile Pro Ile Glu Ala Ile Lys Gly Gly Arg His Leu Ile Phe Cys His 
        195                 200                 205 

Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Thr Gly Leu Gly 
    210                 215                 220 

Leu Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro 
225                 230                 235                 240 

Thr Ser Gly Asp Val Val Val Val Ala Thr Asp Ala Leu Met Thr Gly 
                245                 250                 255 

Phe Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr 
            260                 265                 270 

Gln Thr Val Asp Phe Ser 
        275 

 
           
             269  
             278  
             PRT  
             hepatitis C virus  
           
            269 

Gly Val Ala Lys Ala Val Asp Phe Ile Pro Val Glu Ser Met Glu Thr 
1               5                   10                  15 

Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val 
            20                  25                  30 

Pro Gln Thr Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly 
        35                  40                  45 

Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val 
    50                  55                  60 

Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr 
65                  70                  75                  80 

Met Pro Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg 
                85                  90                  95 

Thr Ile Thr Thr Gly Gly Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe 
            100                 105                 110 

Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys 
        115                 120                 125 

Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu Gly Ile Gly Thr 
    130                 135                 140 

Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala 
145                 150                 155                 160 

Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu 
                165                 170                 175 

Glu Ile Gly Leu Ser Asn Asn Gly Glu Ile Pro Phe Tyr Gly Lys Ala 
            180                 185                 190 

Ile Pro Ile Glu Ala Ile Lys Gly Gly Arg His Leu Ile Phe Cys His 
        195                 200                 205 

Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Thr Gly Leu Gly 
    210                 215                 220 

Leu Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro 
225                 230                 235                 240 

Pro Ile Gly Asp Val Ala Val Val Ala Thr Asp Ala Leu Met Thr Gly 
                245                 250                 255 

Phe Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr 
            260                 265                 270 

Gln Thr Val Asp Phe Ser 
        275 

 
           
             270  
             278  
             PRT  
             hepatitis C virus  
           
            270 

Gly Val Ala Lys Ala Val Asp Phe Ile Pro Val Glu Ser Met Glu Thr 
1               5                   10                  15 

Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val 
            20                  25                  30 

Pro Gln Thr Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly 
        35                  40                  45 

Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val 
    50                  55                  60 

Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr 
65                  70                  75                  80 

Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg 
                85                  90                  95 

Thr Ile Thr Thr Gly Gly Ser Ile Thr Tyr Ser Thr Tyr Gly Lys Phe 
            100                 105                 110 

Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys 
        115                 120                 125 

Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu Gly Ile Gly Thr 
    130                 135                 140 

Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala 
145                 150                 155                 160 

Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu 
                165                 170                 175 

Glu Ile Gly Leu Ser Asn Asn Gly Glu Ile Pro Phe Tyr Gly Lys Ala 
            180                 185                 190 

Ile Pro Ile Glu Ala Ile Lys Gly Gly Arg His Leu Ile Phe Cys His 
        195                 200                 205 

Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Thr Gly Leu Gly 
    210                 215                 220 

Leu Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro 
225                 230                 235                 240 

Pro Ile Gly Asp Val Val Val Val Ala Thr Asp Ala Leu Met Thr Gly 
                245                 250                 255 

Phe Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr 
            260                 265                 270 

Gln Thr Val Asp Phe Ser 
        275 

 
           
             271  
             278  
             PRT  
             hepatitis C virus  
           
            271 

Gly Val Ala Lys Ala Val Asp Phe Ile Pro Val Glu Thr Met Glu Thr 
1               5                   10                  15 

Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val 
            20                  25                  30 

Pro Gln Thr Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly 
        35                  40                  45 

Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val 
    50                  55                  60 

Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr 
65                  70                  75                  80 

Met Ser Lys Ala His Gly Val Asp Pro Asn Ile Arg Thr Gly Val Arg 
                85                  90                  95 

Thr Ile Thr Thr Gly Ala Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe 
            100                 105                 110 

Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys 
        115                 120                 125 

Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu Gly Ile Gly Thr 
    130                 135                 140 

Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala 
145                 150                 155                 160 

Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu 
                165                 170                 175 

Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala 
            180                 185                 190 

Ile Pro Ile Glu Ala Ile Arg Gly Gly Arg His Leu Ile Phe Cys His 
        195                 200                 205 

Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Ser Ser Leu Gly 
    210                 215                 220 

Leu Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro 
225                 230                 235                 240 

Ser Ser Gly Asp Val Val Val Val Ala Thr Asp Ala Leu Met Thr Gly 
                245                 250                 255 

Phe Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr 
            260                 265                 270 

Gln Thr Val Asp Phe Ser 
        275 

 
           
             272  
             278  
             PRT  
             hepatitis C virus  
           
            272 

Gly Val Ala Lys Ala Val Asp Phe Ile Pro Val Glu Ser Met Glu Thr 
1               5                   10                  15 

Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val 
            20                  25                  30 

Pro Gln Thr Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly 
        35                  40                  45 

Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val 
    50                  55                  60 

Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr 
65                  70                  75                  80 

Met Ser Lys Ala His Gly Thr Asp Pro Asn Ile Arg Thr Gly Val Arg 
                85                  90                  95 

Thr Ile Thr Thr Gly Ala Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe 
            100                 105                 110 

Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys 
        115                 120                 125 

Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu Gly Ile Gly Thr 
    130                 135                 140 

Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala 
145                 150                 155                 160 

Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu 
                165                 170                 175 

Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala 
            180                 185                 190 

Ile Pro Leu Glu Ala Ile Lys Gly Gly Arg His Leu Ile Phe Cys His 
        195                 200                 205 

Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Ser Gly Leu Gly 
    210                 215                 220 

Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro 
225                 230                 235                 240 

Thr Ser Gly Asp Val Val Ile Val Ala Thr Asp Ala Leu Met Thr Gly 
                245                 250                 255 

Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr 
            260                 265                 270 

Gln Thr Val Asp Phe Ser 
        275 

 
           
             273  
             278  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (60)..(60)  
               Xaa is any amino acid  
             
           
            273 

Gly Val Ala Lys Ala Val Asp Phe Ile Pro Val Glu Ser Met Glu Thr 
1               5                   10                  15 

Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val 
            20                  25                  30 

Pro Gln Thr Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly 
        35                  40                  45 

Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Xaa Gly Tyr Lys Val 
    50                  55                  60 

Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr 
65                  70                  75                  80 

Met Ser Lys Ala His Gly Thr Asp Pro Asn Ile Arg Thr Gly Val Arg 
                85                  90                  95 

Thr Ile Thr Thr Gly Gly Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe 
            100                 105                 110 

Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys 
        115                 120                 125 

Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu Gly Ile Gly Thr 
    130                 135                 140 

Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala 
145                 150                 155                 160 

Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu 
                165                 170                 175 

Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala 
            180                 185                 190 

Ile Pro Ile Glu Val Ile Lys Gly Gly Arg His Leu Ile Phe Cys His 
        195                 200                 205 

Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Ser Gly Leu Gly 
    210                 215                 220 

Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro 
225                 230                 235                 240 

Thr Ser Gly Asp Val Val Val Val Ala Thr Asp Ala Leu Met Thr Gly 
                245                 250                 255 

Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr 
            260                 265                 270 

Gln Thr Val Asp Phe Ser 
        275 

 
           
             274  
             278  
             PRT  
             hepatitis C virus  
           
            274 

Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu Ser Met Glu Thr 
1               5                   10                  15 

Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val 
            20                  25                  30 

Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly 
        35                  40                  45 

Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val 
    50                  55                  60 

Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr 
65                  70                  75                  80 

Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg 
                85                  90                  95 

Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr Tyr Gly Lys Phe 
            100                 105                 110 

Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys 
        115                 120                 125 

Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu Gly Ile Gly Thr 
    130                 135                 140 

Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala 
145                 150                 155                 160 

Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu 
                165                 170                 175 

Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala 
            180                 185                 190 

Ile Pro Ile Glu Ala Ile Arg Gly Gly Arg His Leu Ile Phe Cys His 
        195                 200                 205 

Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Ser Gly Leu Gly 
    210                 215                 220 

Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro 
225                 230                 235                 240 

Thr Ile Gly Asp Val Val Val Val Ala Thr Asp Ala Leu Met Thr Gly 
                245                 250                 255 

Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr 
            260                 265                 270 

Gln Thr Val Asp Phe Ser 
        275 

 
           
             275  
             278  
             PRT  
             hepatitis C virus  
           
            275 

Gly Val Ala Lys Ala Val Asp Phe Ile Pro Val Glu Ser Met Glu Thr 
1               5                   10                  15 

Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val 
            20                  25                  30 

Pro Gln Thr Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly 
        35                  40                  45 

Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val 
    50                  55                  60 

Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr 
65                  70                  75                  80 

Met Ser Lys Ala His Gly Val Asp Pro Asn Ile Ser Thr Gly Val Arg 
                85                  90                  95 

Thr Ile Thr Thr Gly Ala Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe 
            100                 105                 110 

Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys 
        115                 120                 125 

Asp Glu Cys His Ser Thr Asp Ser Thr Ser Ile Leu Gly Ile Gly Thr 
    130                 135                 140 

Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala 
145                 150                 155                 160 

Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu 
                165                 170                 175 

Glu Val Ala Leu Pro Asn Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala 
            180                 185                 190 

Ile Pro Leu Glu Thr Ile Lys Gly Gly Arg His Leu Ile Phe Cys His 
        195                 200                 205 

Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Ser Ala Leu Gly 
    210                 215                 220 

Val Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro 
225                 230                 235                 240 

Thr Ser Gly Asp Val Val Val Val Ala Thr Asp Ala Leu Met Thr Gly 
                245                 250                 255 

Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr 
            260                 265                 270 

Gln Thr Val Asp Phe Ser 
        275 

 
           
             276  
             278  
             PRT  
             hepatitis C virus  
           
            276 

Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu Ser Met Glu Thr 
1               5                   10                  15 

Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val 
            20                  25                  30 

Pro Gln Ala Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly 
        35                  40                  45 

Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val 
    50                  55                  60 

Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr 
65                  70                  75                  80 

Met Ser Lys Ala His Gly Val Asp Pro Asn Ile Arg Thr Gly Val Arg 
                85                  90                  95 

Thr Ile Thr Thr Gly Ala Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe 
            100                 105                 110 

Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Met Cys 
        115                 120                 125 

Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu Gly Ile Gly Thr 
    130                 135                 140 

Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala 
145                 150                 155                 160 

Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu 
                165                 170                 175 

Glu Ile Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala 
            180                 185                 190 

Ile Pro Ile Glu Thr Ile Lys Gly Gly Arg His Leu Ile Phe Cys His 
        195                 200                 205 

Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Ser Ala Leu Gly 
    210                 215                 220 

Ile His Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro 
225                 230                 235                 240 

Ala Ser Gly Asn Val Val Val Val Ala Thr Asp Ala Leu Met Thr Gly 
                245                 250                 255 

Phe Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr 
            260                 265                 270 

Gln Thr Val Asp Phe Ser 
        275 

 
           
             277  
             277  
             PRT  
             hepatitis C virus  
           
            277 

Gly Val Ala Lys Ser Ile Asp Phe Ile Pro Val Glu Thr Leu Asp Ile 
1               5                   10                  15 

Val Thr Arg Ser Pro Thr Phe Ser Asp Asn Ser Thr Pro Pro Ala Val 
            20                  25                  30 

Pro Gln Thr Tyr Gln Val Gly Tyr Leu His Ala Pro Thr Gly Ser Gly 
        35                  40                  45 

Lys Ser Thr Lys Val Pro Val Ala Tyr Ala Ala Gln Gly Tyr Lys Val 
    50                  55                  60 

Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr 
65                  70                  75                  80 

Leu Ser Lys Ala His Gly Ile Pro Asn Ile Arg Thr Gly Val Arg Thr 
                85                  90                  95 

Val Thr Thr Gly Ala Pro Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Leu 
            100                 105                 110 

Ala Asp Gly Gly Cys Ala Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp 
        115                 120                 125 

Glu Cys His Ala Val Asp Ser Thr Thr Ile Leu Gly Ile Gly Thr Val 
    130                 135                 140 

Leu Asp Gln Ala Glu Thr Ala Gly Val Arg Leu Thr Val Leu Ala Thr 
145                 150                 155                 160 

Ala Thr Pro Pro Gly Ser Val Thr Thr Pro His Pro Asn Ile Glu Glu 
                165                 170                 175 

Val Ala Leu Gly Gln Glu Gly Glu Ile Pro Phe Tyr Gly Arg Ala Ile 
            180                 185                 190 

Pro Leu Ser Tyr Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser 
        195                 200                 205 

Lys Lys Lys Cys Asp Glu Leu Ala Ala Ala Leu Arg Gly Met Gly Leu 
    210                 215                 220 

Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr 
225                 230                 235                 240 

Gln Gly Asp Val Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Phe 
                245                 250                 255 

Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Val Ala Val Thr Gln 
            260                 265                 270 

Val Val Asp Phe Ser 
        275 

 
           
             278  
             277  
             PRT  
             hepatitis C virus  
           
            278 

Gly Val Ala Lys Ser Ile Asp Phe Ile Pro Val Glu Ser Leu Asp Val 
1               5                   10                  15 

Ala Thr Arg Thr Pro Ser Phe Ser Asp Asn Ser Thr Pro Pro Ala Val 
            20                  25                  30 

Pro Gln Ser Tyr Gln Val Gly Tyr Leu His Ala Pro Thr Gly Ser Gly 
        35                  40                  45 

Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ser Gln Gly Tyr Lys Val 
    50                  55                  60 

Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr 
65                  70                  75                  80 

Met Ser Lys Ala His Gly Ile Pro Asn Ile Arg Thr Gly Val Arg Thr 
                85                  90                  95 

Val Thr Thr Gly Asp Ser Ile Thr Tyr Ser Thr Tyr Gly Lys Phe Ile 
            100                 105                 110 

Ala Asp Gly Gly Cys Ala Ala Gly Ala Tyr Asp Ile Ile Ile Cys Asp 
        115                 120                 125 

Glu Cys His Ser Val Asp Ala Thr Thr Ile Leu Gly Ile Gly Thr Val 
    130                 135                 140 

Leu Asp Gln Ala Glu Thr Ala Gly Val Arg Leu Val Val Leu Ala Thr 
145                 150                 155                 160 

Ala Thr Pro Pro Gly Thr Val Thr Thr Pro His Ser Asn Ile Glu Glu 
                165                 170                 175 

Val Ala Leu Gly His Glu Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile 
            180                 185                 190 

Pro Leu Ala Phe Ile Lys Gly Gly Arg His Leu Ile Phe Cys His Ser 
        195                 200                 205 

Lys Lys Lys Cys Asp Glu Leu Ala Ala Ala Leu Arg Gly Met Gly Val 
    210                 215                 220 

Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr 
225                 230                 235                 240 

Gln Gly Asp Val Val Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr 
                245                 250                 255 

Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Val Ala Val Ser Gln 
            260                 265                 270 

Ile Val Asp Phe Ser 
        275 

 
           
             279  
             149  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (30)..(30)  
               Xaa is any amino acid  
             
           
            279 

Asp Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser 
1               5                   10                  15 

Ile Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Xaa Thr Ala 
            20                  25                  30 

His Glu Val Arg Asn Ala Ser Gly Val Tyr His Val Thr Asn Asp Cys 
        35                  40                  45 

Ser Asn Ser Ser Ile Ile Tyr Glu Met Asp Gly Met Ile Met His Tyr 
    50                  55                  60 

Pro Gly Cys Val Pro Cys Val Arg Glu Asp Asn His Leu Arg Cys Trp 
65                  70                  75                  80 

Met Ala Leu Thr Pro Thr Leu Ala Val Lys Xaa Ala Ser Val Pro Thr 
                85                  90                  95 

Xaa Ala Ile Arg Arg His Val Asp Leu Leu Val Gly Xaa Xaa Thr Phe 
            100                 105                 110 

Cys Ser Ala Met Tyr Val Xaa Asp Leu Cys Gly Ser Val Phe Leu Ala 
        115                 120                 125 

Gly Gln Leu Phe Thr Phe Ser Pro Arg Met His His Thr Thr Gln Glu 
    130                 135                 140 

Cys Asn Cys Ser Ile 
145 

 
           
             280  
             149  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (82)..(82)  
               Xaa is any amino acid  
             
           
            280 

Asp Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser 
1               5                   10                  15 

Ile Phe Leu Leu Ala Phe Leu Ser Cys Leu Thr Val Pro Thr Thr Ala 
            20                  25                  30 

His Glu Val Arg Asn Ala Ser Gly Val Tyr His Leu Thr Asn Asp Cys 
        35                  40                  45 

Ser Asn Ser Ser Ile Ile Tyr Glu Met Ser Gly Met Ile Leu His Ala 
    50                  55                  60 

Pro Gly Cys Val Pro Cys Val Arg Glu Asn Asn Ser Ser Arg Cys Trp 
65                  70                  75                  80 

Met Xaa Leu Thr Pro Thr Leu Ala Val Lys Asp Ala Asn Val Pro Thr 
                85                  90                  95 

Ala Ala Ile Arg Arg His Val Asp Leu Leu Val Gly Thr Ala Ala Phe 
            100                 105                 110 

Arg Ser Ala Met Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val 
        115                 120                 125 

Gly Gln Leu Phe Thr Phe Ser Pro Arg Leu Tyr His Thr Thr Gln Glu 
    130                 135                 140 

Cys Asn Cys Ser Ile 
145 

 
           
             281  
             37  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (1)..(1)  
               Xaa is any amino acid  
             
           
            281 

Xaa Arg Ser Arg Asn Asn Gly Lys Val Asn Asp Thr Leu Xaa Cys Gly 
1               5                   10                  15 

Phe Ala Asp Leu Met Gly Tyr Ile Pro Leu Val Xaa Xaa Pro Leu Gly 
            20                  25                  30 

Gly Ile Glu Arg Ala 
        35 

 
           
             282  
             15  
             PRT  
             hepatitis C virus  
           
            282 

Tyr Ile Pro Leu Val Gly Ala Pro Leu Asn Gly Ala Ala Arg Ala 
1               5                   10                  15 

 
           
             283  
             149  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (121)..(121)  
               Xaa is any amino acid  
             
           
            283 

Asp Gly Ile Asn Phe Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser 
1               5                   10                  15 

Ile Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val Pro Ala Ser Ala 
            20                  25                  30 

Ile Asn Tyr Arg Asn Val Ser Gly Ile Tyr Tyr Val Thr Asn Asp Cys 
        35                  40                  45 

Pro Asn Ser Ser Ile Val Tyr Glu Ala Asp His His Ile Leu His Leu 
    50                  55                  60 

Pro Gly Cys Val Pro Cys Val Arg Glu Gly Asn Gln Ser Arg Cys Trp 
65                  70                  75                  80 

Val Ala Leu Thr Pro Thr Val Ala Ala Pro Tyr Ile Gly Ala Pro Leu 
                85                  90                  95 

Glu Ser Leu Arg Ser His Val Asp Leu Met Val Gly Ala Ala Thr Val 
            100                 105                 110 

Cys Ser Ala Leu Tyr Ile Gly Asp Xaa Cys Xaa Gly Leu Phe Leu Val 
        115                 120                 125 

Gly Gln Met Phe Ser Phe Arg Pro Arg Arg His Trp Thr Thr Gln Asp 
    130                 135                 140 

Cys Asn Cys Ser Ile 
145 

 
           
             284  
             149  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (85)..(85)  
               Xaa is any amino acid  
             
           
            284 

Asp Gly Ile Asn Phe Ala Thr Gly Asn Leu Pro Gly Cys Ser Phe Ser 
1               5                   10                  15 

Ile Phe Leu Leu Ala Leu Phe Ser Cys Leu Leu Thr Pro Thr Ala Gly 
            20                  25                  30 

Leu Glu Tyr Arg Asn Ala Ser Gly Leu Tyr Met Val Thr Asn Asp Cys 
        35                  40                  45 

Ser Asn Gly Ser Ile Val Tyr Glu Ala Gly Asp Ile Ile Leu His Leu 
    50                  55                  60 

Pro Gly Cys Val Pro Cys Val Arg Ser Gly Asn Thr Ser Arg Cys Trp 
65                  70                  75                  80 

Ile Pro Val Ser Xaa Thr Val Ala Val Lys Ser Pro Cys Ala Ala Thr 
                85                  90                  95 

Ala Ser Leu Arg Thr His Val Asp Met Met Val Xaa Ala Ala Thr Leu 
            100                 105                 110 

Cys Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ala Leu Phe Leu Xaa 
        115                 120                 125 

Gly Gln Gly Phe Ser Trp Arg His Arg Gln His Trp Thr Val Gln Asp 
    130                 135                 140 

Cys Asn Cys Ser Ile 
145 

 
           
             285  
             24  
             PRT  
             hepatitis C virus  
             
               MISC_FEATURE  
               (3)..(4)  
               Xaa is any amino acid  
             
           
            285 

Thr Cys Xaa Xaa Ala Asp Leu Met Gly Tyr Xaa Pro Val Val Gly Ala 
1               5                   10                  15 

Pro Val Gly Gly Xaa Ala Arg Ala 
            20 

 
           
             286  
             19  
             PRT  
             hepatitis C virus  
           
            286 

Val Gln Asp Cys Asn Cys Ser Ile Tyr Pro Gly His Ile Thr Gly His 
1               5                   10                  15 

Arg Met Ala